we O
report O
the O
case O
of O
a O
14-year-old O
female O
with O
acute O
promyelocytic O
leukemia O
who O
developed O
symptomatic B-ADR
cardiomyopathy I-ADR
only O
4 O
months O
into O
treatment O
with O
a O
combination O
of O
daunomycin O
and O
all-trans O
retinoic O
acid O
( O
atra B-DRUG

hyperammonemia B-ADR
secondary O
to O
valproic B-DRUG
acid I-DRUG
as O
a O
cause O
of O
lethargy O
in O
a O
postictal O
patient O

despite O
minimal O
short-term O
side O
effects O
and O
apparent O
efficacy O
, O
chronic O
treatment O
of O
mg O
with O
mm B-DRUG
may O
be O
associated O
with O
increased O
risk O
of O
lymphoproliferative B-ADR
disorders I-ADR

despite O
a O
hematologic O
response O
in O
all O
3 O
patients O
, O
none O
of O
them O
achieved O
cytogenetic O
remission O
, O
and O
all O
progressed O
to O
blast B-ADR
crisis I-ADR
at O
7 O
to O
10 O
months O
of O
imatinib B-DRUG
therapy O

however O
, O
given O
the O
clinically O
significant O
result O
to O
the O
interaction O
between O
tolazoline B-DRUG
and O
cimetidine O
we O
report O
, O
the O
use O
of O
cimetidine O
in O
tolazoline B-DRUG
induced O
upper B-ADR
gastrointestinal I-ADR
hemorrhage I-ADR
should O
deserve O
more O
attention O

an O
association O
of O
granulocytopenia O
, O
eosinophilia O
, O
skin O
reaction O
and O
hepatitis B-ADR
during O
propylthiouracil B-DRUG
( O
ptu O
) O
therapy O
for O
thyrotoxicosis O
in O
a O
47 O
year O
old O
black O
female O
is O
reported O

visceral B-ADR
leishmaniasis I-ADR
and O
macrophagic O
activation O
syndrome O
in O
a O
patient O
with O
rheumatoid O
arthritis O
under O
treatment O
with O
adalimumab B-DRUG

we O
report O
here O
a O
rare O
case O
of O
ritodrine-hydrochloride-induced O
rhabdomyolysis B-ADR
in O
a O
pregnant O
patient O
with O
myotonic O
dystrophy O

development O
of O
sarcoidosis B-ADR
during O
interferon B-DRUG
alpha I-DRUG
2b I-DRUG
and O
ribavirin O
combination O
therapy O
for O
chronic O
hepatitis O
c O
-- O
a O
case O
report O
and O
review O
of O
the O
literature O

recently O
, O
her O
serum O
theophylline B-ADR
levels I-ADR
had I-ADR
increased I-ADR
to I-ADR
the I-ADR
toxic I-ADR
range I-ADR
( O
133.2 O
micromol O
/ O
l O
[ O
24 O
microg O
/ O
ml O
]) O
shortly O
after O
the O
addition O
of O
zafirlukast O
( O
accolate O
, O
zeneca O
pharmaceuticals O
, O
wilmington O
, O
del O
) O
to O
her O
regimen O

a O
young O
woman O
developed O
galactorrhea B-ADR
during O
treatment O
with O
a O
new O
dibenzoxazepine B-DRUG
antidepressant O
, O
amoxapine O

concomitant O
irradiation O
apparently O
enhanced O
the O
skin B-ADR
toxicity I-ADR
of O
aminoglutethimide B-DRUG
or O
possibly O
aminoglutethimide B-DRUG
had O
a O
radiosensitizing O
role O
in O
this O
patient O

laryngeal B-ADR
dyspnea I-ADR
in O
relation O
to O
an O
interaction O
between O
acenocoumarol O
and O
topical O
econazole B-DRUG
lotion O

anterior B-ADR
lumbosacral I-ADR
radiculopathy I-ADR
after O
intrathecal O
methotrexate B-DRUG
treatment O

we O
report O
four O
cases O
of O
severe B-ADR
corneal I-ADR
ulceration I-ADR
in O
methamphetamine B-DRUG
abusers O

bilateral O
acoustic O
( O
viii O
) O
nerve O
palsy O
in O
this O
patient O
was O
most O
likely O
a O
manifestation O
of O
vincristine B-DRUG
neurotoxicity B-ADR

we O
present O
three O
cases O
from O
the O
provincial O
toxicology O
center O
of O
british O
columbia O
, O
canada O
in O
which O
suicidal B-ADR
overdose I-ADR
deaths I-ADR
were O
associated O
with O
quetiapine B-DRUG

we O
describe O
a O
case O
of O
significant O
elevation B-ADR
of I-ADR
serum I-ADR
transaminases I-ADR
in O
a O
patient O
treated O
with O
6-tg B-DRUG
for O
a O
flare O
of O
crohn O
's O
disease O

after O
intravitreal O
injection O
of O
triamcinolone B-DRUG
acetonide I-DRUG
, O
cataract B-ADR
may O
rapidly O
develop O
in O
eyes O
that O
have O
been O
intensively O
treated O
, O
topically O
and O
systemically O
, O
by O
corticosteroids O
for O
several O
years O

warfarin-associated O
bleeding B-ADR
complication O
saved O
life O

we O
introduce O
a O
case O
of O
a O
sixty O
years O
old O
woman O
with O
several O
previous O
episodes O
of O
rhinitis B-ADR
, O
conjunctivitis O
and O
perspiration O
immediately O
after O
the O
administration O
of O
salmon O
calcitonin B-DRUG
with O
nasal O
spray O
or O
intramuscular O
administration O
( O
calsynar O

the O
clinical O
findings O
and O
laboratory O
studies O
suggested O
an O
autoimmune B-ADR
cell-mediated I-ADR
hypersensitivity I-ADR
reaction O
triggered O
by O
phenobarbital B-DRUG

patients O
treated O
with O
l-asparaginase B-DRUG
may O
present O
with O
hemorrhagic O
and O
thrombotic B-ADR
cerebrovascular I-ADR
events I-ADR

both O
colchicine B-DRUG
and O
statin O
therapy O
may O
be O
associated O
with O
myopathy B-ADR
, O
which O
usually O
occurs O
after O
several O
months O
of O
therapy O

methods O
: O
the O
patient O
required O
insulin B-DRUG
desensitization O
for O
severe B-ADR
urticaria I-ADR
, O
angioedema O
, O
and O
occasional O
wheezing O
resulting O
from O
her O
insulin B-DRUG
dose O

multiple O
pulmonary O
nodules O
: O
an O
unusual O
presentation O
of O
fludarabine B-DRUG
pulmonary B-ADR
toxicity I-ADR
: O
case O
report O
and O
review O
of O
literature O

reversible O
nonthrombocytopenic B-ADR
palpable I-ADR
purpura I-ADR
associated O
with O
metoclopramide B-DRUG

several O
cases O
of O
lithium-induced O
creutzfeldt-jakob B-ADR
syndrome I-ADR
have O
been O
reported O
to O
date O
; O
all O
of O
them O
were O
elderly O
patients O
and O
a O
half O
had O
" O
therapeutic O
" O
lithium B-DRUG
serum O
levels O

methods O
: O
five O
cases O
of O
contact B-ADR
dermatitis I-ADR
due O
to O
budesonide B-DRUG
, O
a O
nonhalogenated O
steroid O
, O
are O
described O

amphotericin O
b O
( O
amb B-DRUG
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal O
impairment O
, O
anaemia O
, O
fever O
, O
malaise B-ADR
, O
and O
hypokalaemia O
are O
common O

we O
report O
two O
young O
patients O
with O
cystic O
fibrosis O
who O
presented O
with O
acute B-ADR
renal I-ADR
insufficiency I-ADR
after O
2-3 O
weeks O
of O
oral O
ciprofloxacin B-DRUG
therapy O

we O
report O
a O
case O
of O
codeine B-ADR
intoxication I-ADR
in O
the O
neonate O
, O
in O
which O
the O
drug O
was O
prescribed O
for O
cough O
control O
during O
an O
emergency O
department O
visit O

rapamycin O
/ O
sirolimus-induced O
pneumonitis B-ADR
has O
been O
described O
previously O
in O
renal O
transplant O
recipients O
, O
and O
this O
report O
describes O
a O
stable O
heart-lung O
transplant O
recipient O
who O
developed O
a O
pulmonary O
infiltrate O
that O
reversed O
after O
ceasing O
sr O
therapy O

the O
authors O
suggest O
that O
in O
patients O
with O
corneal B-ADR
ulcers I-ADR
refractory I-ADR
to I-ADR
conventional I-ADR
treatment I-ADR
who O
are O
receiving O
colchicine B-DRUG
, O
cessation O
of O
colchicine B-DRUG
therapy O
should O
be O
considered O

proliferation B-ADR
of I-ADR
abnormal I-ADR
bone I-ADR
marrow I-ADR
histiocytes I-ADR
, O
an O
undesired O
effect O
of O
granulocyte B-DRUG
macrophage-colony-stimulating I-DRUG
factor I-DRUG
therapy O
in O
a O
patient O
with O
hurler O
's O
syndrome O
undergoing O
bone O
marrow O
transplantation O

under O
the O
suspicion O
of O
amiodarone-induced O
acute B-ADR
pancreatitis I-ADR
, O
amiodarone B-DRUG
was O
substituted O
by O
propafenone O

a O
well-recognized O
complication O
of O
ethambutol O
use O
is O
optic O
neuropathy O
, O
but O
the O
potential O
ocular B-ADR
toxicity I-ADR
of O
isoniazid B-DRUG
is O
often O
overlooked O

while O
both O
amiodarone B-DRUG
and O
digoxin O
can O
cause O
permanent O
visual O
changes O
, O
the O
ocular B-ADR
effects I-ADR
are O
often O
reversible O

the O
patient O
was O
found O
to O
have O
no B-ADR
motile I-ADR
sperm I-ADR
with O
a O
normal O
sperm O
count O
, O
while O
taking O
a O
dose O
of O
400 O
mg O
/ O
day O
of O
carbamazepine B-DRUG

these O
cases O
suggest O
the O
possibility O
that O
, O
in O
some O
patients O
, O
leukopenia B-ADR
or O
agranulocytosis O
during O
olanzapine B-DRUG
treatment O
might O
be O
dose-related O

although O
gabapentin B-DRUG
withdrawal O
has O
been O
previously O
reported O
and O
usually O
consists O
of O
anxiety O
, O
diaphoresis O
, O
and O
palpitations O
, O
this O
is O
the O
first O
reported O
patient O
with O
generalized B-ADR
seizures I-ADR
and O
status O
epilepticus O
secondary O
to O
gabapentin B-DRUG
withdrawal O

a O
fatal B-ADR
pancytopenia I-ADR
occurred O
in O
a O
patient O
with O
an O
history O
of O
depression O
with O
hypomanic O
rebounds O
, O
admitted O
for O
a O
manic O
episode O
and O
treated O
with O
levomepromazine O
, O
diazepam O
and O
lithium B-DRUG
carbonate I-DRUG

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation B-ADR
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

a O
57-year-old O
woman O
developed O
pulmonary B-ADR
sarcoidosis I-ADR
during O
therapy O
with O
interferon B-DRUG
beta I-DRUG
for O
advanced O
renal O
cell O
carcinoma O
metastatic O
to O
mediastinal O
lymph O
nodes O

we O
report O
a O
43-year-old O
woman O
who O
developed O
sore O
throat O
, O
swelling O
of O
the O
lips O
and O
oral O
cavity O
and O
dysphagia B-ADR
, O
2 O
weeks O
after O
the O
use O
of O
budesonide O
spray O
( O
budefat B-DRUG
) O
for O
treatment O
of O
bronchial O
asthma O

this O
case O
extends O
the O
spectrum O
of O
fludarabine B-DRUG
pulmonary O
toxicity O
to O
include O
pulmonary B-ADR
nodules I-ADR

we O
report O
a O
case O
of O
zidovudine B-DRUG
induced O
anaemia B-ADR
and O
bone O
marrow O
aplasia O
in O
a O
patient O
infected O
with O
hiv O

it O
is O
believed O
that O
this O
is O
the O
first O
reported O
case O
of O
reversible O
azathioprine-induced O
cholestasis B-ADR
associated O
with O
histological O
evidence O
of O
bile O
duct O
injury O

emergence O
of O
philadelphia B-ADR
positive I-ADR
chronic I-ADR
myeloid I-ADR
leukaemia I-ADR
during O
treatment O
with O
hydroxyurea B-DRUG
for O
philadelphia O
negative O
essential O
thrombocythaemia O

following O
7 O
days O
of O
tigecycline B-DRUG
she O
developed O
severe B-ADR
abdominal I-ADR
pain I-ADR
and O
elevated O
pancreatic O
enzymes O
suggesting O
acute O
pancreatitis O

we O
describe O
children O
and O
adolescents O
with O
chronic O
hematologic O
and O
oncologic O
diseases O
who O
exhibited O
drug-seeking O
behavior O
or O
anticholinergic B-ADR
symptoms I-ADR
with O
the O
use O
of O
diphenhydramine B-DRUG

we O
describe O
a O
case O
of O
disseminated O
muscular O
cysticercosis O
followed O
by O
myositis O
( O
fever B-ADR
, O
diffuse O
myalgia O
, O
weakness O
of O
the O
lower O
limbs O
, O
and O
inflammatory O
reaction O
around O
dying O
cysticerci O
) O
induced O
by O
praziquantel B-DRUG
therapy O
, O
an O
event O
not O
described O
previously O

a O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity O
drug O
reaction O
developed O
which O
consisted O
of O
fever O
, O
a O
pruritic O
desquamating O
erythrodermic O
rash O
, O
alopecia O
, O
icterus B-ADR
, O
protein-losing O
enteropathy O
, O
myositis O
, O
and O
nephritis O
, O
is O
described O

mi B-ADR
related O
to O
the O
use O
of O
activated O
and O
non-activated O
pccs B-DRUG
predominantly O
affects O
young O
patients O
who O
often O
have O
no O
preceding O
history O
of O
, O
or O
risk O
factors O
for O
, O
mi B-ADR
and O
tends O
to O
be O
associated O
with O
large O
cumulative O
doses O
of O
concentrate O

a O
74-year-old O
hypercholestrerolaemic O
woman O
taking O
cerivastatin B-DRUG
( O
0.15 O
mg O
/ O
day O
) O
for O
22 O
days O
complained O
of O
general O
muscle O
weakness O
and O
muscle B-ADR
pain I-ADR

we O
report O
2 O
cases O
of O
maculopapular B-ADR
eruption I-ADR
and O
fever O
in O
patients O
infected O
with O
human O
immunodeficiency O
virus O
( O
hiv O
) O
on O
the O
2nd O
day O
of O
first O
administration O
of O
ritonavir B-DRUG
, O
a O
protease O
inhibitor O

falling B-ADR
backward I-ADR
in O
two O
elderly O
patients O
taking O
bupropion B-DRUG

conclusions O
: O
this O
case O
report O
showed O
that O
the O
clinical O
appearance O
of O
hashimoto B-ADR
's I-ADR
disease I-ADR
after O
ifn-alpha B-DRUG
therapy O
for O
chronic O
c O
hepatitis O
in O
our O
patient O
was O
associated O
with O
a O
specific O
genetic O
predisposition O
( O
dr5 O
) O
for O
this O
pathology O

a O
16-year-old O
boy O
developed O
fever B-ADR
, O
generalized O
rigidity O
, O
leukocytosis O
, O
and O
increased O
serum O
transaminase O
and O
creatine O
kinase O
levels O
while O
receiving O
treatment O
with O
olanzapine B-DRUG
and O
lithium O

treatment O
of O
chronic O
hepatitis O
c O
with O
interferon B-DRUG
alpha I-DRUG
( O
ifn-alpha O
) O
is O
relatively O
contraindicated O
in O
patients O
with O
psychiatric O
disorders O
because O
of O
possible O
severe O
psychiatric B-ADR
side I-ADR
effects I-ADR

itch B-ADR
and O
skin O
rash O
from O
chocolate O
during O
fluoxetine O
and O
sertraline B-DRUG
treatment O
: O
case O
report O

central B-ADR
pontine I-ADR
myelinolysis I-ADR
manifested O
by O
temporary O
blindness O
: O
a O
possible O
complication O
of O
lithium B-DRUG
toxicity O

our O
report O
suggested O
that O
cbdca B-DRUG
hypersensitivity B-ADR
was O
correlated O
with O
the O
total O
dose O
of O
previously O
administered O
platinum O
agents O
and O
that O
cbdca B-DRUG
should O
be O
excluded O
in O
patients O
who O
have O
received O
multiple O
platinum-based O
chemotherapy O
, O
even O
in O
platinum-sensitive O
cases O
, O
because O
cbdca B-DRUG
hypersensitivity B-ADR
can O
occur O
even O
with O
low-dose O
cbdca B-DRUG
administration O

a O
10-year-old O
asthmatic O
boy O
began O
to O
suffer O
from O
urticarial O
rash O
and O
moderately B-ADR
severe I-ADR
bronchospasm I-ADR
after O
8 O
weeks' O
treatment O
with O
disodium B-DRUG
cromoglycate I-DRUG

diagnosis O
of O
hypothyroidism B-ADR
during O
treatment O
can O
be O
difficult O
because O
of O
the O
common O
side O
effects O
of O
alpha B-DRUG
interferon I-DRUG

acute B-ADR
leukopenia I-ADR
associated O
with O
silver B-DRUG
sulfadiazine I-DRUG
therapy O

four O
days O
after O
intravenous O
zoledronic B-DRUG
acid I-DRUG
, O
the O
patient O
presented O
to O
emergency O
room O
with O
complaints O
of O
carpopedal B-ADR
spasm I-ADR
and O
bronchospasm O

calcification O
and O
ossification B-ADR
of I-ADR
the I-ADR
spinal I-ADR
arachnoid I-ADR
after O
intrathecal O
administration O
of O
depo-medrol B-DRUG

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin O
and O
moxifloxacin B-DRUG
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache B-ADR
, O
dizziness O
and O
insomnia O

this O
paper O
reports O
on O
a O
6.9-year-old O
autistic O
male O
who O
developed O
repeated O
episodes O
of O
acute B-ADR
dystonic I-ADR
reactions I-ADR
associated O
with O
pimozide B-DRUG
administration O
at O
the O
doses O
of O
0.096 O
mg O
/ O
kg O
/ O
day O
and O
0.032 O
mg O
/ O
kg O
/ O
day O
and O
32 O
hours O
following O
pimozide B-DRUG
withdrawal O
, O
as O
well O
as O
during O
subsequent O
thioridazine O
administration O

the O
authors' O
results O
suggest O
that O
l-dopa B-DRUG
may O
cause O
daytime B-ADR
somnolence I-ADR
in O
some O
patients O
with O
parkinson O
's O
disease O

fulminant B-ADR
hepatic I-ADR
failure I-ADR
developed O
in O
a O
24-year-old O
black O
woman O
who O
had O
been O
treated O
with O
propylthiouracil B-DRUG
and O
propranolol O
for O
hyperthyroidism O

pentazocine-induced O
fibrous B-ADR
myopathy I-ADR
and O
localized O
neuropathy O

painful B-ADR
erosion I-ADR
of I-ADR
psoriatic I-ADR
plaques I-ADR
is O
a O
less O
common O
sign O
of O
methotrexate B-DRUG
toxicity O
that O
may O
precede O
evidence O
of O
bone O
marrow O
suppression O

aims O
: O
to O
present O
a O
case O
of O
piloerection B-ADR
after O
replacing O
fluvoxamine O
maleate O
with O
milnacipran B-DRUG
hydrochloride I-DRUG
, O
and O
to O
analyse O
this O
effect O
based O
on O
receptor O
occupancy O
theory O

since O
1979 O
, O
over O
30 O
published O
case O
reports O
have O
documented O
the O
relationship O
between O
phenylpropanolamine B-DRUG
and O
stroke B-ADR

myasthenia B-ADR
gravis I-ADR
during O
low-dose O
ifn-alpha B-DRUG
therapy O
for O
chronic O
hepatitis O
c O

cardiac B-ADR
arrest I-ADR
associated O
with O
sulprostone B-DRUG
use O
during O
caesarean O
section O

in O
a O
series O
of O
104 O
cases O
of O
intentional O
or O
inadvertent O
use O
of O
zidovudine B-DRUG
at O
differing O
gestations O
in O
pregnancy O
, O
there O
were O
eight O
spontaneous O
first O
trimester O
abortions O
, O
eight O
therapeutic O
terminations O
, O
and O
eight O
cases O
of O
fetal B-ADR
abnormality I-ADR
occurring O
among O
a O
total O
of O
88 O
cases O
where O
the O
pregnancy O
progressed O

objective O
: O
to O
test O
the O
hypothesis O
that O
tumor O
necrosis O
factor O
( O
tnf O
)- O
alpha O
may O
mediate O
the O
loss O
and O
the O
dedifferentiation O
of O
subcutaneous O
fat O
tissue O
in O
the O
insulin-induced O
lipoatrophies B-ADR
of O
a O
diabetic O
patient O
who O
presented O
extensive O
lesions O

ceftriaxone O
was O
approved O
in O
1997 O
for O
the O
treatment O
of O
otitis O
media O
despite O
previous O
studies O
that O
documented O
an O
association O
of O
ceftriaxone B-DRUG
with O
elevated B-ADR
hepato-biliary I-ADR
enzymes I-ADR
and O
transient O
biliary O
stasis O

calcipotriol B-DRUG
( O
daivonex O
r O
; O
leo O
pharmaceuticals O
, O
zurich O
, O
switzerland O
) O
may O
cause O
irritation B-ADR
of I-ADR
the I-ADR
skin I-ADR
, O
whereas O
allergic O
reactions O
are O
less O
common O

conversely O
, O
diffuse O
interstitial O
pulmonary O
fibrosis O
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
patients O
receiving O
methotrexate B-DRUG
who O
develop O
bilateral B-ADR
pulmonary I-ADR
infiltrates I-ADR
seen O
on O
chest O
roentgenograms O

the O
current O
report O
describes O
a O
man O
who O
was O
prescribed O
zonisamide B-DRUG
for O
epilepsy O
and O
subsequently O
developed O
widespread O
skin O
rash O
, O
acute O
kidney O
injury O
, O
high-grade O
fever O
, O
eosinophilia O
, O
liver O
dysfunction O
, O
lymphadenopathy B-ADR
and O
an O
increase O
in O
antihuman O
herpesvirus-6 O
immunoglobulin O
g O
titer O

approximately O
15 O
min O
after O
the O
first O
administration O
of O
nebulised O
morphine B-DRUG
the O
patient O
became O
markedly O
bradypneic O
( O
respiratory O
rate O
: O
4-5 O
bpm O
) O
, O
hypotensive B-ADR
( O
bp O
70 O
/ O
40 O
mmhg O
) O
, O
and O
responded O
only O
partially O
to O
command O

common O
adverse O
events O
( O
frequency O
10 O
%) O
of O
lacosamide B-DRUG
doses O
up O
to O
600 O
mg O
/ O
day O
include O
nonspecific O
central O
nervous O
system O
effects O
( O
e.g. O
, O
dizziness O
, O
ataxia O
, O
diplopia O
, O
and O
somnolence B-ADR

pheripheral B-ADR
edema I-ADR
was O
observed O
in O
five O
female O
patients O
after O
taking O
proton O
pump O
inhibitors O
omeprazole O
, O
lansoprazole O
, O
or O
pantoprazole B-DRUG
for O
7-15 O
days O
for O
peptic O
acid O
diseases O
in O
recommended O
standard O
doses O

a O
7-year-old O
girl O
developed O
diabetes O
mellitus O
and O
exocrine B-ADR
pancreatic I-ADR
insufficiency I-ADR
after O
3.5 O
years O
of O
almost O
continuous O
treatment O
with O
azathioprine O
and O
/ O
or O
prednisone B-DRUG
for O
idiopathic O
auto-immune O
haemolytic O
anaemia O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia B-ADR
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

development O
of O
tics B-ADR
in O
a O
thirteen-year-old O
male O
following O
atomoxetine B-DRUG
use O

herein O
we O
report O
four O
patients O
who O
underwent O
liver O
transplantation O
and O
developed O
neutropenia B-ADR
while O
receiving O
mmf B-DRUG

we O
report O
the O
first O
case O
of O
polymorphic B-ADR
ventricular I-ADR
tachycardia I-ADR
with O
normal O
qt O
interval O
associated O
with O
the O
oral O
use O
of O
levofloxacin B-DRUG
in O
the O
absence O
of O
other O
etiologies O
known O
to O
cause O
these O
arrhythmias O

the O
clinical O
course O
suggests O
that O
caffeine B-DRUG
, O
which O
is O
present O
in O
oolong O
tea O
, O
was O
mainly O
responsible O
for O
the O
rhabdomyolysis O
as O
well O
as O
the O
delirium B-ADR
, O
although O
severe O
hyponatremia O
has O
been O
reported O
to O
cause O
rhabdomyolysis O
on O
rare O
occasions O

fibrosis B-ADR
of I-ADR
corpus I-ADR
cavernosum I-ADR
after O
intracavernous O
injection O
of O
phentolamine O
/ O
papaverine B-DRUG

myoclonus B-ADR
associated O
with O
continuous O
dobutamine B-DRUG
infusion O
in O
a O
patient O
with O
end-stage O
renal O
disease O

we O
observed O
3 O
diabetic O
patients O
with O
intolerable B-ADR
dizziness I-ADR
followed O
by O
nausea O
and O
vomiting O
immediately O
after O
an O
initial O
administration O
of O
the O
alpha-glucosidase O
inhibitor O
, O
voglibose B-DRUG

we O
describe O
a O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
capd O
) O
patient O
that O
developed O
vancomycin-induced O
agranulocytosis B-ADR
during O
treatment O
for O
methicillin-resistant O
staphylococcus O
aureus O
( O
mrsa O
)- O
associated O
external O
cuff O
infection O
and O
pneumonia O

objective O
: O
the O
authors O
described O
a O
case O
of O
interferon-induced O
psychosis B-ADR
as O
a O
framework O
to O
review O
the O
literature O
and O
discuss O
the O
decision O
to O
pursue O
antiviral O
treatment O
in O
psychiatrically O
ill O
patients O
with O
hepatitis O
c O

the O
use O
of O
rituximab B-DRUG
has O
been O
uncommonly O
associated O
with O
delayed B-ADR
pulmonary I-ADR
toxicity I-ADR

four O
cases O
of O
oesophageal B-ADR
damage I-ADR
associated O
with O
ingestion O
of O
the O
urinary O
anti-spasmodic O
agent O
emepronium B-DRUG
bromide I-DRUG
are O
described O

there O
are O
now O
reports O
of O
liver B-ADR
failure I-ADR
following O
treatment O
of O
childhood O
cancers O
with O
amd B-DRUG

the O
patient O
continued O
to O
have O
fever B-ADR
and O
autonomic O
instability O
without O
evidence O
of O
infection O
which O
entirely O
resolved O
within O
24 O
hours O
of O
reinstitution O
of O
full O
preadmission O
dosing O
of O
oral O
baclofen B-DRUG

herein O
, O
we O
present O
a O
patient O
with O
severe O
and O
prolonged B-ADR
hypoglycemia I-ADR
after O
long-acting O
octreotide B-DRUG
treatment O

cystoid B-ADR
macular I-ADR
edema I-ADR
in O
a O
low-risk O
patient O
after O
switching O
from O
latanoprost O
to O
bimatoprost B-DRUG

mental B-ADR
nerve I-ADR
neuropathy I-ADR
as O
a O
result O
of O
hepatitis B-DRUG
b I-DRUG
vaccination I-DRUG

rapamycin B-DRUG
/ O
sirolimus O
( O
sr O
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension O
, O
hyperlipidemia B-ADR
, O
and O
infection O

in O
one O
instance O
a O
systemic B-ADR
hypoglycemic I-ADR
reaction I-ADR
resulting O
in O
head O
trauma O
and O
confusion O
ended O
in O
an O
emegency O
hospital O
admission O
following O
the O
substitution O
of O
acetohexamide B-DRUG
for O
acetazolamide O

caution O
with O
use O
of O
cimetidine O
in O
tolazoline B-DRUG
induced O
upper B-ADR
gastrointestinal I-ADR
bleeding I-ADR

cefuroxime-induced O
acute B-ADR
renal I-ADR
failure I-ADR

mitomycin O
c O
( O
mmc B-DRUG
) O
is O
an O
alkylating O
agent O
that O
has O
been O
recently O
associated O
with O
the O
hemolytic-uremic O
syndrome O
( O
hus B-ADR

although O
combinations O
of O
belladonna O
, O
ergotamine B-DRUG
, O
and O
phenobarbital O
have O
been O
used O
for O
medical O
treatment O
of O
menopausal O
symptoms O
since O
the O
1960s O
, O
this O
is O
the O
first O
known O
case O
report O
of O
its O
association O
with O
anticonvulsant B-ADR
hypersensitivity I-ADR
syndrome I-ADR

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady B-ADR
gait I-ADR
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

we O
report O
the O
case O
of O
a O
young O
man O
, O
affected O
by O
rheumatoid O
arthritis O
who O
developed O
a O
rapid-onset O
short-of-breath O
, O
hemoptysis B-ADR
, O
and O
severe O
weakness O
, O
about O
2 O
weeks O
after O
the O
administration O
of O
leflunomide B-DRUG

three O
of O
these O
patients O
had O
convulsions O
attributed O
to O
imipenem B-DRUG
/ O
cilastatin O
; O
3.6 O
% O
of O
the O
patients O
had O
seizure B-ADR
, O
or O
2 O
% O
of O
imipenem B-DRUG
/ O
cilastatin O
administrations O
was O
followed O
by O
a O
seizure B-ADR
attack O

basilar O
invagination O
and O
mid-line B-ADR
skeletal I-ADR
abnormalities I-ADR
due O
to O
in O
utero O
exposure O
to O
phenytoin B-DRUG

sensory B-ADR
neuropathy I-ADR
revealing O
necrotizing O
vasculitis O
during O
infliximab B-DRUG
therapy O
for O
rheumatoid O
arthritis O

disulfiram B-DRUG
encephalopathy O
as O
a O
cause O
of O
the O
catatonia B-ADR
syndrome I-ADR

we O
report O
a O
46-yr-old O
woman O
with O
ovarian O
carcinoma O
who O
developed O
porphyria B-ADR
cutanea I-ADR
tarda I-ADR
while O
undergoing O
treatment O
with O
cisplatin O
and O
cyclophosphamide B-DRUG

probable O
propafenone-induced O
transient B-ADR
global I-ADR
amnesia I-ADR

we O
describe O
a O
patient O
with O
a O
liver O
abscess O
due O
to O
entamoeba O
histolytica O
, O
in O
whom O
metronidazole B-DRUG
therapy O
( O
total O
dose O
, O
21 O
g O
over O
14 O
days O
) O
was O
complicated O
by O
reversible O
deafness O
, O
tinnitus O
, O
and O
ataxia O
and O
who O
relapsed O
5 O
months O
later O
with O
a O
splenic B-ADR
abscess I-ADR

a O
case O
of O
high-grade B-ADR
endometrial I-ADR
stromal I-ADR
sarcoma I-ADR
, O
confined O
into O
an O
intrauterine O
polypoid O
growth O
, O
in O
a O
woman O
with O
a O
history O
of O
breast O
cancer O
who O
was O
treated O
with O
adjuvant O
tamoxifen B-DRUG

objective O
: O
to O
report O
a O
case O
of O
rapidly O
occurring O
hyperglycemia B-ADR
that O
occurred O
in O
a O
geriatric O
patient O
3 O
days O
after O
treatment O
with O
olanzapine B-DRUG

in O
eight O
patients O
, O
a O
mean O
decrease B-ADR
in I-ADR
serum I-ADR
na I-ADR
+ O
of O
8.25 O
+/- O
3.2 O
meq O
/ O
l O
was O
observed O
after O
a O
single O
200 O
mg O
intravenous O
dose O
of O
lorcainide B-DRUG

of O
particular O
interest O
in O
this O
patient O
is O
the O
fluctuation B-ADR
of I-ADR
the I-ADR
qt I-ADR
interval I-ADR
at O
a O
stable O
dose O
of O
methadone B-DRUG
, O
suggesting O
that O
a O
single O
normal O
electrocardiogram O
( O
ecg O
) O
does O
not O
guarantee O
that O
the O
patient O
is O
not O
at O
risk O
of O
ventricular O
arrhythmias O

tiagabine B-DRUG
overdose O
causes O
an O
unusual B-ADR
array I-ADR
of I-ADR
neurological I-ADR
symptoms I-ADR
, O
many O
similar O
to O
reported O
adverse O
effects O
during O
therapeutic O
use O

symptomatic B-ADR
hypoglycemia I-ADR
secondary O
to O
a O
glipizide-trimethoprim O
/ O
sulfamethoxazole B-DRUG
drug O
interaction O

the O
fetal O
valproate B-DRUG
syndrome O
( O
fvs O
) O
is O
characterized O
by O
distinctive O
facial O
appearance O
, O
major O
and O
minor O
malformations O
, O
and O
developmental B-ADR
delay I-ADR

however O
, O
acute B-ADR
cardiomyopathy I-ADR
and O
pericarditis O
secondary O
to O
methylphenidate B-DRUG
use O
has O
been O
rarely O
reported O

drug-induced O
eosinophilia B-ADR
is O
a O
non-dose-dependent O
side O
effect O
of O
clozapine B-DRUG

purpose O
: O
to O
describe O
transient B-ADR
structured I-ADR
visual I-ADR
hallucinations I-ADR
in O
a O
patient O
with O
vascular O
age-related O
macular O
degeneration O
( O
amd O
) O
, O
following O
an O
intravitreal O
avastin-injection O

flutamide B-ADR
withdrawal I-ADR
syndrome I-ADR
is O
characterized O
by O
a O
decrease O
in O
prostate-specific O
antigen O
( O
psa O
) O
after O
flutamide B-DRUG
withdrawal O
in O
a O
subset O
of O
patients O
with O
progressing O
metastatic O
carcinoma O
of O
the O
prostate O

data O
synthesis O
: O
a O
49-year-old O
man O
developed O
symptoms O
of O
severe B-ADR
psychosis I-ADR
concomitant O
with O
ciprofloxacin B-DRUG
( O
250 O
mg O
bid O
) O
treatment O

two O
patients O
treated O
with O
5-fluorouracil B-DRUG
( O
5-fu O
) O
for O
disseminated O
adenocarcinoma O
of O
the O
colon O
developed O
cerebellar B-ADR
dysfunction I-ADR
typical O
of O
5-fu O
neurotoxicity O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine O
and O
sulfadiazine B-DRUG
for O
reactivated O
chorioretinitis O
developed O
fever O
, O
severe O
cutaneous O
involvement O
, O
swelling O
, O
abdominal O
pain O
and O
transaminitis B-ADR
, O
persisting O
weeks O
after O
withholding O
medicines O

naproxen B-DRUG
, O
the O
most O
common O
offender O
, O
has O
been O
associated O
with O
a O
dimorphic O
clinical O
pattern O
: O
a O
pct-like O
presentation O
and O
one O
simulating O
erythropoietic B-ADR
protoporphyria I-ADR
in O
the O
pediatric O
population O

atrial B-ADR
fibrillation I-ADR
following O
methylprednisolone B-DRUG
pulse O
therapy O

syncope B-ADR
induced O
by O
propranolol B-DRUG
in O
hypertrophic O
cardiomyopathy O

we O
report O
5 O
cases O
of O
acute B-ADR
reversible I-ADR
renal I-ADR
failure I-ADR
coinciding O
with O
the O
onset O
of O
treatment O
with O
captopril B-DRUG
in O
patients O
with O
severe O
drug-resistant O
hypertension O

a O
patient O
developed O
restless B-ADR
legs I-ADR
symptoms I-ADR
paralleling O
the O
course O
of O
interferon-alpha B-DRUG
( O
ifn O
alpha O
) O
therapy O
for O
chronic O
hepatitis O
c O

a O
72-year-old O
woman O
with O
a O
history O
of O
thyrotoxicosis O
presented O
with O
sore B-ADR
throat I-ADR
and O
fever O
two O
weeks O
after O
starting O
carbimazole B-DRUG

physicians O
should O
be O
aware O
of O
the O
risk O
of O
severe O
aiha B-ADR
in O
cll O
patients O
with O
a O
history O
of O
aiha B-ADR
or O
positivation O
of O
the O
dat O
during O
previous O
fludarabine B-DRUG
administration O
, O
or O
in O
case O
of O
secondary O
fixation O
of O
complement O
to O
the O
red O
cell O
membrane O
occurring O
during O
fludarabine B-DRUG
treatment O

a O
wide O
variety O
of O
adverse O
central O
nervous O
system O
effects O
have O
been O
reported O
in O
association O
with O
propafenone B-DRUG
; O
dizziness B-ADR
is O
the O
most O
common O

severe O
heparin B-DRUG
associated O
thrombocytopenia B-ADR
is O
a O
rare O
complication O
of O
heparin B-DRUG
therapy O

we O
report O
a O
case O
of O
long O
lasting O
respiratory B-ADR
depression I-ADR
after O
intravenous O
administration O
of O
morphine B-DRUG
to O
a O
7 O
year O
old O
girl O
with O
haemolytic O
uraemic O
syndrome O

we O
report O
the O
first O
case O
of O
fulminant O
adult B-ADR
respiratory I-ADR
distress I-ADR
syndrome I-ADR
( O
ards O
) O
associated O
with O
pegylated O
interferon O
alpha-2a O
( O
pegifnalpha-2a B-DRUG
) O
and O
ribavirin O
use O
for O
hepatitis O
c O
, O
complicated O
by O
subsequent O
and O
ultimately O
fatal O
sepsis O
and O
multiorgan O
failure O

ophthalmologists O
should O
be O
aware O
of O
the O
ocular O
side O
effects O
of O
ifn B-DRUG
therapy O
and O
carefully O
monitor O
patients O
for O
the O
possible O
occurrence O
of O
hypoalbuminemia O
and O
thrombocytopenia B-ADR

three O
days O
after O
receiving O
intravitreal O
injection O
of O
bevacizumab B-DRUG
( O
1.25 O
mg O
in O
0.1 O
ml O
) O
, O
he O
developed O
acute B-ADR
vision I-ADR
loss I-ADR
and O
change O
of O
consciousness O

leukaemoid B-ADR
monocytosis I-ADR
in O
m4 O
aml O
following O
chemotherapy O
and O
g-csf B-DRUG

ards B-ADR
has O
been O
associated O
with O
the O
administration O
of O
other O
monoclonal O
antibodies O
, O
such O
as O
infliximab O
, O
gemtuzumab B-DRUG
ozogamicin I-DRUG
, O
and O
okt3 O
and O
is O
believed O
to O
be O
directly O
mediated O
by O
release O
of O
proinflammatory O
cytokines O

disseminated O
intravascular O
coagulation O
associated O
with O
acute O
hemoglobinemia O
or O
hemoglobinuria B-ADR
following O
rh O
( O
0 O
)( O
d O
) O
immune O
globulin O
intravenous O
administration O
for O
immune O
thrombocytopenic O
purpura O

results O
: O
in O
a O
22-year-old O
thai O
woman O
with O
graves' O
disease O
, O
tinnitus O
, O
hearing O
impairment O
in O
the O
left O
ear O
( O
with O
progression O
to O
the O
right O
ear O
) O
, O
and O
vertigo B-ADR
developed O
after O
3 O
years O
of O
therapy O
with O
ptu B-DRUG

cyclosporin B-DRUG
side O
effects O
included O
hirsutism O
, O
hypertension O
, O
increased O
blood O
levels O
of O
urea O
and O
creatinine O
, O
and O
abnormalities B-ADR
in I-ADR
liver I-ADR
function I-ADR
tests I-ADR

regression O
of O
thyrotoxic B-ADR
ophthalmopathy I-ADR
following O
lithium B-DRUG
withdrawal O

objective O
: O
1 O
) O
to O
describe O
a O
patient O
with O
rheumatoid O
arthritis O
receiving O
adalimumab B-DRUG
who O
developed O
fever B-ADR
, O
pancytopenia O
, O
splenomegaly O
, O
and O
extreme O
hyperferritinemia O

syncope B-ADR
in O
a O
65-year-old O
woman O
after O
nitrate B-DRUG
ingestion O

we O
discuss O
a O
patient O
who O
developed O
severe B-ADR
renal I-ADR
tubular I-ADR
dysfunction I-ADR
secondary O
to O
short-term O
therapy O
with O
amikacin B-DRUG
, O
resulting O
in O
refractory O
hypokalemia O
, O
hypocalcemia O
, O
hypomagnesemia O
, O
metabolic O
alkalosis O
, O
and O
polyuria O

treatment-related O
myelodysplastic B-ADR
syndrome I-ADR
after O
temozolomide B-DRUG
for O
recurrent O
high-grade O
glioma O

pneumonitis O
, O
bilateral O
pleural O
effusions O
, O
echocardiographic O
evidence O
of O
cardiac O
tamponade O
, O
and O
positive B-ADR
autoantibodies I-ADR
developed O
in O
a O
43-year-old O
man O
, O
who O
was O
receiving O
long-term O
sulfasalazine B-DRUG
therapy O
for O
chronic O
ulcerative O
colitis O

in O
the O
absence O
of O
mucositis O
or O
diarrhea O
, O
severe O
dermatologic O
toxicity O
following O
a O
single O
low O
dose O
of O
the O
drug O
suggests O
an O
' O
allergic O
' O
or O
acute B-ADR
hypersensitivity I-ADR
reaction I-ADR
to O
mtx B-DRUG
in O
this O
patient O

methods O
: O
a O
68-year-old O
man O
developed O
intense B-ADR
conjunctival I-ADR
hyperemia I-ADR
and O
cystoid O
macula O
edema O
after O
switching O
from O
latanoprost B-DRUG
to O
bimatoprost O
9 O
months O
after O
cataract O
surgery O
in O
an O
eye O
at O
low-risk O
for O
this O
cystoid O
macular O
edema O

the O
literature O
on O
thiabendazole-induced O
cholestasis B-ADR
and O
its O
association O
with O
sicca O
complex O
is O
reviewed O

two O
patients O
who O
developed O
decreased O
visual O
acuity O
after O
several O
months O
of O
ethambutol B-DRUG
treatment O
for O
mycobacterium O
avium-intracellulare O
infection O
had O
bitemporal B-ADR
visual I-ADR
field I-ADR
defects I-ADR
that O
suggested O
optic O
chiasm O
damage O

gelofusine B-ADR
allergy I-ADR
-- O
the O
need O
for O
identification O
jewellery O

in O
one O
patient O
the O
vasculitis O
resolved O
after O
termination O
of O
the O
ciprofloxacin B-DRUG
therapy O
; O
in O
the O
other O
patient O
the O
ciprofloxacin-induced O
hemorrhagic O
vasculitis O
was O
superimposed O
on O
a O
severe O
forefoot O
infection O
, O
leading O
to O
progressive B-ADR
gangrene I-ADR
and O
a O
below-knee O
amputation O

isonicotinic B-DRUG
acid I-DRUG
hydrazide I-DRUG
induced O
anagen O
effluvium O
and O
associated O
lichenoid B-ADR
eruption I-ADR

we O
report O
the O
case O
of O
a O
20-year-old O
female O
with O
polyarteritis O
nodosa O
( O
pan O
) O
who O
developed O
bilateral B-ADR
sensorineural I-ADR
hearing I-ADR
loss I-ADR
25 O
minutes O
after O
receiving O
30 O
mg O
of O
intravenous O
ketoralac B-DRUG

amphotericin O
b O
( O
amb B-DRUG
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal O
impairment O
, O
anaemia B-ADR
, O
fever O
, O
malaise O
, O
and O
hypokalaemia O
are O
common O

oxcarbazepine-associated O
angioedema B-ADR
manifested O
by O
swelling O
of O
the O
face O
, O
eyes O
, O
lips O
, O
or O
tongue O
or O
difficulty O
swallowing O
or O
breathing O
( O
or O
both O
) O
is O
a O
rare O
but O
potentially O
life-threatening O
reaction O
for O
which O
early O
recognition O
and O
management O
are O
vital O

this O
paper O
reports O
on O
a O
6.9-year-old O
autistic O
male O
who O
developed O
repeated O
episodes O
of O
acute B-ADR
dystonic I-ADR
reactions I-ADR
associated O
with O
pimozide B-DRUG
administration O
at O
the O
doses O
of O
0.096 O
mg O
/ O
kg O
/ O
day O
and O
0.032 O
mg O
/ O
kg O
/ O
day O
and O
32 O
hours O
following O
pimozide B-DRUG
withdrawal O
, O
as O
well O
as O
during O
subsequent O
thioridazine O
administration O

a O
patient O
with O
seropositive O
rheumatoid O
arthritis O
developed O
ascites B-ADR
while O
taking O
weekly O
doses O
of O
methotrexate O
( O
mtx B-DRUG

we O
introduce O
a O
case O
of O
a O
sixty O
years O
old O
woman O
with O
several O
previous O
episodes O
of O
rhinitis O
, O
conjunctivitis B-ADR
and O
perspiration O
immediately O
after O
the O
administration O
of O
salmon O
calcitonin B-DRUG
with O
nasal O
spray O
or O
intramuscular O
administration O
( O
calsynar O

ticlopidine-induced O
interstitial B-ADR
pulmonary I-ADR
disease I-ADR
: O
a O
case O
report O

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general O
erythema O
, O
and O
fever B-ADR

sweet O
's O
syndrome O
is O
an O
acute B-ADR
febrile I-ADR
neutrophilic I-ADR
dermatosis I-ADR
that O
is O
a O
known O
complication O
of O
the O
administration O
of O
filgrastim B-DRUG
, O
a O
drug O
that O
causes O
increased O
neutrophil O
proliferation O
and O
differentiation O

we O
suggest O
that O
objective O
evaluation O
of O
retinal O
function O
with O
electrophysiological O
methods O
should O
be O
performed O
in O
patients O
with O
visual B-ADR
disturbance I-ADR
during O
treatment O
with O
rifabutin B-DRUG

transient O
phenytoin B-DRUG
induced O
iga O
deficiency O
and O
permanent O
ige B-ADR
increase I-ADR

one O
patient O
who O
received O
clindamycin B-DRUG
had O
liver O
biopsy O
findings O
of O
marked O
cholestasis O
, O
portal O
inflammation O
, O
bile O
duct O
injury O
and O
bile B-ADR
duct I-ADR
paucity I-ADR
( O
ductopenia O

phenobarbital B-DRUG
hepatotoxicity B-ADR
in O
an O
8-month-old O
infant O

with O
the O
use O
of O
optical O
coherence O
tomography O
( O
oct O
) O
, O
two O
patients O
with O
ifn-associated O
retinopathy O
who O
had O
developed O
macular O
edema O
and O
reduced B-ADR
visual I-ADR
acuity I-ADR
during O
the O
clinical O
course O
of O
ifn B-DRUG
therapy O
were O
observed O

a O
22-year-old O
black O
man O
developed O
fever B-ADR
, O
chills O
, O
fatigue O
, O
night O
sweats O
, O
tender O
lymphadenopathy O
, O
and O
a O
generalized O
, O
pruritic O
, O
macular O
eruption O
3 O
weeks O
after O
starting O
minocycline B-DRUG
therapy O
for O
acne O

bromocriptine-induced O
schizophrenia B-ADR

this O
case O
suggests O
that O
acyclovir O
when O
given O
intravenously O
in O
doses O
of O
10 O
mg O
/ O
kg O
may O
result O
in O
increased B-ADR
serum I-ADR
lithium I-ADR
concentrations O

increasing O
the O
olanzapine B-DRUG
dosage O
severely O
aggravated O
the O
symptoms O
of O
rls B-ADR

a O
66-year-old O
japanese O
woman O
with O
severe O
scleroderma O
developed O
anemia B-ADR
and O
thrombocytopenia O
due O
to O
d-penicillamine O
( O
d-pen B-DRUG
) O
treatment O
, O
although O
the O
leukopenia O
was O
not O
markedly O
severe O

the O
syndrome O
of O
irreversible O
lithium-effectuated O
neurotoxicity B-ADR
( O
silent O

the O
spectrum O
of O
renal B-ADR
lesions I-ADR
occurring O
during O
antituberculous O
therapy O
, O
particularly O
in O
association O
with O
rifampin B-DRUG
, O
may O
be O
wider O
than O
previously O
suspected O

since O
the O
bronchospasm B-ADR
was O
relieved O
with O
discontinuation O
of O
propranolol B-DRUG
and O
supportive O
bronchodilator O
therapy O
, O
the O
bronchospasm B-ADR
was O
believed O
to O
be O
caused O
by O
propranolol B-DRUG

tacrolimus B-DRUG
( O
fk506 O
) O
, O
an O
immunosuppressant O
, O
has O
been O
associated O
with O
mutism B-ADR
in O
adults O
after O
liver O
transplant O

this O
article O
presents O
a O
patient O
with O
hypoparathyroidism O
who O
was O
treated O
with O
calcium B-DRUG
carbonate I-DRUG
and O
calcitriol O
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk-alkali B-ADR
syndrome I-ADR

doxycycline-induced O
hypoglycemia B-ADR
in O
a O
nondiabetic O
young O
man O

fatal B-ADR
acute I-ADR
tubular I-ADR
necrosis I-ADR
occurred O
in O
1 O
patient O
in O
whom O
intravesical O
formalin B-DRUG
was O
used O
to O
control O
massive O
persistent O
hemorrhage O
from O
radiation O
cystitis O

amiodarone B-DRUG
was O
discontinued O
, O
and O
thyrotoxicosis B-ADR
gradually O
abated O

this O
therapy O
was O
also O
complicated O
by O
warfarin-induced O
skin B-ADR
necrosis I-ADR

after O
5 O
days O
of O
treatment O
with O
il-2 B-DRUG
, O
the O
patient O
developed O
a O
hemorrhagic O
lesion O
that O
progressed O
to O
toxic O
epidermal O
necrolysis O
, O
as O
well O
as O
grade O
4 O
pancytopenia B-ADR

a O
61-year-old O
man O
developed O
clinical O
lupus O
syndrome O
with O
positive O
antinuclear O
antibody O
, O
positive O
lupus O
erythematosus O
( O
le O
) O
cell O
preparation O
, O
and O
diffuse B-ADR
proliferative I-ADR
glomerulonephritis I-ADR
following O
26 O
months O
of O
procainamide B-DRUG
therapy O

insulin-induced O
cardiac B-ADR
failure I-ADR

physicians O
should O
be O
cognizant O
of O
this O
potential O
complication O
in O
patients O
receiving O
thalidomide B-DRUG
or O
thalidomide-like O
drugs O
who O
present O
with O
fever B-ADR
and O
pulmonary O
infiltrates O
and O
fail O
to O
improve O
despite O
treatment O
with O
broad-spectrum O
antibiotics O

treatment O
of O
lithium B-DRUG
tremor B-ADR
with O
metoprolol O

the O
renal O
biopsy O
showed O
focal B-ADR
segmental I-ADR
glomerulosclerosis I-ADR
, O
which O
has O
only O
been O
previously O
reported O
in O
two O
cases O
of O
cml O
treated O
with O
ifnalpha B-DRUG

aseptic O
meningitis O
, O
hemolytic O
anemia O
, O
hepatitis B-ADR
, O
and O
orthostatic O
hypotension O
in O
a O
patient O
treated O
with O
trimethoprim-sulfamethoxazole O

a O
64-year-old O
man O
presented O
with O
proteinuria B-ADR
during O
postoperative O
interferon O
( O
ifn O
)- O
beta O
therapy O
against O
malignant O
melanoma O

a O
dapsone B-DRUG
hypersensitivity O
syndrome O
, O
consisting O
of O
fever O
, O
headache O
, O
nausea O
, O
vomiting B-ADR
, O
lymphadenopathy O
, O
hepatitis O
, O
hemolysis O
, O
leukopenia O
, O
and O
mononucleosis O
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

nicotinic B-DRUG
acid-induced O
fulminant B-ADR
hepatic I-ADR
failure I-ADR

myelodysplasia B-ADR
terminating O
in O
acute O
myeloid O
leukemia O
in O
a O
hairy O
cell O
leukemia O
patient O
treated O
with O
2-deoxycoformycin B-DRUG

methods O
: O
double-blind O
, O
placebo-controlled O
titrated O
oral O
challenges O
with O
pancreatic O
enzymes O
resulted O
in O
definite O
vomiting B-ADR
within O
1 O
to O
1.5 O
hours O
after O
challenges O
with O
viokase O
and O
pancrease B-DRUG
mt I-DRUG
16 I-DRUG
, O
but O
not O
with O
placebo O

magnesium B-DRUG
tocolysis O
as O
the O
cause O
of O
urinary B-ADR
calculus I-ADR
during O
pregnancy O

the O
case O
of O
a O
bipolar O
patient O
who O
developed O
thyrotoxicosis O
with O
severe B-ADR
exophthalmos I-ADR
while O
on O
lithium B-DRUG
therapy O
is O
described O

baclofen B-DRUG
withdrawal O
: O
a O
cause O
of O
prolonged O
fever B-ADR
in O
the O
intensive O
care O
unit O

we O
report O
here O
a O
case O
of O
ten B-ADR
after O
administration O
of O
ciprofloxacin B-DRUG

conclusions O
: O
spontaneous B-ADR
hemothorax I-ADR
is O
a O
rare O
phenomenon O
in O
conjunction O
with O
lmwh B-DRUG
but O
should O
be O
considered O
in O
cases O
of O
acute O
respiratory O
distress O
following O
commencement O
of O
lmwh B-DRUG

the O
present O
report O
suggests O
that O
clarithromycin O
coadministration O
induces O
increased B-ADR
plasma I-ADR
carbamazepine I-ADR
concentrations O
, O
which O
may O
result O
in O
carbamazepine B-DRUG
toxicity O

we O
report O
the O
first O
case O
of O
an O
acute O
flare O
of O
eosinophilic B-ADR
cystitis I-ADR
in O
a O
51-year-old O
woman O
after O
bladder O
instillation O
with O
dimethyl B-DRUG
sulfoxide I-DRUG
( O
dmso O
) O
for O
presumed O
interstitial O
cystitis O

the O
administration O
of O
" O
sweet B-DRUG
spirits I-DRUG
of I-DRUG
nitre I-DRUG
" O
( O
4 O
% O
ethyl O
nitrite O
ch3ch2ono O
in O
70 O
% O
ethyl O
alcohol O
) O
was O
followed O
by O
acute O
methemoglobinemia O
and O
severe O
anoxic O
metabolic O
acidosis O
in O
infant O
twins O
, O
methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died O
from O
the O
consequences O
of O
hypoxemia B-ADR

life-threatening O
acute B-ADR
hyponatraemia I-ADR
induced O
by O
low O
dose O
cyclophosphamide B-DRUG
and O
indomethacin O

a O
patient O
suffering O
from O
heparin-associated O
thrombocytopenia O
( O
hat O
) O
, O
recurrent B-ADR
arteriothromboses I-ADR
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin B-DRUG
is O
described O

tardive B-ADR
dyskinesia I-ADR
in O
2 O
patients O
treated O
with O
ziprasidone B-DRUG

a O
dapsone B-DRUG
hypersensitivity O
syndrome O
, O
consisting O
of O
fever O
, O
headache O
, O
nausea O
, O
vomiting O
, O
lymphadenopathy O
, O
hepatitis O
, O
hemolysis O
, O
leukopenia O
, O
and O
mononucleosis B-ADR
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

renal B-ADR
toxicities I-ADR
have O
been O
reported O
in O
less O
than O
one O
percent O
of O
the O
patients O
receiving O
ciprofloxacin B-DRUG
therapy O

dermatitis B-ADR
to O
captopril B-DRUG

its O
overall O
toxicity B-ADR
is O
considerably O
less O
compared O
to O
standard O
induction O
chemotherapy O
; O
however O
, O
it O
is O
associated O
with O
a O
high O
incidence O
of O
a O
potentially O
fatal O
symptom O
complex O
referred O
to O
as O
" O
retinoic B-DRUG
acid I-DRUG
syndrome. O
" O
this O
report O
describes O
a O
patient O
with O
apl O
who O
developed O
the O
syndrome O
a O
few O
weeks O
after O
initiating O
induction O
therapy O
with O
atra O
despite O
being O
treated O
for O
hyperleukocytosis O

reversible O
cholestasis O
with O
bile B-ADR
duct I-ADR
injury I-ADR
following O
azathioprine B-DRUG
therapy O

it O
also O
highlights O
a O
current O
major O
etiologic O
question O
, O
that O
is O
, O
whether O
and O
to O
what O
degree O
lead B-DRUG
exposure O
contributes O
to O
the O
development O
of O
hypertension O
, O
and O
raises O
the O
issue O
of O
whether O
lead-induced B-ADR
hypertension I-ADR
constitutes O
a O
subset O
of O
hypertension O
that O
is O
especially O
amenable O
to O
therapy O
with O
dietary O
calcium O

a O
patient O
with O
ulcerative O
colitis O
developed O
skin O
pigmentation O
and O
diffuse B-ADR
pulmonary I-ADR
shadowing I-ADR
without O
respiratory O
symptomatology O
, O
while O
taking O
sulfasalazine B-DRUG

therefore O
, O
although O
garenoxacin B-DRUG
reportedly O
causes O
fewer O
adverse O
reactions O
for O
cardiac B-ADR
rhythms I-ADR
than O
third-generation O
quinolone O
antibiotics O
, O
one O
must O
be O
cautious O
of O
the O
interference O
of O
other O
drugs O
during O
hypokalemia O
in O
order O
to O
prevent O
tdp O

we O
describe O
a O
case O
of O
disseminated O
muscular O
cysticercosis O
followed O
by O
myositis O
( O
fever O
, O
diffuse O
myalgia O
, O
weakness B-ADR
of I-ADR
the I-ADR
lower I-ADR
limbs I-ADR
, O
and O
inflammatory O
reaction O
around O
dying O
cysticerci O
) O
induced O
by O
praziquantel B-DRUG
therapy O
, O
an O
event O
not O
described O
previously O

objective O
: O
to O
describe O
the O
development O
of O
valproate-related O
reproductive B-ADR
endocrine I-ADR
disorders I-ADR
in O
women O
with O
epilepsy O

visual B-ADR
changes I-ADR
secondary O
to O
initiation O
of O
amiodarone B-DRUG
: O
a O
case O
report O
and O
review O
involving O
ocular O
management O
in O
cardiac O
polypharmacy O

monitoring O
of O
liver O
function O
tests O
should O
be O
mandatory O
in O
patients O
receiving O
high O
doses O
of O
cyproterone B-DRUG
acetate I-DRUG
; O
the O
drug O
should O
be O
withdrawn O
immediately O
if O
abnormal B-ADR
liver I-ADR
function I-ADR
tests I-ADR
are O
found O

toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
associated O
with O
interleukin-2 B-DRUG

three O
patients O
received O
respectively O
190 O
mg O
, O
175 O
mg O
, O
and O
196 O
mg O
of O
methotrexate B-DRUG
and O
developed O
bilateral B-ADR
pulmonary I-ADR
infiltrates I-ADR
without O
evidence O
of O
peripheral O
blood O
eosinophilia O

although O
there O
is O
one O
case O
report O
of O
cholesterol B-ADR
crystal I-ADR
embolization I-ADR
following O
t-pa B-DRUG
therapy O
with O
only O
extrarenal O
manifestations O
( O
n O
engl O
j O
med O
321:1270 O
, O
1989 O
) O
, O
this O
is O
the O
first O
reported O
case O
of O
atheroembolic O
acute O
renal O
failure O
following O
t-pa B-DRUG
therapy O

the O
case O
history O
and O
toxicological O
findings O
of O
an O
infant O
fatality B-ADR
involving O
pseudoephedrine O
, O
brompheniramine O
, O
and O
dextromethorphan B-DRUG
are O
presented O

terlipressin-induced O
ventricular B-ADR
arrhythmia I-ADR

methotrexate B-DRUG
( O
mtx O
) O
is O
a O
commonly O
used O
second O
line O
agent O
for O
ra O
, O
and O
there O
have O
been O
several O
recent O
reports O
of O
epstein-barr O
virus O
( O
ebv O
)- O
associated O
polyclonal O
b O
cell O
lymphoproliferative O
disorder O
in O
mtx-treated O
ra O
patients O

when O
sasp O
was O
changed O
to O
5-aminosalicylic O
acid O
( O
5-asa B-DRUG
) O
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he O
developed O
weakness O
and O
atrophy O
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening B-ADR
of I-ADR
the I-ADR
dysesthesia I-ADR
in O
his O
legs O
and O
gait O
disturbance O

nitrendipine B-DRUG
is O
an O
experimental O
calcium O
channel O
blocking O
agent O
that O
also O
appears O
to O
cause O
the O
side O
effect O
of O
drug-induced O
gingival B-ADR
hyperplasia I-ADR

an O
association O
of O
granulocytopenia O
, O
eosinophilia O
, O
skin B-ADR
reaction I-ADR
and O
hepatitis O
during O
propylthiouracil B-DRUG
( O
ptu O
) O
therapy O
for O
thyrotoxicosis O
in O
a O
47 O
year O
old O
black O
female O
is O
reported O

a O
case O
report O
of O
a O
patient O
with O
probable O
cisplatin B-DRUG
and O
bleomycin-induced O
tma B-ADR
is O
presented O

all O
developed O
mucocutaneous B-ADR
side I-ADR
effects I-ADR
within O
20 O
weeks O
of O
beginning O
im O
gold B-DRUG
therapy O
, O
at O
a O
time O
when O
ra O
had O
improved O
markedly O
compared O
to O
pretreatment O
status O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia B-ADR
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole B-DRUG
( O
smx O
) O
treatment O

life-threatening O
acute B-ADR
hyponatraemia I-ADR
induced O
by O
low O
dose O
cyclophosphamide O
and O
indomethacin B-DRUG

hypersensitivity O
to O
aspirin B-DRUG
can O
be O
manifested O
as O
acute O
asthma O
, O
urticaria O
and O
/ O
or O
angioedema O
, O
or O
a O
systemic B-ADR
anaphylactoid I-ADR
reaction I-ADR

we O
consider O
asterixis B-ADR
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity O
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium O
or O
clozapine B-DRUG
are O
used O
in O
combination O
with O
cbz O

the O
authors O
intend O
to O
carry O
out O
a O
case-control O
study O
on O
patients O
treated O
with O
tamoxifen B-DRUG
for O
breast O
carcinoma O
to O
reveal O
the O
possible O
presence O
of O
endometrial B-ADR
carcinoma I-ADR

patients O
from O
endemic O
areas O
referred O
to O
transplant O
centers O
may O
be O
at O
high O
risk O
for O
disseminated B-ADR
histoplasmosis I-ADR
when O
treated O
with O
long-term O
prednisone B-DRUG
for O
graft-versus-host O
disease O

uveitis B-ADR
during O
treatment O
of O
disseminated O
mycobacterium O
avium-intracellulare O
complex O
infection O
with O
the O
combination O
of O
rifabutin B-DRUG
, O
clarithromycin O
and O
ethambutol O

keratitis B-ADR
in O
methamphetamine B-DRUG
abusers O

adverse O
effects O
of O
amiodarone B-DRUG
including O
pulmonary O
toxicity O
, O
hepatotoxicity O
, O
aggravation B-ADR
of I-ADR
arrhythmia I-ADR
, O
and O
thyroid O
diseases O
are O
well O
understood O

seven O
of O
the O
eight O
cases O
of O
acute B-ADR
leukemia I-ADR
occurred O
in O
a O
series O
of O
553 O
patients O
treated O
with O
treosulfan B-DRUG
for O
ovarian O
cancer O
in O
the O
period O
from O
1970 O
to O
1977 O
and O
followed O
closely O
for O
a O
total O
of O
1159 O
patient-years O
up O
to O
february O
1978 O

early O
peritoneal O
dialysis O
has O
not O
previously O
been O
reported O
for O
lisinopril B-DRUG
induced O
multiorgan B-ADR
failure I-ADR

after O
a O
second O
dose O
of O
metoclopramide B-DRUG
, O
these O
symptoms O
recurred O
and O
were O
associated O
with O
confusion O
, O
agitation O
, O
fever O
, O
diaphoresis B-ADR
, O
tachypnea O
, O
tachycardia O
, O
and O
hypertension O

a O
56-year-old O
woman O
with O
scleroderma O
developed O
rapidly O
progressive O
glomerulonephritis O
with O
epithelial O
crescents O
associated O
with O
hemoptysis B-ADR
after O
27 O
months O
of O
d-penicillamine B-DRUG
therapy O
and O
a O
cumulative O
dose O
of O
1,200 O
g O

it O
occasionally O
accompanies O
the O
heparin-associated O
thrombocytopenia O
and O
thrombosis B-ADR
syndrome I-ADR

tremor B-ADR
: O
a O
newly O
described O
adverse O
event O
with O
long-term O
itraconazole B-DRUG
therapy O

these O
are O
the O
first O
reported O
patients O
to O
show O
mferg O
abnormalities O
that O
correspond O
to O
bitemporal B-ADR
visual I-ADR
field I-ADR
defects I-ADR
and O
add O
to O
the O
growing O
evidence O
that O
ethambutol B-DRUG
damages O
the O
retina O

methotrexate-induced O
leukoencephalopathy B-ADR
is O
treatable O
with O
high-dose O
folinic O
acid O
: O
a O
case O
report O
and O
analysis O
of O
the O
literature O

study O
design O
: O
case O
report O
of O
a O
31-year-old O
woman O
who O
presented O
with O
toxic B-ADR
myelopathy I-ADR
due O
to O
intrathecal O
administration O
of O
doxorubicin B-DRUG

typically O
, O
drug-induced O
neutropenia B-ADR
occurs O
in O
a O
patient O
receiving O
a O
semisynthetic O
penicillin B-DRUG
for O
two O
weeks O
or O
more O

there O
is O
no O
consensus O
on O
the O
treatment O
of O
ticlopidine-induced O
marrow B-ADR
aplasia I-ADR

the O
possibility O
of O
phenytoin B-DRUG
hypersensitivity O
reactions O
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever O
, O
rash B-ADR
, O
and O
lymphadenopathy O

hepatotoxicity B-ADR
associated O
with O
choline B-DRUG
magnesium I-DRUG
trisalicylate I-DRUG
: O
case O
report O
and O
review O
of O
salicylate-induced O
hepatotoxicity O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate O
with O
folinic B-DRUG
acid I-DRUG
rescue O
, O
resulted O
in O
the O
' O
phosphate B-ADR
shower I-ADR
syndrome I-ADR
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

however O
, O
follow-up O
revealed O
that O
gestational O
diabetes O
when O
associated O
with O
norethisterone B-DRUG
had O
a O
lesser O
risk O
of O
emerging O
diabetes B-ADR
mellitus I-ADR
and O
impaired O
glucose O
tolerance O

angioedema B-ADR
and O
maculopapular O
eruptions O
associated O
with O
carbamazepine B-DRUG
administration O

during O
analysis O
of O
28 O
patients O
receiving O
cap B-DRUG
with O
concomitant O
radiation O
( O
xrt O
) O
for O
pancreatic O
cancer O
( O
resected O
or O
locally O
advanced O
) O
, O
two O
patients O
developed O
signs O
and O
symptoms O
consistent O
with O
peripheral B-ADR
neuropathy I-ADR

unaccountable O
severe O
hypercalcemia B-ADR
in O
a O
patient O
treated O
for O
hypoparathyroidism O
with O
dihydrotachysterol B-DRUG

purple O
glove O
syndrome O
, O
named O
for O
its O
distinctive O
purple O
discoloration O
and O
swelling B-ADR
of I-ADR
the I-ADR
hands I-ADR
in O
the O
distribution O
of O
a O
glove O
, O
is O
an O
uncommon O
complication O
of O
intravenous O
phenytoin B-DRUG
administration O
through O
small O
dorsal O
veins O
of O
the O
hands O

to O
our O
knowledge O
, O
these O
cases O
are O
the O
first O
published O
reports O
of O
lovastatin-induced O
rhabdomyolysis B-ADR
associated O
with O
azithromycin O
and O
clarithromycin B-DRUG

rofecoxib B-DRUG
, O
used O
for O
dysmenorrhea O
, O
caused O
a O
herpetiform B-ADR
fixed I-ADR
drug I-ADR
eruption I-ADR
predominantly O
involving O
the O
lips O
with O
classic O
clinical O
and O
histological O
findings O
in O
a O
red-brown O
lesion O
on O
the O
dorsal O
hand O

in O
one O
instance O
a O
systemic O
hypoglycemic O
reaction O
resulting O
in O
head B-ADR
trauma I-ADR
and O
confusion O
ended O
in O
an O
emegency O
hospital O
admission O
following O
the O
substitution O
of O
acetohexamide B-DRUG
for O
acetazolamide O

intracranial B-ADR
haemorrhage I-ADR
from O
a O
meningioma O
in O
a O
patient O
receiving O
aspirin B-DRUG
prophylaxis O
: O
a O
case O
report O

the O
occurrence O
of O
neuromuscular B-ADR
blockade I-ADR
and O
the O
resulting O
potentiation O
of O
muscle O
relaxants O
during O
magnesium B-DRUG
sulfate I-DRUG
( O
mgso4 O
) O
administration O
is O
well O
known O

the O
patient O
was O
enrolled O
in O
a O
weight-loss O
clinic O
, O
and O
his O
diabetes O
medications O
were O
adjusted.subsequently O
, O
olanzapine B-DRUG
was O
discontinued O
because O
of O
weight B-ADR
gain I-ADR
and O
uncontrolled O
diabetes O

we O
report O
the O
case O
of O
a O
17-year-old O
male O
who O
developed O
chest O
pain O
, O
elevated B-ADR
cardiac I-ADR
biomarkers I-ADR
, O
and O
acute O
left O
ventricular O
dysfunction O
following O
a O
single O
dose O
of O
methylphenidate B-DRUG

adriamycin-induced O
cardiomyopathy O
aggravated O
by O
cis-platinum B-DRUG
nephrotoxicity B-ADR
requiring O
dialysis O

noncardiogenic B-ADR
pulmonary I-ADR
edema I-ADR
during O
intrabiliary O
infusion O
of O
mono-octanoin B-DRUG

levofloxacin B-DRUG
induced O
polymorphic B-ADR
ventricular I-ADR
tachycardia I-ADR
with O
normal O
qt O
interval O

we O
present O
two O
cases O
of O
nitrofurantoin-induced O
pulmonary O
toxicity O
in O
which O
the O
initial O
hrct O
showed O
a O
widespread O
reticular O
pattern O
and O
associated O
distortion B-ADR
of I-ADR
the I-ADR
lung I-ADR
parenchyma I-ADR
, O
thought O
to O
represent O
established O
fibrosis O

this O
report O
presents O
a O
case O
of O
acute B-ADR
lung I-ADR
injury I-ADR
developing O
within O
hours O
after O
administration O
of O
mefloquine B-DRUG
for O
a O
low-level O
plasmodium O
falciparum O
malaria O
, O
which O
was O
persistent O
despite O
halofantrine O
therapy O

we O
report O
here O
a O
rare O
case O
of O
pleuropericarditis B-ADR
due O
to O
methotrexate B-DRUG

carboplatin B-DRUG
hypersensitivity O
presenting O
as O
coronary B-ADR
vasospasm I-ADR
- O
a O
case O
report O

since O
the O
thrombocyte B-ADR
count I-ADR
started I-ADR
to I-ADR
increase I-ADR
immediately O
after O
initiation O
and O
dropped O
immediately O
after O
discontinuation O
of O
ciprofloxacin B-DRUG
and O
tazobactam O
/ O
piperacillin O
and O
all O
other O
drugs O
were O
discontinued O
already O
before O
or O
were O
started O
after O
the O
nadir O
of O
the O
thrombocyte O
count O
, O
these O
two O
antibiotics O
were O
regarded O
causative O

we O
report O
a O
44-year-old O
woman O
with O
t-mds O
( O
refractory B-ADR
anemia I-ADR
with I-ADR
excess I-ADR
blasts I-ADR
) O
following O
treatment O
of O
recurrent O
anaplastic O
astrocytoma O
with O
temozolomide B-DRUG
( O
tmz O

i O
saw O
two O
patients O
with O
kala-azar O
resistant O
to O
sodium O
stibogluconate O
who O
developed O
cardiac B-ADR
arrest I-ADR
after O
amphotericin B-DRUG
infusion O
( O
in O
spite O
of O
tolerating O
a O
test O
dose O

we O
present O
a O
case O
report O
of O
a O
patient O
who O
developed O
a O
prolonged B-ADR
qt I-ADR
while O
being O
treated O
with O
oral O
methadone B-DRUG
for O
a O
chronic O
pain O
syndrome O

the O
rash B-ADR
seen O
in O
this O
patient O
, O
who O
was O
treated O
with O
cephalexin B-DRUG
, O
may O
be O
similar O
to O
the O
rash B-ADR
seen O
with O
ampicillin O
treatment O
of O
patients O
with O
infectious O
mononucleosis O

pamidronate O
therapy O
should O
be O
considered O
in O
patients O
with O
hypercalcemia O
secondary O
to O
acute B-ADR
vitamin I-ADR
d I-ADR
poisoning I-ADR

acute B-ADR
syphilitic I-ADR
posterior I-ADR
placoid I-ADR
chorioretinitis I-ADR
following O
intravitreal O
triamcinolone B-DRUG
acetonide I-DRUG
injection O

even O
after O
a O
strict O
warning O
, O
he O
took O
another O
quinine B-DRUG
tablet O
that O
evening O
, O
which O
triggered O
his O
fifth O
episode O
of O
severe O
thrombocytopenia B-ADR
, O
and O
confirmed O
the O
etiology O
of O
quinine-induced O
thrombocytopenia B-ADR

disulfiram B-DRUG
encephalopathy B-ADR
as O
a O
cause O
of O
the O
catatonia O
syndrome O

we O
report O
three O
cases O
of O
amiodarone-induced O
torsades B-ADR
de I-ADR
pointe I-ADR

objective O
: O
to O
report O
a O
case O
of O
carbamazepine B-ADR
toxicity I-ADR
following O
the O
administration O
of O
oxybutynin O
and O
dantrolene B-DRUG

progressive B-ADR
anemia I-ADR
following O
combination O
therapy O
with O
interferon-alpha B-DRUG
and O
interleukin-2 O
in O
a O
patient O
with O
metastatic O
renal O
cell O
carcinoma O

we O
report O
the O
first O
case O
of O
doxycycline-induced O
hypoglycemia B-ADR
in O
a O
young O
nondiabetic O
man O

case O
report O
: O
we O
describe O
here O
a O
case O
of O
a O
60 O
year O
old O
female O
that O
experienced O
a O
relapse O
of O
symptomatic B-ADR
hyperlactatemia I-ADR
after O
being O
switched O
from O
stavudine B-DRUG
to O
zidovudine O
and O
how O
the O
case O
was O
managed O
at O
the O
infectious O
diseases O
institute O
, O
kampala O
, O
uganda O

acute B-ADR
renal I-ADR
failure I-ADR
during O
lisinopril O
and O
losartan B-DRUG
therapy O
for O
proteinuria O

objective O
: O
we O
report O
a O
patient O
who O
developed O
neutropenia O
on O
clozapine B-DRUG
, O
but O
behind O
the O
cell O
count O
decrease O
showed O
to O
be O
a O
diurnal B-ADR
variation I-ADR
of I-ADR
the I-ADR
white I-ADR
blood I-ADR
cells I-ADR
( O
wbc O

results O
: O
both O
cases O
presented O
here O
describe O
corneal B-ADR
ulcers I-ADR
that O
persisted O
and O
showed O
signs O
of O
worsening O
during O
weeks O
of O
frequent O
topical O
dosing O
with O
moxifloxacin B-DRUG

azathioprine-induced O
myelosuppression B-ADR
due O
to O
thiopurine O
methyltransferase O
deficiency O
in O
a O
patient O
with O
autoimmune O
hepatitis O

we O
report O
the O
first O
case O
of O
an O
acute O
flare O
of O
eosinophilic B-ADR
cystitis I-ADR
in O
a O
51-year-old O
woman O
after O
bladder O
instillation O
with O
dimethyl O
sulfoxide O
( O
dmso B-DRUG
) O
for O
presumed O
interstitial O
cystitis O

second O
cancers O
including O
various O
types O
of O
hematological B-ADR
malignancy I-ADR
have O
been O
reported O
in O
patients O
with O
hairy O
cell O
leukemia O
treated O
with O
chemotherapy O
or O
interferon B-DRUG
alfa I-DRUG

although O
it O
is O
difficult O
to O
be O
certain O
of O
the O
direct O
link O
of O
amiodarone B-DRUG
on O
the O
basis O
of O
a O
single O
case O
, O
it O
is O
reasonable O
to O
presume O
that O
this O
histopathology O
is O
associated O
with O
amiodarone-induced O
hypothyroidism B-ADR
and O
that O
involution O
changes O
represent O
the O
hypofunctional O
status O
of O
this O
drug-induced O
disorder O

neurological B-ADR
side I-ADR
effects I-ADR
in O
two O
patients O
receiving O
gold B-DRUG
injections O
for O
rheumatoid O
arthritis O

intravenous O
diazepam B-DRUG
exacerbated O
the O
seizures B-ADR

because O
etoposide-induced O
pulmonary B-ADR
toxicity I-ADR
is O
an O
uncommon O
but O
serious O
adverse O
event O
, O
clinicians O
must O
be O
vigilant O
about O
the O
possibility O
of O
it O
, O
so O
that O
the O
optimal O
treatment O
can O
start O
as O
soon O
as O
possible O

paradoxical B-ADR
cerebral I-ADR
cortical I-ADR
hyperexcitability I-ADR
following O
flupirtine B-DRUG
overdose O

she O
received O
an O
accidental O
450-mg O
bolus O
injection O
of O
morphine B-DRUG
intrathecally O
and O
developed O
hypertension O
, O
status O
epilepticus O
, O
intracerebral B-ADR
hemorrhage I-ADR
, O
and O
respiratory O
failure O

recent O
reports O
have O
shown O
that O
decadron O
( O
dexamethasone O
; O
merck O
sharp O
& O
dohme O
, O
west O
point O
, O
pa O
) O
has O
a O
significant O
antiemetic O
effect O
on O
cisplatin-induced O
vomiting B-ADR

fatal B-ADR
pulmonary I-ADR
fibrosis I-ADR
associated O
with O
bcnu B-DRUG
: O
the O
relative O
role O
of O
platelet-derived O
growth O
factor-b O
, O
insulin-like O
growth O
factor O
i O
, O
transforming O
growth O
factor-beta1 O
and O
cyclooxygenase-2 O

prolongation B-ADR
of I-ADR
the I-ADR
qt I-ADR
interval I-ADR
observed O
in O
a O
japanese O
patient O
with O
vivax O
malaria O
following O
treatment O
with O
halofantrine B-DRUG

anticonvulsant B-ADR
hypersensitivity I-ADR
syndrome I-ADR
associated O
with O
bellamine B-DRUG
s I-DRUG
, O
a O
therapy O
for O
menopausal O
symptoms O

background O
: O
reproductive O
endocrine O
disorders O
characterized O
by O
menstrual O
disorders O
, O
polycystic O
ovaries O
, O
and O
hyperandrogenism B-ADR
seem O
to O
be O
common O
among O
women O
treated O
with O
sodium B-DRUG
valproate I-DRUG
for O
epilepsy O

interstitial B-ADR
pneumonitis I-ADR
associated O
with O
sirolimus B-DRUG
: O
a O
dilemma O
for O
lung O
transplantation O

we O
present O
four O
cases O
in O
which O
the O
use O
of O
heparin B-DRUG
was O
associated O
with O
hyperkalemia B-ADR
and O
discuss O
the O
pathophysiology O

first O
case O
of O
ivermectin-induced O
severe B-ADR
hepatitis I-ADR

a O
patient O
suffering O
from O
heparin-associated O
thrombocytopenia O
( O
hat O
) O
, O
recurrent O
arteriothromboses O
, O
and O
acute B-ADR
renal I-ADR
failure I-ADR
after O
treatment O
with O
standard O
heparin B-DRUG
is O
described O

encephalopathy O
and O
seizures B-ADR
induced O
by O
intravesical O
alum B-DRUG
irrigations O

we O
report O
a O
patient O
with O
pulmonary O
adenocarcinoma O
complicated O
by O
the O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
secretion I-ADR
of I-ADR
antidiuretic I-ADR
hormone I-ADR
( O
siadh O
) O
following O
systemic O
chemotherapy O
with O
cisplatin O
( O
cddp O
) O
and O
vindesine O
( O
vds B-DRUG

the O
first O
patient O
is O
undergoing O
hemodialysis O
and O
, O
though O
responding O
to O
sunitinib B-DRUG
, O
is O
having O
significant O
fatigue B-ADR
and O
hypertension O

clinical B-ADR
, I-ADR
spectroscopic I-ADR
, I-ADR
and I-ADR
imaging I-ADR
abnormalities I-ADR
resolved O
with O
discontinuation O
of O
metronidazole B-DRUG

case O
report O
: O
dapsone B-DRUG
hypersensitivity B-ADR
syndrome I-ADR
associated O
with O
treatment O
of O
the O
bite O
of O
a O
brown O
recluse O
spider O

a O
teenage O
girl O
with O
crescentic O
glomerulonephritis O
had O
antineutrophil B-ADR
cytoplasmic I-ADR
antibody I-ADR
( O
anca O
) O
detected O
after O
she O
had O
received O
propylthiouracil B-DRUG
( O
ptu O
) O
for O
hyperthyroidism O
without O
cutaneous O
vasculitis O

a O
patient O
with O
a O
large O
hydatid O
cyst O
of O
the O
left O
lobe O
of O
the O
liver O
developed O
metabolic B-ADR
acidosis I-ADR
following O
rather O
liberal O
use O
of O
cetrimide-chlorhexidine O
solution O
as O
a O
scolicidal O
agent O

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis B-ADR
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

although O
visual B-ADR
hallucinations I-ADR
have O
not O
been O
reported O
as O
an O
adverse O
effect O
of O
this O
agent O
, O
we O
describe O
three O
patients O
who O
experienced O
complex O
visual B-ADR
hallucinations I-ADR
and O
altered O
mental O
status O
after O
zonisamide B-DRUG
treatment O
was O
begun O
or O
its O
dosage O
increased O

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea O
, O
stomatitis O
, O
mucositis O
, O
myelosuppression B-ADR
, O
neurotoxicity O
) O
to O
standard O
doses O
of O
5-fu B-DRUG

sixteen O
hours O
after O
the O
first O
administration O
of O
ifn B-DRUG
, O
ifn B-DRUG
was O
suspended O
by O
the O
symptoms O
of O
congestive B-ADR
heart I-ADR
failure I-ADR
( O
chf O

transient B-ADR
left I-ADR
homonymous I-ADR
hemianopsia I-ADR
and O
encephalopathy O
following O
treatment O
of O
testicular O
carcinoma O
with O
cisplatinum O
, O
vinblastine B-DRUG
, O
and O
bleomycin O

two O
patients O
treated O
with O
alprazolam B-DRUG
had O
histories O
suggestive O
of O
a O
bipolar O
disorder O
and O
developed O
lithium-responsive O
manic B-ADR
episodes I-ADR

it O
is O
tempting O
to O
speculate O
that O
interferon B-DRUG
alpha I-DRUG
may O
be O
involved O
in O
the O
pathogenesis O
of O
lichen B-ADR
nitidus I-ADR

results O
: O
brimonidine B-DRUG
was O
observed O
to O
cause O
iop B-ADR
elevation I-ADR
, O
confirmed O
on O
rechallenge O
, O
scoring O
8 O
( O
strong O
probability O
) O
on O
an O
adverse O
drug O
reaction O
probability O
score O

they O
continued O
to O
rise O
for O
five O
more O
days O
before O
salicylate B-DRUG
hepatotoxicity B-ADR
was O
suspected O

a O
52-year-old O
, O
white O
female O
developed O
low-grade O
fever O
, O
cough O
, O
and O
dyspnea B-ADR
after O
8 O
weeks O
treatment O
with O
sodium B-DRUG
aurothiomalate I-DRUG
for O
rheumatoid O
arthritis O

piloerection B-ADR
induced O
by O
replacing O
fluvoxamine O
with O
milnacipran B-DRUG

ifosfamide-induced O
nonconvulsive B-ADR
status I-ADR
epilepticus I-ADR

vancomycin-induced O
vasculitis B-ADR

correction O
of O
serum O
electrolyte O
imbalance O
prevents O
cardiac B-ADR
arrhythmia I-ADR
during O
amphotericin B-DRUG
b I-DRUG
administration O

the O
sub-conjunctival B-ADR
haematoma I-ADR
in O
a O
patient O
receiving O
warfarin B-DRUG
can O
pose O
a O
significant O
management O
challenge O

purpose O
: O
we O
report O
an O
unusual O
paradoxical B-ADR
effect I-ADR
of O
brimonidine B-DRUG

conclusions O
: O
in O
these O
3 O
cases O
, O
the O
unique O
positive O
ocular O
finding O
was O
corneal B-ADR
endothelial I-ADR
deposits I-ADR
, O
which O
may O
be O
related O
to O
the O
use O
of O
rifabutin B-DRUG

this O
is O
the O
first O
report O
of O
an O
adverse B-ADR
effect I-ADR
of I-ADR
fetal I-ADR
renal I-ADR
circulation I-ADR
by O
maternal O
ingestion O
of O
nimesulide B-DRUG

we O
report O
a O
case O
of O
acne B-ADR
fulminans I-ADR
occurring O
during O
treatment O
with O
13-cis-retinoic B-DRUG
acid I-DRUG
for O
cystic O
acne O

severe O
adenovirus O
pneumonia O
( O
avp B-ADR
) O
following O
infliximab B-DRUG
infusion O
for O
the O
treatment O
of O
crohn O
's O
disease O

we O
describe O
a O
patient O
with O
extranodal O
non-hodgkin O
lymphoma O
who O
developed O
systemic B-ADR
candidiasis I-ADR
after O
treatment O
with O
a O
cyclophosphamide-based O
chemotherapy O
regimen O

thus O
, O
an O
immunological O
mechanism O
might O
be O
involved O
in O
the O
mechanism O
of O
pirmenol-induced O
qt O
prolongation O
and O
t B-ADR
wave I-ADR
inversion I-ADR
on O
the O
electrocardiogram O

lichen O
planus O
and O
acne B-ADR
provoked O
by O
gold B-DRUG

in O
these O
patients O
, O
long-acting O
octreotide B-DRUG
may O
trigger O
serious B-ADR
hypoglycemia I-ADR

moreover O
, O
treatment O
with O
immunosuppressive O
drugs O
such O
as O
cyclosporine B-DRUG
, O
cisplatin O
, O
tacrolimus O
, O
and O
interferon-alpha O
can O
induce O
a O
condition O
resembling O
rpls B-ADR

dose-dependent O
olanzapine-associated O
leukopenia B-ADR
: O
three O
case O
reports O

neuropathy B-ADR
is O
a O
significant O
side O
effect O
of O
thalidomide B-DRUG
therapy O
, O
which O
may O
limit O
its O
clinical O
use O

conclusions O
: O
the O
increasing O
prevalence O
of O
type O
2 O
diabetes O
and O
its O
treatment O
with O
metformin B-DRUG
might O
result O
in O
more O
cases O
of O
lactic B-ADR
acidosis I-ADR

one O
patient O
with O
systemic O
lupus O
erythematosus O
developed O
erythema B-ADR
multiforme I-ADR
after O
taking O
griseofulvin B-DRUG

a O
34-year-old O
lady O
developed O
a O
constellation O
of O
dermatitis O
, O
fever O
, O
lymphadenopathy O
and O
hepatitis B-ADR
, O
beginning O
on O
the O
17th O
day O
of O
a O
course O
of O
oral O
sulphasalazine B-DRUG
for O
sero-negative O
rheumatoid O
arthritis O

pleuropulmonary B-ADR
changes I-ADR
during O
treatment O
of O
parkinson O
's O
disease O
with O
a O
long-acting O
ergot O
derivative O
, O
cabergoline B-DRUG

conclusions O
: O
it O
is O
probable O
that O
foscarnet B-DRUG
contributed O
to O
the O
electrolyte B-ADR
disorders I-ADR
and O
symptomatology O
in O
this O
patient O

haemolytic-uraemic B-ADR
syndrome I-ADR
complicating O
long-term O
mitomycin B-DRUG
c I-DRUG
and O
5-fluorouracil O
therapy O
for O
gastric O
carcinoma O

we O
report O
( O
to O
our O
knowledge O
, O
for O
the O
first O
time O
in O
a O
child O
) O
the O
emergence O
of O
psychosis B-ADR
in O
a O
12-year O
old O
white O
girl O
with O
an O
increased O
efavirenz B-DRUG
concentration O
and O
heterozygous O
gene O
polymorphism O
of O
the O
cyp2b6-g516t O

when O
cyanamide-treated O
alcoholics O
relapse O
into O
drinking O
, O
more O
severe O
inflammation B-ADR
develops O
in O
the O
liver O

the O
nz O
pharmacovigilance O
centre O
has O
received O
7 O
additional O
reports O
of O
severe B-ADR
infections I-ADR
in O
patients O
with O
ra O
taking O
leflunomide B-DRUG

we O
describe O
six O
patients O
who O
developed O
tardive B-ADR
dyskinesia I-ADR
after O
treatment O
with O
sulpiride B-DRUG
for O
depression O
or O
gastrointestinal O
symptoms O

on O
the O
second O
day O
of O
hospitalization O
, O
it O
was O
noted O
that O
the O
patient O
's O
dyspnea O
and O
sinus B-ADR
bradycardia I-ADR
could O
be O
related O
to O
a O
recent O
increase O
in O
his O
timolol B-DRUG
dosage O

isoniazid-induced O
anaphylaxis B-ADR

a O
37-year-old O
woman O
with O
relapsing O
invasive O
vertebral O
aspergillosis O
received O
intravenous O
vrc B-DRUG
and O
developed O
angio-oedema B-ADR
10 O
days O
after O
starting O
therapy O

discussion O
: O
the O
occurrence O
of O
priapism B-ADR
in O
our O
patient O
was O
related O
to O
zuclopenthixol B-DRUG

ethambutol B-DRUG
toxicity O
manifesting O
as O
acute B-ADR
onset I-ADR
psychosis I-ADR

methods O
: O
a O
68-year-old O
man O
developed O
intense O
conjunctival O
hyperemia O
and O
cystoid O
macula O
edema O
after O
switching O
from O
latanoprost B-DRUG
to O
bimatoprost O
9 O
months O
after O
cataract O
surgery O
in O
an O
eye O
at O
low-risk O
for O
this O
cystoid B-ADR
macular I-ADR
edema I-ADR

we O
describe O
a O
case O
of O
disseminated O
muscular O
cysticercosis O
followed O
by O
myositis O
( O
fever O
, O
diffuse B-ADR
myalgia I-ADR
, O
weakness O
of O
the O
lower O
limbs O
, O
and O
inflammatory O
reaction O
around O
dying O
cysticerci O
) O
induced O
by O
praziquantel B-DRUG
therapy O
, O
an O
event O
not O
described O
previously O

carbamazepine B-ADR
toxicity I-ADR
induced O
by O
clarithromycin B-DRUG
coadministration O
in O
psychiatric O
patients O

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness O
, O
difficulty O
with O
speech O
, O
weakness O
, O
and O
itching B-ADR
on I-ADR
the I-ADR
trunk I-ADR
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

paroxysmal B-ADR
supraventricular I-ADR
tachycardia I-ADR
during O
treatment O
with O
cisplatin O
and O
etoposide B-DRUG
combination O

cutaneous B-ADR
sarcoidosis I-ADR
during O
interferon B-DRUG
alfa I-DRUG
and O
ribavirin O
treatment O
of O
hepatitis O
c O
virus O
infection O
: O
two O
cases O

we O
present O
the O
case O
of O
a O
patient O
who O
had O
undergone O
cholecystectomy O
previously O
, O
but O
in O
whom O
morphine B-DRUG
given O
in O
the O
emergency O
department O
precipitated O
pain B-ADR
consistent O
with O
biliary O
colic O
; O
the O
pain B-ADR
resolved O
promptly O
after O
administration O
of O
naloxone O

our O
cases O
constitute O
the O
most O
severe O
cases O
of O
benzarone B-DRUG
hepatotoxicity O
reported O
so O
far O
, O
and O
comprise O
the O
first O
cases O
of O
( O
sub O
) O
fulminant O
hepatitis O
and O
cirrhosis B-ADR
related O
to O
benzarone B-DRUG

restless B-ADR
legs I-ADR
syndrome I-ADR
and O
periodic O
limb O
movements O
during O
sleep O
probably O
associated O
with O
olanzapine B-DRUG

despite O
a O
very O
low O
complication O
rate O
, O
several O
severe B-ADR
arterial I-ADR
thrombotic I-ADR
events I-ADR
have O
been O
reported O
following O
thrombin B-DRUG
injection O
of O
pseudoaneurysms O

we O
report O
a O
case O
of O
a O
young O
woman O
with O
sle O
and O
thrombocytopenia O
, O
who O
developed O
severe O
perspiration O
, O
headache O
, O
and O
seizure B-ADR
after O
receiving O
cyclosporine B-DRUG

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia B-ADR
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic O
syndrome O
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

eleven O
patients O
developed O
infection O
requiring O
hospitalization O
while O
taking O
leflunomide B-DRUG
including O
: O
lower B-ADR
respiratory I-ADR
tract I-ADR
infections I-ADR
( O
3 O
) O
, O
cellulitis O
( O
2 O
) O
, O
disseminated O
herpes O
zoster O
( O
2 O
) O
, O
probable O
tb O
liver O
( O
1 O
) O
, O
abdominal O
sepsis O
( O
1 O
) O
, O
mycotic O
aneurysm O
( O
1 O
) O
and O
gastroenteritis O
( O
1 O

niflumic B-DRUG
acid-induced O
skeletal B-ADR
fluorosis I-ADR
: O
iatrogenic O
disease O
or O
therapeutic O
perspective O
for O
osteoporosis O

possible O
recurrence O
of O
amiodarone B-DRUG
pulmonary B-ADR
toxicity I-ADR
following O
corticosteroid O
therapy O

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
that O
demonstrates O
the O
occurrence O
of O
fever B-ADR
with O
low-dose O
amifostine B-DRUG
therapy O
without O
the O
manifestation O
of O
accompanying O
rash O
or O
hypotension O

myoglobinuria O
and O
acute B-ADR
renal I-ADR
failure I-ADR
associated O
with O
intravenous O
vasopressin B-DRUG
infusion O

with O
itraconazole B-DRUG
, O
hepatotoxic B-ADR
reactions O
have O
only O
very O
rarely O
been O
reported O
, O
and O
histologic O
data O
are O
lacking O

he O
had O
an O
immediate O
hypersensitivity O
reaction O
during O
the O
initiation O
of O
the O
mtx B-DRUG
infusion O
with O
diffuse O
urticaria O
, O
facial O
swelling O
, O
cough B-ADR
, O
and O
chest O
tightness O

the O
authors O
describe O
a O
case O
of O
valvular B-ADR
heart I-ADR
disease I-ADR
in O
a O
48-year-old O
woman O
receiving O
benfluorex B-DRUG
( O
150 O
mg O
t.i.d. O
for O
8 O
years O
) O
and O
leading O
to O
surgical O
mitral O
valve O
replacement O

in O
patients O
with O
swallowing O
dysfunction O
and O
pneumonia O
, O
a O
history O
of O
mineral B-DRUG
oil I-DRUG
use O
should O
be O
obtained O
and O
a O
diagnosis O
of O
elp B-ADR
should O
be O
considered O
in O
the O
differential O
diagnoses O
if O
mineral B-DRUG
oil I-DRUG
use O
has O
occurred O

persisent B-ADR
ocular I-ADR
hypertension I-ADR
following O
intravitreal O
ranibizumab B-DRUG

poorly O
controlled O
hypertension O
in O
a O
painter O
with O
chronic O
lead B-ADR
toxicity I-ADR

we O
report O
here O
a O
26-year-old O
female O
with O
diffuse O
large O
b-cell O
lymphoma O
who O
died O
of O
severe B-ADR
pulmonary I-ADR
fibrosis I-ADR
81 O
days O
after O
the O
administration O
of O
high-dose O
bcnu B-DRUG
( O
600 O
mg O
/ O
m2 O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
polyserositis B-ADR
( O
pericardial O
effusion O
, O
pleural O
effusion O
, O
and O
pericarditis O
) O
after O
being O
started O
on O
clozapine B-DRUG
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine B-DRUG

however O
, O
recurrent O
staphylococcus B-ADR
aureus I-ADR
sepsis I-ADR
developed O
during O
cya B-DRUG
therapy O

conclusions O
: O
this O
case O
describes O
the O
clinically O
significant O
increase B-ADR
of I-ADR
inr I-ADR
in O
an O
elderly O
patient O
after O
adding O
a O
chemotherapy O
regimen O
of O
levamisole O
and O
5-fu O
to O
a O
previous O
regimen O
of O
warfarin B-DRUG
alone O

a O
14-year-old O
girl O
with O
newly O
diagnosed O
sle O
developed O
a O
pruritic B-ADR
bullous I-ADR
eruption I-ADR
while O
on O
prednisone B-DRUG

pet O
scintigraphy O
of O
etoposide-induced O
pulmonary B-ADR
toxicity I-ADR

during O
clarithromycin B-DRUG
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic B-ADR
symptoms I-ADR
of O
carbamazepine O
, O
such O
as O
drowsiness O
, O
dizziness O
, O
and O
ataxia O
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin B-DRUG
discontinuation O

anterior B-ADR
ischemic I-ADR
optic I-ADR
neuropathy I-ADR
secondary O
to O
interferon B-DRUG
alfa I-DRUG

a O
patient O
with O
the O
wolff-parkinson-white O
syndrome O
presented O
with O
incessant B-ADR
orthodromic I-ADR
atrioventricular I-ADR
tachycardia I-ADR
following O
initiation O
of O
procainamide B-DRUG
therapy O

the O
day O
after O
clozapine O
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine B-DRUG
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating O
profusely O
, O
shivering B-ADR
, O
and O
became O
tremulous O
, O
agitated O
, O
and O
confused O

introduction O
: O
in O
resource O
limited O
settings O
patients O
on O
antiretroviral O
treatment O
who O
develop O
stavudine B-DRUG
induced O
hyperlactatemia B-ADR
are O
often O
switched O
to O
zidovudine O
on O
the O
basis O
of O
published O
studies O
that O
demonstrate O
that O
this O
agent O
can O
be O
a O
safe O
alternative O

fluphenazine-induced O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
in O
a O
schizophrenic O
patient O

flare O
of O
kaposi B-ADR
's I-ADR
sarcoma I-ADR
( O
ks O
) O
is O
well O
described O
in O
immunosuppressed O
patients O
treated O
with O
corticosteroids O
and O
rituximab B-DRUG
, O
but O
has O
not O
yet O
been O
reported O
during O
treatment O
with O
imatinib O

physicians O
should O
be O
aware O
of O
the O
possible O
association O
between O
the O
use O
of O
alteplase B-DRUG
and O
the O
development O
of O
subfascial B-ADR
hemorrhage I-ADR

though O
hypotension O
, O
dry O
mouth O
, O
and O
constipation B-ADR
are O
well-documented O
possible O
adverse O
effects O
, O
the O
possibility O
of O
clonidine-induced O
bradycardia O
is O
less O
well O
recognized O
and O
is O
rare O

scrotal B-ADR
ulceration I-ADR
induced O
by O
all-trans O
retinoic B-DRUG
acid I-DRUG
in O
a O
patient O
with O
acute O
promyelocytic O
leukemia O

rituximab-based O
therapy O
for O
gemcitabine-induced O
hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
in O
a O
patient O
with O
metastatic O
pancreatic O
adenocarcinoma O
: O
a O
case O
report O

the O
harlequin B-ADR
color I-ADR
change I-ADR
and O
association O
with O
prostaglandin B-DRUG
e1 I-DRUG

we O
report O
the O
case O
of O
a O
60-year-old O
woman O
who O
developed O
erythema B-ADR
and O
erosions O
in O
the O
axilla O
and O
groin O
while O
on O
pld B-DRUG
for O
breast O
cancer O

a O
65-year-old O
woman O
with O
angina O
pectoris O
presented O
with O
syncope B-ADR
after O
sublingual O
ingestion O
of O
isosorbide B-DRUG
dinitrate I-DRUG
( O
5 O
mg O

we O
report O
3 O
cases O
of O
hiv-1 O
infected O
patients O
who O
experienced O
symptomatic O
angiolipomas B-ADR
shortly O
after O
starting O
antiretroviral O
therapy O
including O
the O
protease O
inhibitor O
indinavir B-DRUG

objective O
: O
to O
report O
a O
case O
of O
toxin-positive B-ADR
clostridium I-ADR
difficile-induced I-ADR
colitis I-ADR
( O
cdic O
) O
after O
use O
of O
clindamycin B-DRUG
phosphate I-DRUG
vaginal O
cream O

since O
this O
amount O
of O
fab O
was O
insufficient O
to O
bind O
all O
dgtx B-DRUG
present O
in O
the O
serum O
, O
cardiac B-ADR
dgtx I-ADR
toxicity I-ADR
( O
total O
av-block O
) O
persisted O

this O
case O
report O
describes O
the O
development O
of O
asymptomatic O
visual O
field O
defects O
( O
vfds B-ADR
) O
in O
a O
psychiatric O
patient O
with O
bipolar O
disorder O
receiving O
adjunctive O
tiagabine B-DRUG
treatment O

based O
upon O
the O
observed O
fall O
of O
the O
filtration O
fraction O
, O
the O
rise O
in O
the O
relative O
clearance O
of O
99tc-dimercaptosuccinic O
acid O
and O
the O
increase O
in O
proteinuria O
, O
we O
suggest O
that O
in O
this O
case O
the O
tubules O
and O
/ O
or O
interstitium O
are O
the O
main O
targets O
for O
cyclosporine B-DRUG
a I-DRUG
nephrotoxicity B-ADR

after O
having O
received O
gemcitabine B-DRUG
on O
day O
1 O
of O
the O
second O
course O
, O
the O
patient O
developed O
dry O
cough O
, O
subfebrile O
temperatures O
and O
dyspnea B-ADR
within O
48 O
h O

3. O
thus O
, O
the O
decreased B-ADR
plasma I-ADR
cortisol I-ADR
level I-ADR
during O
alprazolam B-DRUG
treatment O
of O
panic O
disorder O
was O
suggested O
to O
be O
caused O
not O
by O
symptom O
alleviation O
due O
to O
alprazolam B-DRUG
but O
by O
alprazolam B-DRUG
administration O
itself O

hepatotoxicity B-ADR
resolved O
once O
erlotinib B-DRUG
was O
discontinued O
and O
serum O
transaminases O
returned O
to O
baseline O
normal O
values O

aplastic O
anemia O
and O
agranulocytosis B-ADR
in O
patients O
using O
methazolamide B-DRUG
for O
glaucoma O

thus O
, O
the O
eosinophilia B-ADR
myalgia I-ADR
syndrome I-ADR
can O
be O
associated O
with O
parenteral O
tryptophan B-DRUG
administration O

nephrotic B-ADR
syndrome I-ADR
related O
to O
systemic O
lupus O
erythematosus O
after O
griseofulvin B-DRUG
therapy O

a O
16-year-old O
boy O
developed O
fever O
, O
generalized B-ADR
rigidity I-ADR
, O
leukocytosis O
, O
and O
increased O
serum O
transaminase O
and O
creatine O
kinase O
levels O
while O
receiving O
treatment O
with O
olanzapine O
and O
lithium B-DRUG

thus O
, O
an O
immunological O
mechanism O
might O
be O
involved O
in O
the O
mechanism O
of O
pirmenol-induced O
qt B-ADR
prolongation I-ADR
and O
t O
wave O
inversion O
on O
the O
electrocardiogram O

it O
was O
hypothesized O
that O
valproic B-DRUG
acid I-DRUG
may O
interfere O
with O
glucuronidation O
of O
lamotrigine O
, O
leading O
to O
increased B-ADR
serum I-ADR
lamotrigine I-ADR
levels I-ADR
, O
or O
perhaps O
alter O
the O
drug O
's O
metabolism O
, O
resulting O
in O
accumulation O
of O
a O
toxic O
intermediate O
metabolite O

we O
observed O
ventricular B-ADR
fibrillation I-ADR
in O
2 O
patients O
who O
presented O
to O
the O
emergency O
department O
with O
pre-excited O
atrial O
fibrillation O
and O
were O
given O
12 O
mg O
of O
adenosine B-DRUG

a O
5-month-old O
infant O
became O
lethargic B-ADR
and O
poorly O
responsive O
after O
receiving O
1 O
drop O
of O
brimonidine B-DRUG
in O
each O
eye O

ulcer B-ADR
became I-ADR
worse I-ADR
after O
tobramycin B-DRUG
and O
gentamycin O
treatment O
for O
2 O
days O

it O
is O
thought O
that O
the O
clinico-pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so-called O
" O
3-week O
sulphasalazine B-DRUG
syndrome O
" O
, O
a O
rare O
, O
but O
often O
fatal B-ADR
, O
immunoallergic O
reaction O
to O
sulphasalazine B-DRUG

the O
more O
common O
grade O
3 O
or O
4 O
adverse O
effects O
of O
sunitinib B-DRUG
include O
hypertension O
, O
fatigue O
, O
hand-foot B-ADR
syndrome I-ADR
, O
elevated O
lipase O
and O
lymphopenia O

occurrence O
of O
withdrawal O
dyskinesia B-ADR
indicates O
that O
the O
neuroleptic O
effects O
of O
amoxapine B-DRUG
may O
be O
clinically O
significant O

acute B-ADR
coronary I-ADR
syndrome I-ADR
induced O
by O
capecitabine B-DRUG
therapy O

pancreatitis O
is O
a O
very O
rare O
adverse O
effect O
associated O
with O
the O
use O
of O
amiodarone B-DRUG
, O
and O
only O
four O
cases O
of O
amiodarone-induced O
pancreatitis B-ADR
have O
been O
reported O
in O
literature O

acute B-ADR
myopathy I-ADR
with O
selective O
degeneration O
of O
myosin O
filaments O
following O
status O
asthmaticus O
treated O
with O
methylprednisolone B-DRUG
and O
vecuronium O

the O
other O
woman O
had O
rheumatoid O
arthritis O
and O
developed O
acute B-ADR
tubular I-ADR
necrosis I-ADR
after O
treatment O
with O
gentamicin O
and O
cefoxitin B-DRUG

it O
remains O
to O
be O
seen O
whether O
the O
hepatotoxicity B-ADR
associated O
with O
troglitazone B-DRUG
is O
a O
drug-class O
effect O
or O
specific O
to O
troglitazone B-DRUG

conclusions O
: O
this O
observation O
of O
" O
on-off O
" O
risperidone B-DRUG
treatment O
suggests O
that O
risperidone B-DRUG
may O
have O
worsened O
both O
psychiatric B-ADR
and I-ADR
physical I-ADR
manifestations I-ADR
of O
the O
mitochondrial O
disorder O
in O
this O
adolescent O

we O
describe O
in O
detail O
the O
first O
u.s. O
case O
report O
, O
of O
a O
4 O
( O
1 O
/ O
2 O
)- O
year-old O
boy O
who O
experienced O
angioedema B-ADR
during O
treatment O
with O
oxcarbazepine B-DRUG

physicians O
treating O
patients O
with O
methotrexate B-DRUG
for O
juvenile O
rheumatoid O
arthritis O
must O
be O
aware O
of O
this O
extraarticular B-ADR
side I-ADR
effect I-ADR

these O
findings O
support O
previous O
studies O
that O
showed O
that O
the O
use O
of O
aspirin B-DRUG
during O
the O
antecedent O
illness O
may O
be O
a O
risk O
factor O
for O
the O
development O
of O
rs B-ADR

morphine B-DRUG
, O
an O
opium O
alkaloid O
, O
frequently O
causes O
side O
effects O
such O
as O
hyperhidrosis O
and O
facial B-ADR
flushing I-ADR
, O
but O
serious O
cutaneous O
adverse O
drug O
reactions O
are O
seldom O
observed O

results O
: O
our O
patient O
developed O
crohn O
's O
disease O
while O
on O
copaxone B-DRUG
treatment O
as O
a O
consequence O
of O
long-term B-ADR
immunosuppression I-ADR

we O
postulate O
that O
gastritis B-ADR
caused O
by O
dexamethasone B-DRUG
, O
mucositis O
caused O
by O
doxorubicin O
, O
and O
the O
unique O
anatomic O
nature O
of O
a O
meckel O
diverticulum O
may O
have O
contributed O
to O
this O
extremely O
unlikely O
and O
previously O
unreported O
event O

transient B-ADR
hemiparesis I-ADR
caused O
by O
phenytoin B-DRUG
toxicity O

we O
experienced O
a O
male O
patient O
with O
psoriasis O
and O
hypertension O
whose O
conditions O
were O
treated O
with O
tacalcitol O
ointment O
and O
thiazide B-DRUG
, O
respectively O
, O
resulting O
in O
hypercalciuria B-ADR
and O
hypercalcemia O

we O
report O
the O
case O
of O
a O
20-year-old O
woman O
originally O
from O
cameroon O
who O
was O
infected O
by O
the O
l. O
loa O
parasite O
and O
developed O
severe B-ADR
hepatitis I-ADR
, O
identified O
1 O
month O
after O
a O
single O
dose O
of O
ivermectin B-DRUG

zoledronic B-DRUG
acid-induced O
severe B-ADR
hypocalcaemia I-ADR
in O
a O
prostate O
cancer O
patient O
with O
extensive O
osteoblastic O
bone O
metastases O

nephrotic B-ADR
range I-ADR
pseudoproteinuria I-ADR
in O
a O
tolmetin-treated O
patient O

a O
further O
case O
of O
anaphylactoid B-ADR
reaction I-ADR
to O
methylprednisolone B-DRUG
is O
reported O

hashimoto B-ADR
's I-ADR
disease I-ADR
during O
interferon-alpha B-DRUG
therapy O
in O
a O
patient O
with O
pre-treatment O
negative O
anti-thyroid O
autoantibodies O
and O
with O
the O
specific O
genetic O
susceptibility O
to O
the O
thyroid O
disease O

successful O
recovery O
from O
interstitial B-ADR
pneumonitis I-ADR
, O
induced O
by O
bicalutamide O
and O
leuprorelin B-DRUG
acetate I-DRUG
given O
as O
treatment O
for O
prostate O
cancer O

tamoxifen B-DRUG
retinopathy B-ADR

our O
patient O
had O
headache B-ADR
, O
mild O
fever O
, O
nausea O
, O
vomiting O
, O
rash O
, O
and O
eosinophilia O
after O
3 O
weeks O
of O
disulfiram B-DRUG
therapy O

amphotericin O
b O
( O
amb B-DRUG
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal B-ADR
impairment I-ADR
, O
anaemia O
, O
fever O
, O
malaise O
, O
and O
hypokalaemia O
are O
common O

this O
article O
describes O
two O
cases O
of O
aplastic B-ADR
anemia I-ADR
, O
at O
least O
one O
of O
which O
was O
almost O
certainly O
induced O
by O
the O
use O
of O
methazolamide B-DRUG
, O
and O
one O
case O
of O
agranulocytosis O
related O
to O
the O
use O
of O
methazolamide B-DRUG

myoclonus O
and O
seizures B-ADR
in O
a O
patient O
with O
parkinsonism O
: O
induction O
by O
levodopa B-DRUG
and O
its O
confirmation O
on O
seps O

hypoxia B-ADR
is O
a O
predisposing O
factor O
for O
premature O
ductal O
closure O
and O
often O
occurs O
after O
maternal O
indomethacin B-DRUG
therapy O

the O
most O
serious O
dental O
side O
effect O
of O
bisphosphonate B-DRUG
treatment O
( O
particularly O
when O
it O
is O
administered O
intravenously O
) O
is O
, O
paradoxically O
, O
osteonecrosis B-ADR
of I-ADR
the I-ADR
mandible I-ADR
or O
the O
maxilla O
represented O
by O
exposed O
nonhealing O
bone O

review O
of O
the O
literature O
relating O
to O
methicillin-induced O
nephropathy B-ADR
suggests O
a O
hypersensitivity O
origin O
for O
this O
disorder O
, O
but O
immunologic O
and O
ultrastructural O
investigation O
to O
date O
has O
failed O
to O
elucidate O
pathogenesis O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate B-DRUG
with O
folinic O
acid O
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute B-ADR
renal I-ADR
impairment I-ADR
) O
are O
described O

until O
additional O
data O
are O
available O
, O
if O
intravenous O
acyclovir B-DRUG
is O
administered O
concurrently O
with O
lithium O
, O
we O
recommend O
closely O
monitoring O
patients O
for O
signs O
of O
lithium B-ADR
toxicity I-ADR
and O
measuring O
serum O
lithium O
levels O
every O
second O
or O
third O
day O

the O
occurrence O
of O
neuromuscular B-ADR
blockade I-ADR
and O
the O
resulting O
potentiation O
of O
muscle O
relaxants O
during O
magnesium O
sulfate O
( O
mgso4 B-DRUG
) O
administration O
is O
well O
known O

case O
summaries O
: O
while O
conducting O
a O
protocol O
evaluating O
the O
efficacy O
of O
intraperitoneal O
cisplatin B-DRUG
and O
hyperthermia O
in O
the O
treatment O
of O
recurrent O
ovarian O
cancer O
, O
3 O
patients O
were O
noted O
to O
exhibit O
anaphylactoid B-ADR
reactions I-ADR

we O
report O
a O
case O
of O
pancytopenia B-ADR
in O
a O
23-year-old O
man O
with O
crohn O
's O
disease O
who O
was O
treated O
with O
5-aminosalicylic B-DRUG
acid I-DRUG
( O
pentasa O
; O
nisshin O
, O
tokyo O
, O
japan O
) O
3.0 O
g O
/ O
day O

case O
: O
we O
present O
an O
11-year O
old O
male O
with O
budd-chiari O
syndrome O
who O
experienced O
profound O
worsening B-ADR
of I-ADR
chronic I-ADR
aphthous I-ADR
ulcers I-ADR
after O
immunosuppressive O
therapy O
was O
changed O
from O
tacrolimus B-DRUG
to O
sirolimus O

in O
the O
following O
case O
report O
, O
a O
patient O
developed O
acute O
interstitial O
nephritis O
with O
renal O
failure O
and O
exfoliative B-ADR
dermatitis I-ADR
following O
ampicillin B-DRUG
therapy O

we O
now O
report O
the O
first O
known O
cancer O
patient O
who O
developed O
life-threatening B-ADR
complications I-ADR
after O
treatment O
with O
topical O
5-fu B-DRUG
and O
was O
shown O
subsequently O
to O
have O
profound O
dpd O
deficiency O

this O
is O
the O
first O
report O
of O
a O
catatonic B-ADR
syndrome I-ADR
occurring O
in O
a O
patient O
receiving O
disulfiram B-DRUG
treatment O

the O
clinical O
symptoms O
of O
gastric B-ADR
mucosa I-ADR
foveolar I-ADR
hyperplasia I-ADR
due O
to O
long-term O
pge1 B-DRUG
therapy O
simulate O
hypertrophic O
pyloric O
stenosis O

a O
wide O
variety O
of O
adverse B-ADR
central I-ADR
nervous I-ADR
system I-ADR
effects I-ADR
have O
been O
reported O
in O
association O
with O
propafenone B-DRUG
; O
dizziness O
is O
the O
most O
common O

the O
relationship O
between O
infliximab B-DRUG
treatment O
and O
lymphoma B-ADR
in O
crohn O
's O
disease O

introduction O
: O
we O
describe O
the O
neurointensive O
care O
( O
nic O
) O
management O
of O
a O
patient O
with O
severe O
cerebral O
swelling O
and O
raised B-ADR
intracranial I-ADR
pressure I-ADR
( O
icp O
) O
after O
severe O
sodium B-DRUG
valproic I-DRUG
acid I-DRUG
( O
vpa O
) O
intoxication O

gangrene B-ADR
of O
the O
fingertips O
after O
bleomycin O
and O
methotrexate B-DRUG

we O
experienced O
a O
male O
patient O
with O
psoriasis O
and O
hypertension O
whose O
conditions O
were O
treated O
with O
tacalcitol B-DRUG
ointment O
and O
thiazide O
, O
respectively O
, O
resulting O
in O
hypercalciuria O
and O
hypercalcemia B-ADR

gynecomastia B-ADR
in O
epileptics O
treated O
with O
phenobarbital O
, O
phenytoin O
and O
fluoresone B-DRUG
: O
two O
case O
reports O

the O
reversal O
of O
heparin O
by O
protamine B-DRUG
may O
cause O
severe B-ADR
hemodynamic I-ADR
deterioration I-ADR
, O
characterized O
by O
systemic O
hypotension O
, O
pulmonary O
hypertension O
, O
and O
bronchoconstriction O

acute B-ADR
non-lymphocytic I-ADR
leukemia I-ADR
occurred O
in O
eight O
women O
following O
long-term O
treatment O
with O
treosulfan B-DRUG
(= O
dihydroxybusulfan O
) O
for O
ovarian O
carcinoma O

marked O
sinus B-ADR
tachycardia I-ADR
resulting O
from O
the O
synergistic O
effects O
of O
marijuana O
and O
nortriptyline B-DRUG

acute B-ADR
delirium I-ADR
resulting O
from O
levofloxacin B-DRUG
therapy O
is O
an O
exceedingly O
rare O
complication O
that O
has O
been O
thought O
to O
occur O
more O
commonly O
in O
elderly O
patients O

we O
hypothesize O
that O
decreased O
renal O
elimination O
of O
mtx B-DRUG
induced O
by O
the O
cox-2 O
inhibitor O
resulted O
in O
enhanced O
hematopoietic B-ADR
toxicity I-ADR
and O
immunosuppression O
causing O
the O
ebv-associated O
lymphoproliferative O
disease O

a O
patient O
is O
described O
who O
developed O
a O
rapid O
onset O
of O
pulmonary B-ADR
fibrosis I-ADR
following O
treatment O
with O
a O
new O
non-steroidal O
anti-inflammatory O
drug O
, O
nabumetone B-DRUG

two O
patients O
who O
were O
receiving O
tolazoline B-DRUG
by O
infusion O
developed O
duodenal B-ADR
ulceration I-ADR
and O
subsequent O
intestinal O
perforation O

a O
variety O
of O
movement B-ADR
disorders I-ADR
are O
known O
to O
occur O
in O
association O
with O
carbamazepine O
( O
cbz B-DRUG
) O
therapy O
in O
adults O
and O
children O
, O
but O
development O
of O
tics O
has O
been O
described O
infrequently O
and O
only O
in O
patients O
with O
underlying O
tourette O
's O
syndrome O
or O
other O
movement B-ADR
disorders I-ADR

incomplete B-ADR
posterior I-ADR
hyaloid I-ADR
detachment I-ADR
after O
intravitreal O
pegaptanib B-DRUG
injection O
in O
diabetic O
macular O
edema O

angioedema O
and O
dysphagia B-ADR
caused O
by O
contact O
allergy O
to O
inhaled O
budesonide B-DRUG

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness O
, O
difficulty O
with O
speech O
, O
weakness B-ADR
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

physicians O
who O
use O
sulfasalazine B-DRUG
to O
treat O
patients O
with O
inflammatory O
bowel O
disease O
should O
be O
aware O
of O
the O
signs O
of O
sulfasalazine-induced O
lupus B-ADR
syndrome I-ADR

objective O
: O
to O
report O
on O
the O
possible O
development O
of O
serotonin B-ADR
syndrome I-ADR
in O
a O
patient O
receiving O
clomipramine B-DRUG
after O
clozapine O
was O
withdrawn O
from O
the O
treatment O
regimen O

the O
site O
of O
thrombosis O
and O
the O
chronological O
relationship O
with O
the O
iir O
implicates O
a O
hypersensitivity B-ADR
to O
infliximab B-DRUG
in O
the O
causation O
of O
the O
venous O
thrombosis O
in O
this O
case O

although O
adverse O
effects O
are O
usually O
mild O
, O
the O
author O
reports O
here O
a O
case O
of O
leucocytopenia O
and O
thrombocytopenia B-ADR
with O
quetiapine B-DRUG
treatment O
that O
required O
its O
discontinuation O

on O
the O
fifth O
day O
of O
tocolysis O
with O
magnesium O
sulfate O
, O
nifedipine B-DRUG
, O
terbutaline O
and O
betamethasone O
, O
edema B-ADR
developed O
in O
both O
labia O

objective O
: O
to O
report O
a O
fatal O
case O
of O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
in O
a O
man O
who O
was O
treated O
with O
oral O
ofloxacin B-DRUG
for O
epididymitis O

a O
64 O
year O
old O
man O
with O
recurrent O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
severe B-ADR
skin I-ADR
rash I-ADR
and O
bone O
marrow O
aplasia O
4 O
and O
7 O
days O
, O
respectively O
, O
following O
a O
single O
dose O
of O
40 O
mg O
/ O
m2 O
methotrexate B-DRUG
( O
mtx O

experience O
with O
five O
patients O
in O
whom O
impaired B-ADR
renal I-ADR
function I-ADR
developed O
early O
during O
amphotericin B-DRUG
b I-DRUG
therapy O
is O
reported O

isotretinoin B-DRUG
, O
a O
drug O
used O
for O
the O
treatment O
of O
acne O
, O
has O
been O
shown O
to O
have O
teratogenic B-ADR
effects I-ADR

the O
following O
is O
a O
case O
report O
analysis O
intended O
to O
draw O
attention O
to O
the O
need O
for O
better O
care O
coordination O
by O
describing O
the O
observed O
relationship O
of O
olanzapine B-DRUG
to O
metabolic O
changes O
manifested O
as O
uncontrolled B-ADR
diabetes I-ADR
mellitus I-ADR
and O
weight O
gain O

peripheral B-ADR
nerve I-ADR
dysfunction I-ADR
is O
a O
potentially O
serious O
complication O
of O
high-dose O
cytosine B-DRUG
arabinoside I-DRUG

camptocormia B-ADR
, O
a O
new O
side O
effect O
of O
sodium B-DRUG
valproate I-DRUG

the O
probability O
of O
developing O
acute B-ADR
leukemia I-ADR
in O
this O
study O
was O
not O
significantly O
correlated O
to O
the O
total O
cumulative O
dosage O
of O
treosulfan B-DRUG

basilar B-ADR
invagination I-ADR
and O
mid-line O
skeletal O
abnormalities O
due O
to O
in O
utero O
exposure O
to O
phenytoin B-DRUG

the O
patient O
experienced O
hallucinations B-ADR
, O
agitation O
, O
vomiting O
, O
tachycardia O
and O
seizures O
after O
ingestion O
of O
1050 O
( O
48 O
mg O
/ O
kg O
) O
of O
extended-release O
bupropion B-DRUG

we O
report O
a O
case O
of O
reversible O
encephalopathy B-ADR
syndrome I-ADR
in O
a O
16-year-old O
girl O
with O
acute O
myelogenous O
leukemia O
( O
aml O
) O
, O
who O
is O
undergoing O
during O
consolidation O
chemotherapy O
composed O
of O
bh-ac O
( O
n4-behenoyl-1-beta-d-arabinofuranosyl O
cytosine O
) O
and O
idarubicin B-DRUG

discussion O
: O
anaphylactoid B-ADR
reactions I-ADR
have O
been O
described O
previously O
with O
cisplatin B-DRUG
administration O

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches B-ADR
, O
dizziness O
, O
difficulty O
with O
speech O
, O
weakness O
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

salicylate O
intoxication B-ADR
was O
excluded O
, O
and O
theophylline B-DRUG
was O
finally O
incriminated O

we O
report O
the O
case O
of O
an O
87-year-old O
white O
woman O
with O
myasthenia O
gravis O
who O
presented O
with O
nausea O
, O
shortness O
of O
breath O
, O
azotemia B-ADR
, O
and O
hyperkalemia O
shortly O
after O
completing O
a O
course O
of O
intravenous O
immunoglobulin B-DRUG
( O
ivig O

discussion O
: O
electrolyte B-ADR
disorders I-ADR
associated O
with O
foscarnet B-DRUG
are O
reviewed O

gestational B-ADR
diabetes I-ADR
was O
no O
less O
severe O
( O
degree O
of O
hyperglycaemia O
, O
need O
for O
insulin O
therapy O
) O
when O
associated O
with O
norethisterone B-DRUG

since O
tamoxifen B-DRUG
therapy O
can O
induce O
endometrial B-ADR
disorders I-ADR
, O
surveillance O
schemes O
of O
women O
taking O
tamoxifen B-DRUG
have O
been O
recommended O

carbamazepine-induced O
hyperammonemia B-ADR

rta B-ADR
is O
one O
type O
of O
nephrotoxicity O
induced O
by O
fk506 B-DRUG
, O
and O
it O
is O
reversible O
in O
mild O
cases O
when O
appropriately O
treated O

this O
patient O
rapidly O
progressed O
from O
mild B-ADR
neurotoxicity I-ADR
to O
fatal O
encephalopathy O
after O
one O
dose O
of O
intrathecal O
methotrexate B-DRUG
during O
his O
third O
cycle O
of O
chemotherapy O

primary B-ADR
cutaneous I-ADR
coccidioidomycosis I-ADR
and O
subsequent O
drug O
eruption O
to O
itraconazole B-DRUG
in O
a O
dog O

severe B-ADR
symptomatic I-ADR
hyponatremia I-ADR
during O
sibutramine B-DRUG
therapy O
: O
a O
case O
report O

methods O
: O
a O
55-year-old O
woman O
became O
stuporous B-ADR
after O
overdose O
with O
lamotrigine O
( O
ltg O
) O
and O
valproic B-DRUG
acid I-DRUG
( O
vpa O
) O
tablets O

fever O
, O
lymphadenopathy O
, O
eosinophilia B-ADR
, O
lymphocytosis O
, O
hepatitis O
, O
and O
dermatitis O
: O
a O
severe O
adverse O
reaction O
to O
minocycline B-DRUG

objective O
: O
to O
describe O
a O
patient O
with O
asymptomatic O
bronchial O
asthma O
and O
hypertension O
who O
developed O
an O
acute B-ADR
asthma I-ADR
attack O
after O
receiving O
sustained-release O
verapamil B-DRUG

rosaceiform B-ADR
eruption I-ADR
induced O
by O
erlotinib B-DRUG

lithium B-DRUG
is O
known O
to O
cause O
acute O
renal O
failure O
and O
tubulo-interstitial O
disease O
, O
but O
the O
recently O
described O
association O
with O
proteinuria O
or O
nephrotic B-ADR
syndrome I-ADR
is O
little O
recognized O

physicians O
should O
keep O
in O
mind O
that O
taxanes O
such O
as O
paclitaxel B-DRUG
have O
the O
potential O
to O
cause O
pneumonitis B-ADR
and O
lung O
fibrosis O

we O
present O
the O
case O
of O
a O
5-year-old O
girl O
who O
developed O
bilateral B-ADR
vocal I-ADR
cord I-ADR
paralysis I-ADR
following O
preoperative O
peritonsillar O
bupivacaine B-DRUG
infiltration O

methotrexate B-DRUG
pneumonitis B-ADR
in O
nonsurgical O
treatment O
of O
ectopic O
pregnancy O

cholestyramine B-DRUG
induced O
hyperchloremic B-ADR
metabolic I-ADR
acidosis I-ADR

after O
receiving O
3 O
doses O
of O
ifosfamide O
/ O
mesna B-DRUG
, O
she O
was O
found O
to O
be O
unresponsive B-ADR

bulbar B-ADR
and O
pseudobulbar O
palsy O
complicating O
therapy O
with O
high-dose O
cytosine B-DRUG
arabinoside I-DRUG
in O
children O
with O
leukemia O

intraventricular O
nafcillin-induced O
seizures B-ADR
in O
a O
neonate O

we O
report O
a O
case O
of O
reversible O
dka O
and O
new-onset O
dm B-ADR
that O
developed O
in O
a O
demented O
patient O
who O
was O
treated O
with O
quetiapine B-DRUG
for O
14 O
days O

favorable O
outcome O
of O
de O
novo O
hepatitis B-ADR
b I-ADR
infection I-ADR
after O
liver O
transplantation O
with O
lamivudine B-DRUG
and O
adefovir O
therapy O

an O
infant O
girl O
with O
choanal B-ADR
atresia I-ADR
, O
athelia O
, O
minor O
anomalies O
, O
and O
mild O
to O
moderate O
mental O
retardation O
was O
born O
to O
a O
woman O
treated O
for O
hyperthyroidism O
throughout O
pregnancy O
with O
methimazole B-DRUG
and O
propranolol O

a O
64 O
year O
old O
woman O
with O
previous O
history O
of O
coronary O
stenting O
five O
days O
before O
was O
admitted O
in O
our O
institution O
for O
intracranial B-ADR
bleeding I-ADR
while O
receiving O
aspirin O
and O
clopidogrel B-DRUG

during O
and O
after O
ifn B-DRUG
therapy O
we O
should O
consider O
the O
possibility O
of O
occurrence O
of O
iddm B-ADR
as O
well O
as O
other O
autoimmune O
diseases O
and O
observe O
the O
clinical O
course O
carefully O

the O
authors O
describe O
pericardial B-ADR
hemorrhage I-ADR
, O
which O
is O
related O
to O
the O
use O
of O
low-dose O
acetylsalicylic B-DRUG
acid I-DRUG
in O
a O
patient O
with O
essential O
thrombocythemia O

we O
present O
an O
aids O
patient O
with O
severe O
and O
prolonged O
lactic B-ADR
acidosis I-ADR
on O
stavudine O
and O
lamivudine B-DRUG

rapamycin O
/ O
sirolimus O
( O
sr O
) O
, O
trade O
named O
rapammune B-DRUG
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension O
, O
hyperlipidemia O
, O
and O
infection B-ADR

a O
patient O
suffering O
from O
heparin-associated O
thrombocytopenia B-ADR
( O
hat O
) O
, O
recurrent O
arteriothromboses O
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin B-DRUG
is O
described O

results O
: O
a O
patient O
developed O
a O
bilaterally B-ADR
symmetric I-ADR
bull's-eye I-ADR
maculopathy I-ADR
45 O
years O
after O
taking O
quinacrine B-DRUG
for O
18 O
months O
as O
prophylaxis O
against O
malaria O

a O
60-year-old O
woman O
with O
diabetes O
mellitus O
( O
type O
2 O
) O
developed O
an O
acute B-ADR
icteric I-ADR
hepatitis-like I-ADR
illness I-ADR
6 O
weeks O
after O
the O
initiation O
of O
gliclazide B-DRUG
therapy O

results O
: O
the O
estimated O
number O
of O
accutane B-DRUG
prescriptions O
for O
reproductive-aged O
women O
has O
more O
than O
doubled O
in O
the O
past O
10 O
years O
; O
it O
is O
the O
most O
widely O
used O
teratogenic B-ADR
drug O
in O
the O
united O
states O
, O
with O
approximately O
2.5 O
per O
1,000 O
reproductive-aged O
women O
exposed O
to O
accutane B-DRUG
in O
1999 O

treatment O
of O
elp B-ADR
in O
children O
is O
generally O
supportive O
, O
with O
the O
symptoms O
and O
roentgenographic O
abnormalities O
resolving O
within O
months O
after O
stopping O
the O
use O
of O
mineral B-DRUG
oil I-DRUG

two O
of O
our O
patients O
developed O
td B-ADR
after O
23 O
months O
and O
34 O
months O
of O
ziprasidone B-DRUG
monotherapy O
, O
respectively O

the O
more O
common O
grade O
3 O
or O
4 O
adverse O
effects O
of O
sunitinib B-DRUG
include O
hypertension O
, O
fatigue O
, O
hand-foot O
syndrome O
, O
elevated B-ADR
lipase I-ADR
and O
lymphopenia O

in O
a O
female O
with O
acute O
lymphoblastic O
leukemia O
, O
inadvertent O
doxorubicin B-DRUG
administration O
intrathecally O
caused O
severe O
, O
life-threatening O
, O
acute O
encephalopathy O
with O
high-pressure B-ADR
hydrocephalus I-ADR

however O
, O
continued O
low-dose O
mtx B-DRUG
led O
, O
in O
spite O
of O
normal O
liver O
tests O
, O
8 O
years O
after O
the O
last O
biopsy O
to O
liver O
failure O
and O
death B-ADR
in O
1 O
of O
our O
patients O

objective O
: O
to O
report O
teicoplanin-related O
neutropenia B-ADR
that O
developed O
after O
an O
episode O
of O
neutropenia B-ADR
induced O
by O
vancomycin B-DRUG
therapy O

after O
having O
received O
gemcitabine B-DRUG
on O
day O
1 O
of O
the O
second O
course O
, O
the O
patient O
developed O
dry B-ADR
cough I-ADR
, O
subfebrile O
temperatures O
and O
dyspnea O
within O
48 O
h O

this O
concerns O
2 O
male O
patients O
who O
experienced O
incontinence B-ADR
while O
taking O
venlafaxine B-DRUG

muscle O
biopsy O
revealed O
variation O
in O
muscle O
fiber O
size O
and O
few O
vacuolated B-ADR
fibers I-ADR
which O
were O
features O
of O
colchicine-induced O
myopathy O

several O
possible O
explanations O
of O
the O
mechanism O
of O
renal B-ADR
failure I-ADR
associated O
with O
the O
use O
of O
dextran-40 B-DRUG
are O
discussed O

discussion O
: O
the O
main O
adverse O
effects O
of O
leflunomide B-DRUG
consist O
of O
diarrhea O
, O
nausea O
, O
liver B-ADR
enzyme I-ADR
elevation I-ADR
, O
hypertension O
, O
alopecia O
, O
and O
allergic O
skin O
reactions O

this O
case O
demonstrates O
the O
association O
of O
selective O
iga B-ADR
deficiency I-ADR
with O
remission O
in O
rheumatoid O
arthritis O
induced O
by O
fenclofenac O
as O
well O
as O
aurothiomalate B-DRUG
and O
sulphasalazine O

after O
1 O
week O
of O
nefazodone B-DRUG
therapy O
the O
patient O
experienced O
headache O
, O
confusion B-ADR
, O
and O
" O
gray O
areas O
" O
in O
her O
vision O
, O
without O
abnormal O
ophthalmologic O
findings O

based O
on O
our O
experience O
and O
on O
previously O
published O
data O
, O
serum O
ammonia O
levels O
appear O
to O
be O
indicated O
in O
all O
ed O
patients O
on O
valproic B-DRUG
acid I-DRUG
therapy O
who O
present O
with O
altered B-ADR
mental I-ADR
status I-ADR

we O
report O
two O
cases O
of O
tenofovir B-DRUG
( O
tdf O
)- O
associated O
nephrotoxicity B-ADR
in O
perinatally O
hiv-infected O
adolescents O

conclusion O
: O
fixed O
drug O
eruption B-ADR
is O
associated O
with O
many O
drugs O
but O
this O
is O
the O
first O
such O
report O
with O
omeprazole B-DRUG

conclusion O
: O
the O
new O
quinolone O
derivatives O
( O
levofloxacin O
, O
sparfloxacin O
, O
grepafloxacin O
, O
trovafloxacin O
, O
gatifloxacin B-DRUG
and O
moxifloxacin O
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system-related O
adverse O
effects O
, O
including O
headache O
, O
dizziness B-ADR
and O
insomnia O

a O
case O
of O
pyridoxine-dependent O
seizures B-ADR
is O
reported O

the O
authors O
also O
determined O
that O
their O
case O
of O
myositis B-ADR
developing O
in O
the O
rectus O
abdominus O
muscle O
of O
a O
patient O
with O
pancreatic O
adenocarcinoma O
was O
the O
manifestation O
of O
radiation O
recall O
, O
thereby O
bringing O
the O
number O
of O
patients O
who O
developed O
radiation O
recall O
to O
gemcitabine B-DRUG
and O
were O
discussed O
in O
the O
current O
study O
to O
13 O

case O
summary O
: O
a O
25-year-old O
postpartum O
white O
woman O
developed O
multiple B-ADR
watery I-ADR
stools I-ADR
and O
abdominal O
cramping O
on O
day O
6 O
of O
therapy O
with O
clindamycin B-DRUG
vaginal O
cream O
for O
bacterial O
vaginosis O

we O
present O
a O
case O
of O
an O
elderly O
woman O
with O
a O
pre-existing O
history O
of O
ischaemic O
heart O
disease O
, O
who O
was O
treated O
with O
venlafaxine B-DRUG
, O
and O
developed O
acute B-ADR
myocardial I-ADR
ischaemia I-ADR
within O
the O
first O
week O
of O
treatment O

pneumocystis B-ADR
pneumonia I-ADR
should O
be O
considered O
in O
asthmatic O
patients O
taking O
methotrexate B-DRUG
who O
present O
with O
fever O
, O
pulmonary O
infiltrates O
, O
and O
hypoxia O

the O
clinical O
course O
suggests O
that O
caffeine B-DRUG
, O
which O
is O
present O
in O
oolong O
tea O
, O
was O
mainly O
responsible O
for O
the O
rhabdomyolysis B-ADR
as O
well O
as O
the O
delirium O
, O
although O
severe O
hyponatremia O
has O
been O
reported O
to O
cause O
rhabdomyolysis B-ADR
on O
rare O
occasions O

the O
first O
patient O
developed O
mild B-ADR
nitritoid I-ADR
symptoms I-ADR
and O
pain O
in O
a O
band-like O
distribution O
, O
corresponding O
to O
t10-t12 O
dermatomes O
, O
shortly O
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
( O
gstm O
) O
injection O

ticlopidine-induced O
aplastic O
anemia O
( O
tiaa B-ADR
) O
is O
considered O
very O
uncommon O

vancomycin B-DRUG
is O
widely O
used O
against O
methicillin-resistant O
staphylococcus O
aureus O
infections O
, O
but O
it O
is O
associated O
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity B-ADR
, O
ototoxicity O
, O
gastrointestinal O
disturbances O
, O
blood O
disorders O
, O
and O
two O
types O
of O
hypersensitivity O
reactions O
- O
an O
anaphylactoid O
reaction O
known O
as O
" O
red O
man O
syndrome O
" O
and O
anaphylaxis O

this O
report O
describes O
two O
patients O
who O
developed O
acute B-ADR
myelocytic I-ADR
leukemia I-ADR
only O
after O
exposure O
to O
cyclophosphamide O
, O
methotrexate O
, O
and O
5-fluorouracil B-DRUG
adjuvant O
therapy O

we O
report O
a O
case O
of O
biopsy O
proven O
myositis B-ADR
whose O
symptoms O
began O
within O
10 O
days O
of O
receiving O
leuprolide B-DRUG
acetate I-DRUG
therapy O
for O
prostate O
cancer O

background O
: O
to O
describe O
the O
occurrence O
of O
ocular B-ADR
hypertension I-ADR
in O
four O
patients O
following O
injection O
of O
ranibizumab B-DRUG
intravitreally O

an O
objective O
causality O
assessment O
suggests O
that O
the O
jhr B-ADR
in O
our O
patient O
was O
probably O
related O
to O
penicillin B-DRUG

we O
report O
a O
43-year-old O
woman O
who O
developed O
sore B-ADR
throat I-ADR
, O
swelling O
of O
the O
lips O
and O
oral O
cavity O
and O
dysphagia O
, O
2 O
weeks O
after O
the O
use O
of O
budesonide O
spray O
( O
budefat B-DRUG
) O
for O
treatment O
of O
bronchial O
asthma O

the O
possibility O
of O
phenytoin B-DRUG
hypersensitivity O
reactions O
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever O
, O
rash B-ADR
, O
and O
lymphadenopathy O

optic B-ADR
neuropathy I-ADR
developed O
in O
a O
patient O
with O
rheumatoid O
arthritis O
who O
had O
been O
receiving O
d-penicillamine B-DRUG
for O
about O
1 O
year O

pulmonary O
eosinophilia O
or O
granulomas B-ADR
, O
classically O
seen O
in O
previously O
reported O
cases O
of O
methotrexate B-DRUG
pneumonitis O
, O
were O
not O
observed O

we O
report O
on O
a O
14-year-old O
boy O
with O
severe O
haemophilia O
a O
who O
developed O
a O
portal B-ADR
vein I-ADR
thrombosis I-ADR
during O
continuous O
infusion O
of O
f B-DRUG
viii I-DRUG

ards B-ADR
is O
rarely O
associated O
with O
rituximab B-DRUG
infusion O
for O
lympho-proliferative O
disorders O
, O
but O
it O
should O
be O
considered O
by O
those O
administering O
rituximab B-DRUG
, O
especially O
when O
a O
patient O
develops O
severe O
pulmonary O
symptoms O
soon O
after O
infusion O

retinal O
abnormalities O
, O
including O
retinal B-ADR
hemorrhage I-ADR
and O
" O
cotton-wool O
" O
spots O
, O
often O
occur O
within O
the O
first O
8 O
weeks O
in O
the O
course O
of O
interferon B-DRUG
therapy O
in O
patients O
with O
chronic O
hepatitis O
c O

this O
case O
suggests O
that O
acyclovir B-DRUG
when O
given O
intravenously O
in O
doses O
of O
10 O
mg O
/ O
kg O
may O
result O
in O
increased B-ADR
serum I-ADR
lithium I-ADR
concentrations O

a O
case O
is O
reported O
in O
which O
severe O
hypocalcemia O
, O
with O
a O
low B-ADR
plasma I-ADR
parathyroid I-ADR
hormone I-ADR
( O
pth O
) O
concentration O
, O
resulted O
from O
the O
therapeutic O
use O
of O
magnesium B-DRUG
sulfate I-DRUG
for O
toxemia O
of O
pregnancy O

we O
conclude O
that O
the O
presence O
of O
this O
metabolic O
defect O
combined O
with O
topical O
5-fu B-DRUG
( O
a O
drug O
demonstrating O
a O
narrow O
therapeutic O
index O
) O
results O
in O
the O
unusual O
presentation O
of O
life-threatening B-ADR
toxicity I-ADR
after O
treatment O
with O
a O
topical O
drug O

infliximab-induced O
lupus B-ADR
in O
crohn O
's O
disease O
: O
a O
case O
report O

a O
21-year-old O
patient O
developed O
rhabdomyolysis B-ADR
during O
his O
nineteenth O
week O
of O
treatment O
with O
clozapine B-DRUG
for O
drug-resistant O
schizophrenia O

this O
case O
report O
describes O
a O
38-year-old O
male O
in O
whom O
siadh B-ADR
was O
strongly O
suspected O
secondary O
to O
tegretol B-DRUG
therapy O
to O
control O
a O
seizure O
disorder O

olanzapine-associated O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR

acute B-ADR
bilateral I-ADR
phrenic I-ADR
neuropathy I-ADR
following O
treatment O
with O
adalimumab B-DRUG

conclusions O
: O
this O
case O
describes O
the O
clinically O
significant O
increase B-ADR
of I-ADR
inr I-ADR
in O
an O
elderly O
patient O
after O
adding O
a O
chemotherapy O
regimen O
of O
levamisole B-DRUG
and O
5-fu O
to O
a O
previous O
regimen O
of O
warfarin O
alone O

during O
clarithromycin O
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate-to-severe O
toxic O
symptoms O
of O
carbamazepine B-DRUG
, O
such O
as O
drowsiness O
, O
dizziness B-ADR
, O
and O
ataxia O
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin O
discontinuation O

oxygen B-DRUG
potentiation O
of O
bleomycin-induced O
pulmonary B-ADR
toxicity I-ADR
is O
discussed O

reversible O
valproic B-DRUG
acid-induced O
dementia B-ADR
was O
documented O
in O
a O
21-year-old O
man O
with O
epilepsy O
who O
had O
a O
3-year O
history O
of O
insidious O
progressive O
decline O
in O
global O
cognitive O
abilities O
documented O
by O
serial O
neuropsychological O
studies O

methods O
: O
we O
report O
a O
patient O
who O
had O
an O
anaphylactic B-ADR
reaction I-ADR
during O
the O
intravenous O
infusion O
of O
cyclosporine B-DRUG

a O
second O
patient O
with O
a O
similar O
glucose O
tolerance O
test O
result O
showed O
postprandial B-ADR
hyperglycemia I-ADR
when O
treated O
similarly O
with O
betamethasone B-DRUG
valerate I-DRUG
cream O
0.1 O

interstitial B-ADR
pneumonitis I-ADR
and O
alveolar O
hemorrhage O
complicating O
use O
of O
rituximab B-DRUG
: O
case O
report O
and O
review O
of O
the O
literature O

a O
combination O
of O
behavioural O
and O
cognitive O
adverse O
effects O
is O
illustrated O
in O
this O
case O
report O
of O
a O
recurrent O
triazolam-induced O
eating B-ADR
disorder I-ADR

objective O
: O
to O
report O
a O
case O
of O
severe B-ADR
chloroquine I-ADR
toxicity I-ADR
in O
the O
presence O
of O
high-grade O
chloroquine-resistant O
plasmodium O
vivax O

rapid O
identification O
of O
speech B-ADR
loss I-ADR
linked O
to O
fk506 B-DRUG
may O
be O
important O
because O
reduction O
or O
cessation O
of O
the O
drug O
may O
be O
associated O
with O
reverse O
of O
speech B-ADR
loss I-ADR

we O
report O
a O
case O
of O
rta B-ADR
secondary O
to O
fk506 B-DRUG
administration O
in O
liver O
transplantation O

results O
: O
a O
previously O
healthy O
42-year-old O
woman O
presented O
with O
acute-onset B-ADR
delirium I-ADR
with I-ADR
psychotic I-ADR
features I-ADR
as O
a O
consequence O
of O
levofloxacin B-DRUG
therapy O

severe B-ADR
osteomalacia I-ADR
was O
present O
in O
two O
epileptic O
patients O
who O
were O
under O
long-term O
treatment O
with O
congeners O
of O
phenytoin B-DRUG
, O
phenobarbital O
, O
and O
acetazolamide O

rapamycin B-DRUG
/ O
sirolimus O
( O
sr O
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension O
, O
hyperlipidemia O
, O
and O
infection B-ADR

dyspnea O
, O
hypoxemia O
, O
and O
pleuritic B-ADR
chest I-ADR
pain I-ADR
occurred O
within O
24 O
hours O
of O
rituximab B-DRUG
administration O
, O
and O
there O
was O
no O
other O
apparent O
explanation O

a O
51-year-old O
man O
developed O
type B-ADR
1 I-ADR
diabetes I-ADR
mellitus I-ADR
following O
24 O
weeks O
of O
treatment O
with O
recombinant O
alpha-2b O
peginterferon O
plus O
ribavirin B-DRUG
for O
chronic O
hepatitis O
c O

proconvulsive B-ADR
tendency O
of O
imipenem O
/ O
cilastatin B-DRUG
is O
one O
of O
its O
well-known O
side O
effects O

naproxen B-DRUG
is O
a O
commonly O
used O
nonsteroidal O
anti-inflammatory O
drug O
( O
nsaid O
) O
whose O
side O
effects O
include O
tinnitus B-ADR
and O
transient O
hearing O
loss O

nevertheless O
, O
the O
coagulopathy B-ADR
seemed O
to O
be O
most O
closely O
associated O
with O
the O
administration O
of O
the O
cephalosporin B-DRUG

sensory O
neuropathy O
revealing O
necrotizing B-ADR
vasculitis I-ADR
during O
infliximab B-DRUG
therapy O
for O
rheumatoid O
arthritis O

thus O
, O
the O
possible O
in O
vivo O
effects O
of O
insulin B-DRUG
on O
adipocytes O
were O
clearly O
observed O
in O
this O
case O
of O
insulin-induced O
lipohypertrophy B-ADR

gold B-DRUG
nephropathy B-ADR
: O
tissue O
analysis O
by O
x-ray O
fluorescent O
spectroscopy O

we O
report O
on O
three O
cases O
wherein O
treatment O
of O
dexmedetomidine-induced O
bradycardia O
with O
i.v. O
glycopyrrolate B-DRUG
( O
5.0 O
microg O
/ O
kg O
) O
not O
only O
resulting O
in O
resolution O
of O
bradycardia O
but O
also O
resulting O
in O
an O
exaggerated B-ADR
increase I-ADR
of I-ADR
arterial I-ADR
blood I-ADR
pressure I-ADR

the O
newborn O
manifested O
a O
four O
day O
course O
of O
lethargy B-ADR
with O
unexplained O
high O
lithium B-DRUG
levels O
in O
the O
adult O
toxic O
range O

his O
fever O
resolved O
, O
but O
he O
developed O
symptoms O
consistent O
with O
those O
of O
chloroquine B-ADR
toxicity I-ADR

sudden B-ADR
death I-ADR
in O
an O
infant O
from O
methemoglobinemia O
after O
administration O
of O
" O
sweet B-DRUG
spirits I-DRUG
of I-DRUG
nitre I-DRUG

the O
reported O
cases O
of O
in O
utero O
exposure O
to O
cyclosposphamide B-DRUG
shared O
the O
following O
manifestations O
with O
our O
patient O
: O
growth O
deficiency O
, O
developmental O
delay O
, O
craniosynostosis B-ADR
, O
blepharophimosis O
, O
flat O
nasal O
bridge O
, O
abnormal O
ears O
, O
and O
distal O
limb O
defects O
including O
hypoplastic O
thumbs O
and O
oligodactyly O

acute O
esmolol B-ADR
toxicity I-ADR
may O
be O
self-limiting O
because O
of O
its O
extremely O
short O
half-life O

this O
case O
and O
a O
review O
of O
the O
literature O
show O
the O
severe O
and O
unpredictable O
nature O
of O
ethambutol B-DRUG
toxicity O
and O
its O
potential O
for O
irreversible O
vision B-ADR
loss I-ADR
despite O
careful O
ophthalmologic O
monitoring O

we O
present O
a O
case O
in O
which O
dipyridamole B-DRUG
induced O
high-grade O
atrioventricular O
( O
av O
) O
block O
that O
responded O
promptly O
to O
intravenous O
aminophylline O
but O
not O
to O
atropine O

no O
explanation O
for O
this O
delay O
was O
found O
, O
other O
than O
the O
possibility O
that O
magnesium B-DRUG
sulfate I-DRUG
treatment O
impeded B-ADR
lactogenesis I-ADR

rapamycin O
/ O
sirolimus O
( O
sr B-DRUG
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension B-ADR
, O
hyperlipidemia O
, O
and O
infection O

we O
present O
a O
case O
of O
acute O
epinephrine B-DRUG
toxicity O
resulting O
in O
acute B-ADR
myocardial I-ADR
ischemia I-ADR
in O
a O
young O
boy O
with O
combined O
variable O
immunodeficiency O
syndrome O
who O
developed O
severe O
allergic O
reaction O
to O
intravenous O
immunoglobulin O
, O
and O
was O
subsequently O
given O
epinephrine B-DRUG
by O
mistake O
intravenously O
rather O
than O
subcutaneously O

a O
58-year-old O
man O
with O
advanced O
renal O
cell O
carcinoma O
developed O
grade O
3 O
proteinuria B-ADR
( O
8.5 O
g O
/ O
24 O
h O
) O
without O
microscopic O
hematuria O
or O
renal O
insufficiency O
five O
days O
after O
temsirolimus B-DRUG
infusion O

we O
describe O
2 O
children O
with O
cerebral O
palsy O
who O
suffered O
significant O
morbidity B-ADR
immediately O
after O
treatment O
with O
hyperbaric B-DRUG
oxygen I-DRUG

5-fluorouracil O
( O
5-fu B-DRUG
)- O
associated O
peripheral B-ADR
neuropathy I-ADR
is O
an O
uncommon O
event O

after O
therapy O
with O
parenteral O
amiodarone B-DRUG
( O
2300 O
mg O
in O
3 O
days O
) O
and O
other O
measures O
, O
signs O
of O
congestive O
heart O
failure O
disappeared O
; O
subsequently O
the O
patient O
developed O
jaundice B-ADR
, O
marked O
increase O
in O
serum O
transaminase O
levels O
and O
fall O
in O
prothrombin O
time O
, O
and O
histologic O
changes O
of O
severe O
centrilobular O
necrosis O
were O
observed O
in O
hepatic O
biopsy O

methamphetamine B-DRUG
's O
extensive O
physiologic O
effects O
, O
inconsistent O
street O
purity O
, O
and O
multiple O
routes O
of O
administration O
offer O
many O
possibilities O
for O
injury B-ADR
to I-ADR
the I-ADR
cornea I-ADR

a O
patient O
receiving O
vancomycin B-DRUG
for O
a O
serious O
staphylococcal O
infection O
had O
a O
lupus-like O
syndrome O
characterized O
by O
a O
malar O
rash O
, O
pain B-ADR
and O
erythema O
of O
the O
cartilage O
of O
both O
ears O
, O
and O
tender O
erythematous O
and O
hemorrhagic O
lesions O
of O
the O
finger O
tips O

purpose O
: O
to O
present O
a O
case O
of O
respiratory B-ADR
depression I-ADR
following O
the O
administration O
of O
nebulised O
morphine B-DRUG

a O
patient O
is O
described O
with O
the O
characteristic O
features O
of O
phenytoin B-DRUG
hypersensitivity O
syndrome O
( O
phs O
) O
including O
fever O
, O
erythroderma O
, O
tibial O
and O
facial O
oedema O
, O
pinhead-sized O
facial O
pustules O
and O
abnormal B-ADR
liver I-ADR
function I-ADR
tests I-ADR

objective O
: O
to O
report O
a O
case O
of O
fatal B-ADR
hyperkalemia I-ADR
owing O
to O
succinylcholine B-DRUG
administration O
in O
a O
patient O
with O
mucositis O
secondary O
to O
chemotherapy O

after O
taking O
cholestyramine B-DRUG
ii I-DRUG
sachets O
twice O
daily O
for O
two O
months O
she O
presented O
with O
lethargy O
, O
confusion O
and O
drowsiness B-ADR

we O
report O
a O
case O
of O
seizure B-ADR
associated O
with O
l-asparaginase B-DRUG
therapy O
but O
no O
evidence O
of O
hemorrhagic O
or O
thrombotic O
cerebrovascular O
events O

piloerection B-ADR
induced O
by O
replacing O
fluvoxamine B-DRUG
with O
milnacipran O

we O
present O
the O
first O
case O
( O
to O
our O
knowledge O
) O
of O
a O
potentially O
serious O
drug-drug B-ADR
interaction I-ADR
between O
zafirlukast O
and O
theophylline B-DRUG

we O
describe O
the O
infectious O
toxicities O
experienced O
by O
the O
first O
two O
patients O
in O
our O
institution O
treated O
with O
dexamethasone B-DRUG
( O
10 O
mg O
/ O
m O
( O
2 O
)/ O
day O
for O
4 O
weeks O
with O
gradual O
tapering O
) O
during O
induction O
according O
to O
the O
dexamethasone B-DRUG
arm O
of O
bfm O
2000 O
and O
review O
the O
relevant O
literature O
that O
suggests O
an O
increased O
risk O
of O
infectious B-ADR
complications I-ADR
with O
dexamethasone B-DRUG

rapid O
resolution O
of O
topiramate-induced O
angle-closure B-ADR
glaucoma I-ADR
with O
methylprednisolone O
and O
mannitol B-DRUG

warfarin-associated O
thoracic B-ADR
aortic I-ADR
dissection I-ADR
in O
an O
elderly O
woman O

in O
rare O
cases O
mitomycin B-DRUG
c I-DRUG
( O
mmc O
) O
may O
induce O
cancer-associated O
hemolytic O
uremic O
syndrome O
, O
which O
is O
characterized O
by O
hemolytic O
anemia O
, O
thrombocytopenia O
and O
progressive B-ADR
renal I-ADR
failure I-ADR

in O
a O
patient O
suffering O
from O
rheumatoid O
arthritis O
, O
we O
report O
the O
first O
simultaneous O
occurrence O
of O
two O
side O
effects O
of O
low-dose O
methotrexate B-DRUG
: O
an O
acute O
megaloblastic O
anaemia O
and O
a O
pneumonitis B-ADR

the O
responsibility O
of O
ccnu B-DRUG
in O
the O
pathogenesis O
of O
pulmonary B-ADR
fibrosis I-ADR
seems O
very O
likely O

accelerated B-ADR
nodulosis I-ADR
during O
methotrexate B-DRUG
therapy O
for O
juvenile O
rheumatoid O
arthritis O

two O
patients O
treated O
with O
5-fluorouracil B-DRUG
( O
5-fu O
) O
for O
disseminated O
adenocarcinoma O
of O
the O
colon O
developed O
cerebellar O
dysfunction O
typical O
of O
5-fu O
neurotoxicity B-ADR

two O
of O
the O
five O
patients O
who O
worsened B-ADR
motorically I-ADR
also O
developed O
encephalopathy O
during O
risperidone B-DRUG
treatment O
; O
the O
encephalopathy O
resolved O
when O
the O
patients O
were O
switched O
to O
clozapine O
treatment O

temozolomide B-DRUG
was O
restarted O
2 O
months O
later O
; O
the O
patient O
again O
developed O
a O
fever B-ADR

when O
the O
acute O
manic O
state O
is O
characterized O
by O
marked O
psychotic O
symptoms O
and O
intense B-ADR
anxiety I-ADR
, O
it O
may O
be O
associated O
with O
increased O
vulnerability O
to O
the O
development O
of O
severe O
lithium B-DRUG
neurotoxicity O

she O
was O
thus O
diagnosed O
as O
having O
az B-ADR
intoxication I-ADR

conclusion O
: O
long-term O
treatment O
with O
rifabutin B-DRUG
may O
have O
a O
reversible O
and O
previously O
undescribed O
side-effect B-ADR
on I-ADR
retinal I-ADR
function I-ADR

pulmonary B-ADR
edema I-ADR
occurred O
24 O
hours O
after O
intravenous O
ritodrine O
therapy O
and O
10 O
hours O
after O
subcutaneous O
terbutaline B-DRUG
therapy O

we O
report O
an O
hiv-infected O
woman O
who O
developed O
mild O
leukopenia O
as O
the O
first O
sign O
of O
a O
nevirapine-related O
adverse O
event O
, O
which O
was O
followed O
by O
skin B-ADR
and I-ADR
hepatic I-ADR
toxicity I-ADR
associated O
with O
a O
more O
severe O
leukopenia O

asthenozoospermia B-ADR
: O
possible O
association O
with O
long-term O
exposure O
to O
an O
anti-epileptic O
drug O
of O
carbamazepine B-DRUG

cutaneous B-ADR
mycobacterial I-ADR
infection I-ADR
post O
intravesical O
bcg B-DRUG
installation O

data O
have O
been O
published O
regarding O
the O
possibility O
that O
tamoxifen B-DRUG
may O
be O
responsible O
for O
the O
subsequent O
development O
of O
carcinoma B-ADR
of I-ADR
the I-ADR
corpus I-ADR
uteri I-ADR
in O
these O
patients O

this O
progressed O
to O
tracheal B-ADR
compression I-ADR
with O
stridor O
after O
he O
had O
taken O
some O
aspirin B-DRUG
for O
relief O
of O
the O
neck O
pain O

only O
a O
few O
reports O
of O
overt O
jaundice B-ADR
are O
associated O
with O
streptokinase B-DRUG

discussion O
: O
patients O
with O
5-fu-induced O
ectropion O
experience O
tender B-ADR
, I-ADR
red I-ADR
, I-ADR
scaled I-ADR
lids I-ADR
, O
making O
contact O
lens O
wear O
difficult O

laryngeal B-ADR
dyspnea I-ADR
in O
relation O
to O
an O
interaction O
between O
acenocoumarol B-DRUG
and O
topical O
econazole O
lotion O

there O
is O
a O
putative O
role O
of O
liothyronine B-DRUG
administration O
in O
precipitating O
or O
activating O
hyperthyroidism B-ADR

she O
was O
placed O
on O
adjuvant O
adriamycin B-DRUG
( O
doxorubicin O
) O
chemotherapy O
, O
but O
6 O
months O
later O
died B-ADR
of O
adriamycin B-DRUG
toxicity O

a O
22-year-old O
black O
man O
developed O
fever O
, O
chills B-ADR
, O
fatigue O
, O
night O
sweats O
, O
tender O
lymphadenopathy O
, O
and O
a O
generalized O
, O
pruritic O
, O
macular O
eruption O
3 O
weeks O
after O
starting O
minocycline B-DRUG
therapy O
for O
acne O

after O
discontinuing O
captopril B-DRUG
and O
starting O
systemic O
steroids O
, O
her O
symptomatology O
rapidly O
improved O
, O
and O
her O
eosinophilia O
and O
radiographic B-ADR
abnormalities I-ADR
both O
resolved O

treatment O
/ O
outcome O
: O
standard O
anti-tuberculosis O
therapy O
was O
administered O
but O
was O
complicated O
by O
interaction O
with O
cyclosporine B-DRUG
and O
drug-induced O
cholestasis B-ADR

gemcitabine B-DRUG
therapy O
has O
been O
associated O
with O
radiation B-ADR
recall I-ADR
reactions I-ADR
when O
used O
in O
the O
treatment O
of O
carcinoma O

cough B-ADR
induced O
by O
quinapril B-DRUG
with O
resolution O
after O
changing O
to O
fosinopril O

the O
literature O
search O
revealed O
22 O
cases O
of O
hypersensitivity B-ADR
reaction I-ADR
to O
cyclosporine B-DRUG

after O
approximately O
two O
weeks O
of O
sertraline B-DRUG
treatment O
he O
noted O
an O
intense B-ADR
itching I-ADR
sensation I-ADR
in O
his O
scalp O
after O
eating O
a O
piece O
of O
chocolate O
cake O

acute O
renal B-ADR
failure I-ADR
should O
be O
recognized O
as O
a O
potential O
complication O
of O
suramin B-DRUG
treatment O

this O
case O
of O
linezolid-associated O
acute B-ADR
interstitial I-ADR
nephritis I-ADR
within O
the O
context O
of O
a O
drug O
rash O
with O
eosinophilia O
and O
systemic O
symptoms O
( O
dress O
) O
syndrome O
in O
a O
patient O
treated O
with O
linezolid B-DRUG
raises O
concerns O
about O
the O
presumed O
renal O
safety O
of O
this O
drug O

divalproex B-DRUG
sodium-induced O
eosinophilic B-ADR
pleural I-ADR
effusion I-ADR

a O
case O
is O
presented O
of O
a O
patient O
who O
experienced O
benzodiazepine B-ADR
withdrawal I-ADR
symptoms I-ADR
on O
discontinuation O
of O
nefazodone B-DRUG
, O
an O
antidepressant O
that O
inhibits O
the O
cytochrome O
p450 O
3a4 O
isoenzyme O

these O
results O
indicate O
that O
lithium B-DRUG
may O
cause O
biochemical B-ADR
hyperparathyroidism I-ADR

the O
evidence O
of O
high O
plasmatic O
levels O
of O
cbz B-DRUG
and O
the O
absence O
of O
other O
aetiologic O
factors O
lead O
the O
authors O
to O
conclude O
that O
the O
overdose O
of O
cbz B-DRUG
could O
have O
represented O
the O
precipitating O
of O
the O
episode O
of O
acute B-ADR
pancreatitis I-ADR

the O
authors O
report O
the O
first O
case O
of O
bucillamine-induced O
giant B-ADR
mammary I-ADR
hyperplasia I-ADR

heparin-induced O
thrombocytopenia B-ADR
complicated O
with O
massive O
thrombosis O
of O
the O
inferior O
vena O
cava O
after O
filter O
placement O

while O
both O
amiodarone O
and O
digoxin B-DRUG
can O
cause O
permanent O
visual B-ADR
changes I-ADR
, O
the O
ocular O
effects O
are O
often O
reversible O

we O
report O
an O
unusual O
case O
of O
simultaneous O
transitional O
cell O
carcinoma O
of O
the O
renal O
pelvis O
and O
distal B-ADR
ureter I-ADR
without I-ADR
transitional I-ADR
cell I-ADR
carcinoma I-ADR
of I-ADR
the I-ADR
bladder I-ADR
occurring O
after O
chronic O
cyclophosphamide B-DRUG
therapy O
for O
nonhodgkin O
's O
lymphoma O

aseptic O
meningitis O
, O
hemolytic O
anemia O
, O
hepatitis B-ADR
, O
and O
orthostatic O
hypotension O
in O
a O
patient O
treated O
with O
trimethoprim-sulfamethoxazole O

we O
report O
a O
patient O
with O
pulmonary O
adenocarcinoma O
complicated O
by O
the O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
secretion I-ADR
of I-ADR
antidiuretic I-ADR
hormone I-ADR
( O
siadh O
) O
following O
systemic O
chemotherapy O
with O
cisplatin O
( O
cddp O
) O
and O
vindesine B-DRUG
( O
vds O

seizures B-ADR
and O
transient O
blindness O
following O
intravenous O
pulse O
methylprednisolone B-DRUG
in O
children O
with O
primary O
glomerulonephritis O

conclusion O
: O
all O
doctors O
need O
to O
be O
aware O
of O
the O
need O
to O
review O
the O
indications O
for O
gabapentin B-DRUG
use O
during O
periods O
of O
acute O
illness O
, O
especially O
with O
regard O
to O
renal B-ADR
impairment I-ADR

mitomycin-c B-DRUG
induced O
hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
: O
a O
case O
report O

a O
patient O
developed O
optic B-ADR
neuropathy I-ADR
while O
being O
treated O
with O
isoniazid O
and O
ethambutol B-DRUG

we O
present O
the O
management O
of O
agranulocytosis O
and O
neutropenic B-ADR
sepsis I-ADR
secondary O
to O
carbimazole B-DRUG
with O
recombinant O
human O
granulocyte O
colony O
stimulating O
factor O
( O
g-csf O

the O
potential O
role O
of O
propranolol B-DRUG
in O
inducing O
central B-ADR
nervous I-ADR
system I-ADR
disturbances I-ADR
is O
emphasized O
, O
and O
the O
literature O
on O
the O
subject O
is O
reviewed O

sustained B-ADR
monomorphic I-ADR
ventricular I-ADR
tachycardia I-ADR
after O
adenosine B-DRUG
infusion O

we O
report O
two O
cases O
of O
fulminant B-ADR
hepatic I-ADR
failure I-ADR
in O
hiv-1-infected O
patients O
treated O
with O
didanosine O
( O
ddi B-DRUG

two O
children O
with O
rheumatic O
fever O
developed O
anicteric B-ADR
hepatitis I-ADR
while O
on O
high-dose O
aspirin B-DRUG
therapy O

long O
lasting O
respiratory B-ADR
depression I-ADR
induced O
by O
morphine-6-glucuronide B-DRUG

a O
case O
of O
tuberculosis B-ADR
in O
a O
patient O
on O
efalizumab B-DRUG
and O
etanercept O
for O
treatment O
of O
refractory O
palmopustular O
psoriasis O
and O
psoriatic O
arthritis O

pvt B-ADR
during O
chemotherapy O
in O
children O
is O
a O
rare O
event O
and O
appears O
to O
be O
closely O
related O
to O
intensive O
chemotherapy O
containing O
busulfan B-DRUG
and O
to O
be O
associated O
with O
hvod O

we O
report O
a O
case O
of O
contact B-ADR
dermatitis I-ADR
due O
to O
sodium B-DRUG
bisulfite I-DRUG
in O
tathion O
eye O
drops O

dyspnea B-ADR
, O
hypoxemia O
, O
and O
pleuritic O
chest O
pain O
occurred O
within O
24 O
hours O
of O
rituximab B-DRUG
administration O
, O
and O
there O
was O
no O
other O
apparent O
explanation O

we O
report O
a O
case O
of O
amiodarone-induced O
thyrotoxicosis B-ADR
of O
protracted O
duration O
, O
unresponsive O
to O
conventional O
thionamide O
therapy O
, O
with O
therapy O
limited O
by O
severe O
adverse O
drug O
reactions O

evidence O
obtained O
indicated O
that O
the O
reye-like O
syndrome O
might O
be O
caused O
by O
calcium B-DRUG
hopantenate I-DRUG
possibly O
due O
to O
the O
induction O
of O
pantothenic B-ADR
acid I-ADR
deficiency I-ADR

we O
report O
an O
unusual O
case O
of O
simultaneous O
transitional B-ADR
cell I-ADR
carcinoma I-ADR
of I-ADR
the I-ADR
renal I-ADR
pelvis I-ADR
and O
distal O
ureter O
without O
transitional O
cell O
carcinoma O
of O
the O
bladder O
occurring O
after O
chronic O
cyclophosphamide B-DRUG
therapy O
for O
nonhodgkin O
's O
lymphoma O

lymphoma B-ADR
developing O
in O
a O
patient O
with O
rheumatoid O
arthritis O
taking O
methotrexate B-DRUG

children O
receiving O
zonisamide B-DRUG
should O
be O
monitored O
for O
oligohidrosis B-ADR
and O
the O
development O
of O
neurological O
symptoms O
associated O
with O
an O
elevation O
of O
body O
temperature O

acute B-ADR
acoustic I-ADR
nerve I-ADR
palsy I-ADR
associated O
with O
vincristine B-DRUG
therapy O

we O
report O
a O
case O
of O
a O
previously O
healthy O
, O
postmenopausal O
woman O
who O
developed O
anticonvulsant B-ADR
hypersensitivity I-ADR
syndrome I-ADR
while O
taking O
bellamine O
s O
( O
belladonna O
alkaloids O
; O
ergotamine O
; O
phenobarbital B-DRUG
) O
for O
hot O
flashes O

transient B-ADR
acute I-ADR
myopia I-ADR
resulting O
from O
isotretinoin B-DRUG
( O
accutane O
) O
therapy O

introduction O
: O
although O
gefitinib B-DRUG
used O
for O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
is O
a O
well-known O
cause O
of O
interstitial B-ADR
lung I-ADR
disease I-ADR
( O
ild O
) O
, O
few O
case O
reports O
on O
erlotinib-induced O
ild O
have O
been O
issued O

focal B-ADR
glomerulonephritis I-ADR
and O
interstitial O
nephritis O
in O
methicillin-treated O
, O
heroin-related O
infective O
endocarditis O

this O
report O
presents O
a O
case O
of O
colon B-ADR
perforation I-ADR
which O
occurred O
4 O
months O
after O
treatment O
with O
intraperitoneal O
chromic B-DRUG
phosphate I-DRUG
for O
stage O
ib O
ovarian O
papillary O
serous O
cystadenocarcinoma O

abrupt O
, O
accidental O
withdrawal O
of O
trihexyphenidyl B-DRUG
triggered O
severe O
exacerbation O
of O
the O
cranial B-ADR
dystonia I-ADR
associated O
with O
inspiratory O
stridor O
and O
acute O
respiratory O
difficulties O
, O
prompting O
emergency O
admission O

objective O
: O
to O
study O
therapy O
with O
indapamide B-DRUG
impairing O
carbohydrate O
metabolism O
in O
essential O
hypertension O
patients O
and O
achieve O
earlier O
prevention O
, O
diagnoses O
and O
treatment O
of O
diabetes B-ADR
induced O
by O
indapamide B-DRUG

the O
international O
literature O
regarding O
opportunistic B-ADR
infections I-ADR
after O
immunosuppressive O
therapy O
with O
alemtuzumab B-DRUG
with O
particular O
attention O
on O
fungal O
infections O
has O
also O
been O
reviewed O

gemcitabine-induced O
rectus B-ADR
abdominus I-ADR
radiation I-ADR
recall I-ADR

methylphenidate O
( O
ritalin B-DRUG
)- O
associated O
cataract O
and O
glaucoma B-ADR

treatment O
with O
infliximab B-DRUG
is O
known O
to O
produce O
an O
increase B-ADR
of I-ADR
autoantibodies I-ADR
( O
antinuclear O
antibodies O
, O
anti-double-stranded O
dna O
) O
, O
but O
not O
clinical O
disease O

we O
observed O
3 O
diabetic O
patients O
with O
intolerable O
dizziness O
followed O
by O
nausea O
and O
vomiting B-ADR
immediately O
after O
an O
initial O
administration O
of O
the O
alpha-glucosidase O
inhibitor O
, O
voglibose B-DRUG

after O
infliximab B-DRUG
treatment O
, O
additional O
sleep O
studies O
revealed O
an O
increase B-ADR
in I-ADR
the I-ADR
number I-ADR
of I-ADR
apneic I-ADR
events I-ADR
and O
sao2 O
dips O
suggesting O
that O
tnfalpha O
plays O
an O
important O
role O
in O
the O
pathophysiology O
of O
sleep O
apnea O

overdose O
of O
magnesium B-DRUG
sulfate I-DRUG
in O
combination O
with O
renal O
insufficiency O
, O
hypocalcemia O
, O
or O
compromise O
of O
intestinal O
integrity O
may O
predispose O
horses O
to O
magnesium B-ADR
toxicosis I-ADR

conclusion O
: O
zidovudine B-DRUG
is O
well O
a O
known O
cause O
of O
anaemia B-ADR
and O
thus O
should O
be O
used O
with O
caution O
in O
the O
initiation O
of O
antiretroviral O
therapy O

serious B-ADR
adverse I-ADR
events I-ADR
experienced O
by O
patients O
with O
chronic O
heart O
failure O
taking O
spironolactone B-DRUG

cardiac B-ADR
arrest I-ADR
after O
esmolol B-DRUG
administration O
: O
a O
review O
of O
acute O
beta-blocker O
toxicity O

thrombo-embolic B-ADR
complication I-ADR
after O
streptokinase B-DRUG
therapy O
of O
pulmonary O
emboli O

the O
association O
of O
central O
diabetes O
insipidus O
( O
cdi B-ADR
) O
with O
lithium B-DRUG
use O
is O
rare O

the O
more O
common O
grade O
3 O
or O
4 O
adverse O
effects O
of O
sunitinib B-DRUG
include O
hypertension O
, O
fatigue O
, O
hand-foot O
syndrome O
, O
elevated O
lipase O
and O
lymphopenia B-ADR

it O
is O
suggested O
that O
the O
patient O
had O
sulfasalazine-induced O
lupus O
, O
which O
manifested O
with O
serositis O
and O
pulmonary B-ADR
parenchymal I-ADR
involvement I-ADR
in O
the O
absence O
of O
joint O
symptoms O

herein O
, O
we O
describe O
a O
patient O
with O
aids O
who O
presented O
to O
medical O
attention O
with O
pancytopenia B-ADR
48 O
months O
postchemotherapy O
with O
etoposide B-DRUG
, O
prednisone O
, O
vincristine O
, O
cyclophosphamide O
, O
doxorubicin O
, O
and O
rituximab O
( O
r-epoch O
) O
for O
diffuse O
large O
b-cell O
lymphoma O

background O
: O
methotrexate B-DRUG
( O
mtx O
) O
may O
induce O
liver B-ADR
damage I-ADR
, O
which O
in O
some O
psoriatics O
will O
lead O
to O
fibrosis O
or O
cirrhosis O

an O
83-year-old O
man O
receiving O
glipizide O
10 O
mg O
bid O
developed O
symptomatic B-ADR
hypoglycemia I-ADR
within O
three O
days O
of O
adding O
trimethoprim O
/ O
sulfamethoxazole O
( O
tmp O
/ O
smx B-DRUG
) O
to O
his O
regimen O

the O
literature O
search O
found O
12 O
cases O
of O
radiation B-ADR
recall I-ADR
caused O
by O
gemcitabine B-DRUG

six O
patients O
with O
rheumatoid O
arthritis O
developed O
a O
syndrome O
resembling O
lupus B-ADR
erythematosus I-ADR
while O
being O
treated O
with O
penicillamine B-DRUG

we O
report O
a O
case O
of O
chronic O
use O
of O
hcq B-DRUG
associated O
with O
torsade B-ADR
de I-ADR
pointes I-ADR

this O
report O
describes O
a O
probable O
case O
of O
infliximab-induced O
membranous B-ADR
nephropathy I-ADR

idiosyncratic O
factors O
involving O
vasopressin B-DRUG
receptor O
affinity O
and O
distribution O
, O
vasopressin-associated O
vasodilation O
in O
some O
vascular O
beds O
, O
and O
the O
effect O
of O
vasopressin B-DRUG
on O
the O
renin-angiotensin O
system O
may O
further O
contribute O
to O
impaired B-ADR
tissue I-ADR
perfusion I-ADR

the O
current O
report O
describes O
a O
man O
who O
was O
prescribed O
zonisamide B-DRUG
for O
epilepsy O
and O
subsequently O
developed O
widespread O
skin O
rash O
, O
acute O
kidney O
injury O
, O
high-grade O
fever O
, O
eosinophilia O
, O
liver B-ADR
dysfunction I-ADR
, O
lymphadenopathy O
and O
an O
increase O
in O
antihuman O
herpesvirus-6 O
immunoglobulin O
g O
titer O

the O
case O
demonstrates O
that O
hypersensitivity B-ADR
reaction I-ADR
to O
pranlukast B-DRUG
and O
resultant O
atin O
is O
possible O
, O
and O
that O
periodic O
urine O
testing O
in O
patients O
receiving O
pranlukast B-DRUG
should O
be O
considered O

evaluation O
revealed O
elevated B-ADR
serum I-ADR
ltg I-ADR
levels I-ADR
and O
no O
other O
etiology O
for O
encephalopathy O

some O
patients O
develop O
hypersensitivity B-ADR
rash I-ADR
in O
response O
to O
hcq B-DRUG

no O
cases O
of O
renal O
acidosis O
, O
and O
only O
one O
case O
of O
nephrogenic B-ADR
diabetes I-ADR
insipidus I-ADR
, O
has O
been O
previously O
reported O
as O
a O
complication O
of O
foscarnet B-DRUG
treatment O

the O
most O
common O
side O
effects O
associated O
with O
amifostine B-DRUG
are O
nausea O
, O
vomiting O
, O
hypotension B-ADR
, O
hypocalcemia O
and O
allergic O
reactions O

conclusions O
: O
the O
fundus O
picture O
shown O
in O
these O
cases O
may O
be O
typical O
of O
asppc B-ADR
after O
ivta B-DRUG
injection O

a O
case O
of O
propranolol B-DRUG
overdose O
complicated O
by O
esophageal B-ADR
spasm I-ADR
preventing O
extrication O
of O
an O
orogastric O
lavage O
tube O
and O
relieved O
by O
intravenous O
glucagon O
is O
presented O

purpose O
: O
to O
describe O
the O
clinical O
and O
electrophysiological O
findings O
in O
a O
young O
boy O
with O
decreased O
vision O
possibly O
due O
to O
retinal B-ADR
damage I-ADR
by O
rifabutin B-DRUG

recurrent O
palmar-plantar B-ADR
erythrodysaesthesia I-ADR
following O
high-dose O
cytarabine B-DRUG
treatment O
for O
acute O
lymphoblastic O
leukemia O

dyspnea B-ADR
possibly O
associated O
with O
controlled-release O
morphine B-DRUG
sulfate I-DRUG
tablets O

we O
believe O
that O
these O
skin B-ADR
eruptions I-ADR
belong O
to O
a O
spectrum O
of O
neutrophilic O
dermatoses O
that O
can O
be O
induced O
or O
aggravated O
by O
g-csf B-DRUG
therapy O

gold-induced O
pneumonitis B-ADR
is O
a O
rare O
complication O
of O
gold O
salt O
therapy O

clozapine-induced O
eosinophilia B-ADR
and O
switch O
to O
quetiapine O
in O
a O
patient O
with O
chronic O
schizophrenia O
with O
suicidal O
tendencies O

materials O
and O
methods O
: O
we O
present O
two O
cases O
of O
significant O
morbidity O
related O
to O
primary B-ADR
and I-ADR
secondary I-ADR
perforation I-ADR
of I-ADR
the I-ADR
bladder I-ADR
following O
two O
instillations O
of O
epirubicin B-DRUG

a O
new O
type O
of O
minocycline-induced O
cutaneous B-ADR
hyperpigmentation I-ADR

prominent B-ADR
eye I-ADR
movements I-ADR
during I-ADR
nrem I-ADR
sleep I-ADR
and O
rem O
sleep O
behavior O
disorder O
associated O
with O
fluoxetine B-DRUG
treatment O
of O
depression O
and O
obsessive-compulsive O
disorder O

we O
suggest O
that O
nicotinic B-DRUG
acid I-DRUG
was O
the O
cause O
of O
his O
liver O
disease O
, O
that O
this O
case O
is O
of O
particular O
note O
because O
of O
the O
rather O
short O
period O
of O
therapy O
before O
the O
onset O
of O
liver O
injury O
and O
the O
severity O
of O
the O
hepatic O
failure O
, O
and O
that O
the O
probable O
increased O
use O
of O
nicotinic B-DRUG
acid I-DRUG
for O
serum O
cholesterol O
control O
makes O
it O
especially O
important O
for O
physicians O
and O
their O
patients O
to O
be O
alert O
to O
the O
signs O
of O
hepatotoxicity B-ADR

acute B-ADR
pancreatitis I-ADR
in O
a O
child O
with O
idiopathic O
ulcerative O
colitis O
on O
long-term O
5-aminosalicylic B-DRUG
acid I-DRUG
therapy O

in O
this O
report O
we O
described O
a O
case O
of O
juvenile O
idiopathic O
arthritis O
patient O
who O
developed O
thymic B-ADR
enlargement I-ADR
( O
true O
thymic O
hyperplasia O
) O
, O
mediastinal O
lymphadenopathy O
and O
pleurisy O
associated O
with O
systemic O
symptoms O
under O
etanercept B-DRUG
treatment O

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine O
, O
topiramate O
, O
divalproex B-DRUG
sodium I-DRUG
, O
risperidone O
, O
and O
carbamazepine O
) O
presenting O
with O
mixed O
ss B-ADR
/ O
nms O
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss B-ADR
/ O
nms O
in O
critical O
care O
settings O

multiple O
myeloma O
complicated O
by O
congestive B-ADR
heart I-ADR
failure I-ADR
following O
first O
administration O
of O
recombinant B-DRUG
alpha-interferon I-DRUG

polymyoclonus B-ADR
seizure I-ADR
resulting O
from O
accidental O
injection O
of O
tranexamic B-DRUG
acid I-DRUG
in O
spinal O
anesthesia O

para-aminosalicylic B-DRUG
acid-induced O
hypoglycaemia B-ADR
in O
a O
patient O
with O
diabetic O
nephropathy O

in O
both O
patients O
the O
rippling B-ADR
phenomena I-ADR
worsened I-ADR
with O
pyridostigmine B-DRUG
treatment O
but O
markedly O
improved O
after O
immunosuppression O
with O
azathioprine O

after O
therapy O
with O
parenteral O
amiodarone B-DRUG
( O
2300 O
mg O
in O
3 O
days O
) O
and O
other O
measures O
, O
signs O
of O
congestive O
heart O
failure O
disappeared O
; O
subsequently O
the O
patient O
developed O
jaundice O
, O
marked B-ADR
increase I-ADR
in I-ADR
serum I-ADR
transaminase I-ADR
levels I-ADR
and O
fall O
in O
prothrombin O
time O
, O
and O
histologic O
changes O
of O
severe O
centrilobular O
necrosis O
were O
observed O
in O
hepatic O
biopsy O

when O
sasp O
was O
changed O
to O
5-aminosalicylic B-DRUG
acid I-DRUG
( O
5-asa O
) O
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he O
developed O
weakness O
and O
atrophy O
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening O
of O
the O
dysesthesia O
in O
his O
legs O
and O
gait B-ADR
disturbance I-ADR

reye B-ADR
syndrome I-ADR
( O
rs O
) O
is O
believed O
to O
occur O
infrequently O
among O
children O
receiving O
long-term O
aspirin B-DRUG
therapy O

purpose O
: O
to O
report O
patients O
who O
presented O
to O
the O
oculoplastics O
department O
for O
repair O
of O
cicatrical B-ADR
entropion I-ADR
after O
topical O
use O
of O
dipivefrin B-DRUG

in O
this O
case O
senna B-DRUG
was O
likely O
the O
cause O
of O
a O
subacute B-ADR
cholestatic I-ADR
hepatitis I-ADR
exemplifying O
again O
the O
potential O
role O
of O
herbal O
related O
liver O
injury O

the O
patient O
was O
initially O
treated O
with O
hydration O
and O
furosemide B-DRUG
but O
developed O
congestive B-ADR
heart I-ADR
failure I-ADR

goiter O
and O
hypothyroidism O
during O
re-treatment O
with O
amiodarone B-DRUG
in O
a O
patient O
who O
previously O
experienced O
amiodarone-induced O
thyrotoxicosis B-ADR

uveitis B-ADR
during O
treatment O
of O
disseminated O
mycobacterium O
avium-intracellulare O
complex O
infection O
with O
the O
combination O
of O
rifabutin O
, O
clarithromycin B-DRUG
and O
ethambutol O

interstitial O
pneumonitis O
and O
alveolar B-ADR
hemorrhage I-ADR
complicating O
use O
of O
rituximab B-DRUG
: O
case O
report O
and O
review O
of O
the O
literature O

aluminum B-ADR
intoxication I-ADR
, O
along O
with O
other O
factors O
, O
was O
considered O
to O
be O
the O
cause O
of O
tc O
development O

however O
, O
one O
patient O
exhibited O
severe O
hypersensitivity O
reactions O
including O
cardiac O
arrest O
and O
apnea O
, O
and O
another O
four O
patients O
developed O
eruptions B-ADR
, O
hypotension O
, O
and O
tachycardia O
soon O
after O
administration O
of O
cbdca B-DRUG

disopyramide B-DRUG
( O
norpace O
)- O
induced O
hypoglycemia B-ADR

hypersensitivity O
to O
carboplatin B-DRUG
is O
a O
rare O
but O
real O
complication O
of O
therapy O
and O
should O
be O
considered O
in O
patients O
presenting O
with O
hyperacute B-ADR
changes I-ADR
on I-ADR
ecg I-ADR
whilst O
receiving O
carboplatin B-DRUG
therapy O

ophthalmologic B-ADR
and I-ADR
neurologic I-ADR
findings I-ADR
in O
two O
children O
exposed O
to O
vigabatrin B-DRUG
in O
utero O

eye B-ADR
movement I-ADR
disorders I-ADR
in O
bone O
marrow O
transplant O
patients O
on O
cyclosporin O
and O
ganciclovir B-DRUG

conclusions O
: O
itraconazole-induced O
liver O
injury O
presents O
with O
a O
cholestatic B-ADR
pattern I-ADR
of I-ADR
injury I-ADR
with O
damage O
to O
the O
interlobular O
bile O
ducts O
, O
possibly O
leading O
to O
ductopenia O

three O
years O
later O
, O
treatment O
with O
ampicillin B-DRUG
caused O
another O
episode O
of O
cholestatic O
hepatitis O
with O
cholestasis O
and O
duct B-ADR
paucity I-ADR
on O
rebiopsy O

lethal B-ADR
anuria I-ADR
complicating O
high O
dose O
ifosfamide B-DRUG
chemotherapy O
in O
a O
breast O
cancer O
patient O
with O
an O
impaired O
renal O
function O

we O
introduce O
a O
case O
of O
a O
sixty O
years O
old O
woman O
with O
several O
previous O
episodes O
of O
rhinitis O
, O
conjunctivitis O
and O
perspiration B-ADR
immediately O
after O
the O
administration O
of O
salmon O
calcitonin O
with O
nasal O
spray O
or O
intramuscular O
administration O
( O
calsynar B-DRUG

methods O
: O
two O
patients O
with O
exudative O
age-related B-ADR
macular I-ADR
degeneration I-ADR
were O
treated O
sequentially O
with O
an O
intravitreal O
injection O
of O
bevacizumab B-DRUG
and O
developed O
signs O
of O
severe O
but O
painless O
infectious O
endophthalmitis O
2 O
days O
later O

hypoxemia O
improved O
during O
continuous O
tolazoline B-DRUG
infusion O
, O
but O
gastrointestinal B-ADR
bleeding I-ADR
occurred O

prolonged O
responses O
were O
achieved O
with O
low O
doses O
of O
hu B-DRUG
( O
3-10 O
mg O
/ O
kg O
/ O
day O
) O
and O
higher O
doses O
were O
associated O
with O
mild O
reversible O
hematologic O
or O
hepatic B-ADR
toxicity I-ADR
and O
no O
further O
increases O
in O
hb O

desipramine-associated O
siadh B-ADR
in O
an O
elderly O
woman O
: O
case O
report O

the O
clinical O
course O
suggested O
that O
recombinant B-DRUG
alpha-2b I-DRUG
peginterferon I-DRUG
plus O
ribavirin O
provoked O
type B-ADR
1 I-ADR
diabetes I-ADR
mellitus I-ADR
, O
therefore O
, O
in O
patients O
who O
are O
candidates O
for O
interferon O
therapy O
the O
presence O
of O
pancreatic O
autoantibodies O
and O
the O
fasting O
plasma O
glucose O
level O
should O
be O
investigated O
before O
and O
during O
treatment O

a O
case O
of O
siadh B-ADR
associated O
with O
desipramine B-DRUG
treatment O
in O
an O
elderly O
depressed O
woman O
is O
described O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly B-ADR
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp B-DRUG
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

this O
report O
describes O
a O
case O
of O
acute O
compromise O
of O
renal O
function O
associated O
with O
hypotension B-ADR
in O
a O
7-year-old O
boy O
treated O
with O
the O
ace O
inhibitor O
lisinopril O
and O
the O
arb O
losartan B-DRUG

thrombolytic O
therapy O
with O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
( O
tpa O
) O
for O
acute O
myocardial O
infarction O
may O
result O
in O
major O
bleeding O
complications O
such O
as O
gastrointestinal B-ADR
or I-ADR
intracranial I-ADR
bleeding I-ADR

the O
pulmonary O
toxicity O
of O
gold B-DRUG
salts O
is O
an O
uncommon O
cause O
of O
life-threatening O
respiratory B-ADR
failure I-ADR

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever B-ADR
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim B-DRUG
( O
tmp O
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

acute B-ADR
vision I-ADR
loss I-ADR
after O
intravitreal O
injection O
of O
bevacizumab O
( O
avastin B-DRUG
) O
associated O
with O
ocular O
ischemic O
syndrome O

pulmonary B-ADR
hemorrhage I-ADR
is O
an O
uncommon O
feature O
in O
the O
hus O
, O
and O
seems O
to O
appear O
especially O
in O
the O
hus O
associated O
with O
mmc B-DRUG
therapy O

the O
sulfonamides B-DRUG
are O
the O
best O
verified O
drug-trigger O
for O
erythema B-ADR
multiforme I-ADR
and O
stevens-johnson O
syndrome O

case O
summaries O
: O
in O
each O
case O
, O
the O
patients O
were O
treated O
over O
5 O
years O
with O
lovastatin B-DRUG
and O
developed O
rhabdomyolysis B-ADR
that O
coincided O
with O
the O
completion O
of O
a O
prescribed O
regimen O
of O
a O
newer O
macrolide O
antibiotic O

amphotericin O
b O
( O
amb B-DRUG
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal O
impairment O
, O
anaemia O
, O
fever O
, O
malaise O
, O
and O
hypokalaemia B-ADR
are O
common O

linear B-ADR
immunoglobulin I-ADR
a I-ADR
bullous I-ADR
dermatosis I-ADR
induced O
by O
gemcitabine B-DRUG

a O
35-year-old O
woman O
presented O
with O
neurotoxicity B-ADR
correlated O
to O
an O
i.v. O
regimen O
of O
5-fluorouracil B-DRUG
as O
episodes O
of O
acute O
confusional O
state O
and O
abnormalities O
of O
symmetrically O
restricted O
diffusion O
in O
the O
periventricular O
white O
matter O
and O
corpus O
callosum O

in O
a O
61-year-old O
man O
receiving O
chronic O
low-dosage O
amiodarone B-DRUG
an O
interstitial B-ADR
pneumopathy I-ADR
was O
observed O

heparin-associated O
thrombocytopenia B-ADR
: O
successful O
therapy O
with O
the O
heparinoid O
org O
10172 O
in O
a O
patient O
showing O
cross-reaction O
to O
lmw O
heparins O

the O
day O
after O
methotrexate B-DRUG
administration O
, O
the O
patient O
complained O
of O
severe B-ADR
back I-ADR
pain I-ADR
and O
urinary O
retention O

radiation B-ADR
recall I-ADR
from O
gemcitabine B-DRUG
is O
rare O
, O
but O
can O
potentially O
arise O
in O
any O
site O
that O
has O
been O
previously O
irradiated O

after O
therapy O
for O
diabetic O
coma O
with O
insulin O
( O
containing O
the O
preservative O
cresol B-DRUG
) O
and O
electrolyte O
solutions O
was O
started O
, O
the O
patient O
complained O
of O
increasing O
myalgia O
, O
developed O
a O
high O
fever O
and O
respiratory O
and O
metabolic O
acidosis O
and O
lost B-ADR
consciousness I-ADR

a O
dapsone B-DRUG
hypersensitivity O
syndrome O
, O
consisting O
of O
fever B-ADR
, O
headache O
, O
nausea O
, O
vomiting O
, O
lymphadenopathy O
, O
hepatitis O
, O
hemolysis O
, O
leukopenia O
, O
and O
mononucleosis O
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

the O
case O
history O
confirms O
that O
gold B-DRUG
treatment O
, O
even O
in O
the O
same O
patient O
, O
can O
give O
rise O
to O
a O
wide O
range O
of O
skin B-ADR
disturbances I-ADR
, O
which O
in O
many O
cases O
do O
not O
break O
out O
until O
long O
after O
the O
drug O
has O
been O
withdrawn O

ischaemia B-ADR
following O
selfadministered O
intra-arterial O
injection O
of O
methylphenidate B-DRUG
and O
diamorphine O

the O
majority O
of O
radiation B-ADR
recall I-ADR
reactions I-ADR
attributed O
to O
gemcitabine B-DRUG
are O
reported O
to O
affect O
internal O
tissue O
or O
organs O

objective O
: O
to O
describe O
onset O
of O
syndrome O
of O
inappropriate O
antidiuretic O
hormone O
( O
siadh B-ADR
) O
associated O
with O
vinorelbine B-DRUG
therapy O
for O
advanced O
breast O
cancer O

painful O
neutrophilic B-ADR
skin I-ADR
lesions I-ADR
were O
observed O
in O
two O
children O
receiving O
granulocyte B-DRUG
colony-stimulating I-DRUG
factor I-DRUG
( O
g-csf O
) O
for O
treatment O
of O
idiopathic O
neutropenia O

transient B-ADR
asymptomatic I-ADR
bradycardia I-ADR
in O
patients O
on O
infusional O
5-fluorouracil B-DRUG

hemodynamic B-ADR
collapse I-ADR
following O
labetalol B-DRUG
administration O
in O
preeclampsia O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
polyserositis O
( O
pericardial O
effusion O
, O
pleural B-ADR
effusion I-ADR
, O
and O
pericarditis O
) O
after O
being O
started O
on O
clozapine B-DRUG
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine B-DRUG

we O
report O
a O
patient O
with O
advanced O
colonic O
carcinoma O
who O
was O
treated O
with O
concomitant O
chemoirradiation O
with O
oxaliplatin B-DRUG
and O
developed O
a O
peculiar O
dermnatitis B-ADR
in O
the O
irradiated O
field O
after O
being O
exposed O
to O
subsequent O
chemotherapy O
with O
oxaliplatin B-DRUG

we O
speculate O
that O
platelet O
activation O
induced O
by O
pfviii B-DRUG
may O
have O
contributed O
to O
thrombosis B-ADR
and O
suggest O
that O
pfviii B-DRUG
be O
used O
with O
caution O
in O
elderly O
patients O
with O
pre-existing O
cardiovascular O
risk O
factors O

we O
report O
a O
cae O
of O
paranoid O
psychosis O
following O
use O
of O
a O
decongestant O
containing O
ppa B-DRUG
and O
summarize O
the O
case O
report O
literature O
of O
psychiatric B-ADR
adverse I-ADR
effects I-ADR
to O
ppa B-DRUG
in O
which O
doses O
were O
known O
and O
stated O
to O
be O
within O
recommended O
guidelines O

findings O
on O
discontinuation O
and O
rechallenge O
supported O
the O
assumption O
that O
the O
hair B-ADR
loss I-ADR
was O
a O
side O
effect O
of O
the O
paroxetine B-DRUG

early O
ritonavir-induced O
maculopapular B-ADR
eruption I-ADR

two O
cases O
of O
mequitazine-induced O
photosensitivity B-ADR
reactions I-ADR

two O
children O
, O
1 O
with O
idiopathic O
nephrotic O
syndrome O
and O
1 O
with O
endo-extracapillary O
glomerulonephritis O
, O
presented O
an O
episode O
of O
seizures B-ADR
and O
transient O
blindness O
at O
different O
times O
after O
i.v. O
pulse O
methylprednisolone B-DRUG
( O
ivpmp O
) O
treatment O

a O
40-year-old O
man O
with O
advanced O
hiv O
infection O
and O
mycobacterium O
avium O
complex O
infection O
experienced O
rapid B-ADR
cognitive I-ADR
decline I-ADR
after O
commencement O
of O
ethambutol B-DRUG
, O
and O
symptoms O
fully O
resolved O
with O
cessation O

subacute B-ADR
cholestatic I-ADR
hepatitis I-ADR
likely O
related O
to O
the O
use O
of O
senna B-DRUG
for O
chronic O
constipation O

this O
case O
demonstrates O
an O
occupational O
activity O
( O
construction O
) O
that O
has O
now O
become O
the O
dominant O
source O
of O
lead B-DRUG
exposure O
for O
u.s. O
adults O
, O
the O
importance O
of O
a O
good O
occupational O
history O
to O
suspecting O
and O
making O
a O
diagnosis O
, O
the O
possible O
outcomes O
of O
chronic O
lead B-ADR
toxicity I-ADR
, O
and O
the O
importance O
of O
preventing O
further O
exposure O
and O
using O
proper O
methods O
to O
treat O
acute O
toxicity O

our O
patient O
had O
headache O
, O
mild O
fever O
, O
nausea O
, O
vomiting O
, O
rash B-ADR
, O
and O
eosinophilia O
after O
3 O
weeks O
of O
disulfiram B-DRUG
therapy O

we O
report O
a O
case O
of O
hypoglycaemia B-ADR
after O
mefloquine B-DRUG
therapy O
( O
1,500 O
mg O
over O
two O
days O
) O
for O
severe O
gastrointestinal O
cryptosporidiasis O
in O
a O
cachectic O
aids O
patient O
with O
protracted O
diarrhoea O

in O
addition O
, O
a O
31-year-old O
man O
with O
obsessive-compulsive O
disorder O
developed O
rbd B-ADR
soon O
after O
starting O
fluoxetine B-DRUG
therapy O
, O
which O
persisted O
at O
psg O
study O
19 O
months O
after O
fluoxetine B-DRUG
discontinuation O

ptosis B-ADR
occurring O
24 O
h O
after O
chloroquine B-DRUG
therapy O
, O
with O
full O
recovery O
48 O
h O
after O
cessation O
of O
chloroquine B-DRUG
, O
has O
not O
been O
described O
previously O

we O
describe O
two O
dark-skinned O
patients O
who O
developed O
hyperpigmented B-ADR
skin I-ADR
and O
tongue O
lesions O
during O
combination O
therapy O
with O
ifn B-DRUG
and O
ribavirin O

propoxyphene-induced O
wide B-ADR
complex I-ADR
dysrhythmia I-ADR
responsive O
to O
sodium O
bicarbonate O
therapy O
has O
not O
been O
previously O
reported O
in O
the O
literature O

protease O
inhibitors O
( O
ritonavir O
and O
saquinavir O
) O
were O
added O
to O
the O
treatment O
and O
the O
patient O
developed O
progressive B-ADR
ataxia I-ADR
related O
to O
carbamazepine B-DRUG
toxicity O

conclusions O
: O
clinicians O
treating O
elderly O
patients O
with O
olanzapine B-DRUG
should O
be O
aware O
of O
the O
potential O
for O
rapidly O
developing O
hyperglycemia B-ADR
and O
monitor O
such O
patients O
accordingly O

since O
amiodarone B-DRUG
was O
first O
marketed O
in O
1992 O
in O
japan O
, O
the O
incidence O
of O
amiodarone-induced O
thyrotoxicosis B-ADR
( O
ait O
) O
has O
been O
increasing O

herein O
is O
reported O
an O
unusual O
case O
of O
coexistent O
warfarin-induced O
skin O
necrosis O
and O
heparin-induced O
thrombocytopenia B-ADR
following O
mitral O
valve O
replacement O
for O
thromboembolic O
phenomena O
associated O
with O
marantic O
endocarditis O
and O
bronchial O
adenocarcinoma O

less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia O
and O
agranulocytosis O
, O
cutaneous O
eruptions O
, O
peripheral O
neuropathy O
, O
psychosis O
, O
toxic O
hepatitis O
, O
cholestatic O
jaundice O
, O
nephrotic B-ADR
syndrome I-ADR
, O
renal O
papillary O
necrosis O
, O
severe O
hypoalbuminemia O
without O
proteinuria O
, O
an O
infectious O
mononucleosis-like O
syndrome O
, O
and O
minor O
neurological O
and O
gastrointestinal O
complaints O

zolpidem B-DRUG
tissue O
concentrations O
in O
a O
multiple O
drug O
related O
death B-ADR
involving O
ambien O

development O
of O
crohn B-ADR
's I-ADR
disease I-ADR
in O
a O
patient O
with O
multiple O
sclerosis O
treated O
with O
copaxone B-DRUG

muscle O
biopsy O
revealed O
variation O
in O
muscle O
fiber O
size O
and O
few O
vacuolated O
fibers O
which O
were O
features O
of O
colchicine-induced O
myopathy B-ADR

hyponatremia B-ADR
in O
patients O
treated O
with O
lorcainide B-DRUG
, O
a O
new O
antiarrhythmic O
drug O

the O
risk O
of O
cardiac B-ADR
decompensation I-ADR
in O
infants O
with O
supraventricular O
tachycardia O
and O
congestive O
cardiac O
failure O
should O
be O
kept O
in O
mind O
prior O
to O
administration O
of O
verapamil B-DRUG

acute B-ADR
pulmonary I-ADR
reactions I-ADR
to O
nitrofurantoin B-DRUG
are O
an O
uncommon O
side O
effect O
of O
therapy O
and O
can O
cause O
minor O
or O
life-threatening O
pulmonary O
dysfunction O

presently O
, O
treatment O
of O
acute O
ibuprofen B-ADR
intoxication I-ADR
with O
complications O
requires O
supportive O
therapy O
until O
the O
symptoms O
resolve O
over O
24 O
to O
48 O
hours O

objective O
: O
to O
report O
two O
cases O
of O
fixed B-ADR
drug I-ADR
eruption I-ADR
induced O
by O
methylphenidate B-DRUG

intravitreal O
triamcinolone B-DRUG
may O
have O
had O
an O
influence O
on O
the O
exacerbation B-ADR
of I-ADR
retinochoroiditis I-ADR
in O
the O
posterior O
pole O
of O
the O
patient O

ticlopidine-induced O
aplastic B-ADR
anemia I-ADR
( O
tiaa O
) O
is O
considered O
very O
uncommon O

erythromycin O
is O
a O
macrolide O
antibiotic O
that O
may O
increase O
the O
risk O
of O
lovastatin-induced O
rhabdomyolysis B-ADR

in O
patients O
with O
a O
known O
access O
to O
inh B-DRUG
, O
seizures B-ADR
should O
be O
considered O
to O
be O
caused O
by O
inh B-DRUG
toxicity O
unless O
proved O
otherwise O

anaphylaxis B-ADR
from O
isoniazid B-DRUG
is O
a O
possible O
side O
effect O
to O
this O
commonly O
prescribed O
antibiotic O

case O
3 O
: O
a O
29-year-old O
female O
alcoholic O
complained O
of O
general O
fatigue B-ADR
and O
a O
slight O
fever O
after O
1.5 O
years O
of O
abstinence O
with O
cyanamide B-DRUG
treatment O

the O
diagnosis O
was O
based O
on O
the O
rapid O
onset O
of O
renal B-ADR
failure I-ADR
, O
presence O
of O
eosinophilia O
, O
skin O
rash O
, O
and O
characteristic O
renal O
biopsy O
finding O
, O
following O
the O
administration O
of O
ampicillin B-DRUG

these O
findings O
are O
consistent O
with O
an O
immune-complex O
form O
of O
glomerulopathy O
in O
which O
gold B-DRUG
is O
neither O
the O
antigen O
nor O
a O
hapten O
in O
the O
glomerular O
deposits O
, O
and O
they O
suggest O
the O
hypothesis O
that O
antibodies O
to O
tubular O
epithelial O
antigens O
induced O
by O
gold B-DRUG
therapy O
may O
be O
a O
causative O
factor O
in O
the O
renal B-ADR
disease I-ADR
associated O
with O
gold B-DRUG
therapy O
in O
rheumatoid O
arthritis O

this O
case O
illustrates O
the O
potential O
decoupling B-ADR
of I-ADR
psa I-ADR
response I-ADR
from O
disease O
status O
in O
flutamide B-DRUG
withdrawal O

gemcitabine-related O
radiation B-ADR
recall I-ADR
in O
a O
patient O
with O
pancreatic O
cancer O

however O
, O
one O
patient O
exhibited O
severe B-ADR
hypersensitivity I-ADR
reactions I-ADR
including O
cardiac O
arrest O
and O
apnea O
, O
and O
another O
four O
patients O
developed O
eruptions O
, O
hypotension O
, O
and O
tachycardia O
soon O
after O
administration O
of O
cbdca B-DRUG

conclusions O
: O
topiramate B-DRUG
may O
be O
associated O
with O
ciliochoroidal O
effusion O
with O
forward O
displacement B-ADR
of I-ADR
the I-ADR
lens-iris I-ADR
diaphragm I-ADR
and O
anterior O
chamber O
shallowing O
, O
resulting O
in O
acute O
myopia O
and O
angle-closure O
glaucoma O

to O
our O
knowledge O
, O
our O
report O
is O
one O
of O
the O
first O
on O
shock B-ADR
and O
angio-oedema O
from O
irbesartan B-DRUG

conclusions O
: O
priapism B-ADR
is O
an O
uncommon O
but O
potentially O
serious O
adverse O
effect O
of O
zuclopenthixol B-DRUG
that O
practitioners O
, O
as O
with O
many O
other O
antipsychotics O
, O
should O
be O
aware O
of O

this O
case O
of O
linezolid-associated O
acute O
interstitial O
nephritis O
within O
the O
context O
of O
a O
drug O
rash O
with O
eosinophilia O
and O
systemic O
symptoms O
( O
dress B-ADR
) O
syndrome O
in O
a O
patient O
treated O
with O
linezolid B-DRUG
raises O
concerns O
about O
the O
presumed O
renal O
safety O
of O
this O
drug O

our O
findings O
suggest O
that O
hyperkalemia B-ADR
can O
develop O
with O
the O
use O
of O
low-dose O
heparin B-DRUG
, O
within O
seven O
days O
of O
initiating O
heparin B-DRUG
therapy O
, O
and O
that O
patients O
with O
diabetes O
mellitus O
or O
chronic O
renal O
insufficiency O
are O
especially O
predisposed O
to O
this O
complication O

because O
of O
a O
hypersensitivity B-ADR
reaction I-ADR
, O
initial O
therapy O
with O
penicillin O
g O
and O
gentamicin B-DRUG
was O
stopped O
and O
substituted O
with O
cefazolin O

such O
a O
case O
induced O
by O
hypothyroidism B-ADR
complicating O
long-term O
therapy O
with O
amiodarone B-DRUG
in O
a O
45 O
year O
old O
woman O
with O
pre-excitation O
is O
presented O

idiosyncratic B-ADR
pulmonary I-ADR
reactions I-ADR
to O
nitrofurantoin B-DRUG
are O
not O
unusual O
, O
often O
presenting O
as O
eosinophilic O
pneumonia O

two O
65-year-old O
white O
men O
with O
coronary O
heart O
disease O
, O
given O
niacin B-DRUG
therapy O
for O
dyslipidemia O
for O
5 O
months O
, O
developed O
intense B-ADR
dental I-ADR
and I-ADR
gingival I-ADR
pain I-ADR
that O
was O
associated O
with O
increases O
in O
dose O
and O
that O
was O
relieved O
with O
discontinuance O
of O
niacin B-DRUG
treatment O

magnesium B-ADR
toxicosis I-ADR
in O
two O
horses O

hypokalemia B-ADR
after O
normal O
doses O
of O
neubulized O
albuterol B-DRUG
( O
salbutamol O

in O
this O
report O
we O
present O
four O
patients O
treated O
with O
a O
combination O
of O
different O
psychotropic O
drugs O
, O
in O
whom O
asterixis B-ADR
was O
triggered O
either O
by O
adding O
carbamazepine O
( O
cbz B-DRUG
) O
to O
a O
treatment O
regimen O
, O
or O
by O
increasing O
its O
dosage O

the O
toxic O
effects O
of O
methotrexate B-DRUG
included O
elevated O
liver O
transaminases O
( O
3 O
/ O
4 O
) O
, O
nausea O
( O
2 O
/ O
4 O
) O
, O
abdominal B-ADR
pain I-ADR
( O
2 O
/ O
4 O
) O
, O
bone O
pain O
( O
2 O
/ O
4 O
) O
, O
mild O
neutropenia O
( O
1 O
/ O
4 O
) O
, O
and O
mild O
pruritus O
( O
1 O
/ O
4 O

purpose O
: O
to O
report O
a O
case O
of O
severe O
corticosteroid-induced O
glaucoma B-ADR
after O
intravitreal O
injection O
of O
triamcinolone O
acetate O
in O
a O
34-year-old O
man O
without O
a O
history O
of O
glaucoma B-ADR

severe O
sulfadiazine B-DRUG
hypersensitivity B-ADR
in O
a O
child O
with O
reactivated O
congenital O
toxoplasmic O
chorioretinitis O

glomerulonephritis B-ADR
in O
procainamide B-DRUG
induced O
lupus O
erythematosus O
: O
report O
of O
a O
case O
and O
review O
of O
the O
literature O

to O
our O
knowledge O
, O
drug-induced O
fever B-ADR
has O
not O
been O
reported O
with O
the O
use O
of O
diltiazem B-DRUG
hydrochloride I-DRUG
, O
a O
commonly O
prescribed O
calcium O
channel O
blocker O

a O
review O
of O
the O
literature O
found O
11 O
children O
and O
2 O
adults O
in O
whom O
intranasal O
desmopressin B-DRUG
was O
associated O
with O
hyponatremia O
, O
all O
of O
whom O
experienced O
seizures B-ADR
or O
altered O
mental O
status O

initial O
treatment O
with O
heparin B-DRUG
was O
substituted O
with O
thrombolysis O
, O
which O
resulted O
in O
clinical O
improvement O
and O
dissolution O
of O
right O
heart O
thrombus O
but O
was O
followed O
by O
fatal B-ADR
intracerebral I-ADR
haemorrhage I-ADR

the O
case O
history O
and O
toxicological O
findings O
of O
an O
infant O
fatality B-ADR
involving O
pseudoephedrine O
, O
brompheniramine B-DRUG
, O
and O
dextromethorphan O
are O
presented O

the O
toxic O
effects O
of O
methotrexate B-DRUG
included O
elevated O
liver O
transaminases O
( O
3 O
/ O
4 O
) O
, O
nausea O
( O
2 O
/ O
4 O
) O
, O
abdominal O
pain O
( O
2 O
/ O
4 O
) O
, O
bone O
pain O
( O
2 O
/ O
4 O
) O
, O
mild O
neutropenia O
( O
1 O
/ O
4 O
) O
, O
and O
mild B-ADR
pruritus I-ADR
( O
1 O
/ O
4 O

the O
authors O
describe O
a O
case O
of O
combined O
lithium O
and O
haloperidol B-DRUG
toxicity O
characterized O
by O
hyperpyrexia O
, O
severe B-ADR
rigidity I-ADR
, O
mutism O
, O
and O
development O
of O
irreversible O
tardive O
dyskinesia O

case O
description O
: O
a O
59-year-old O
man O
with O
known O
neurocysticercosis O
developed O
a O
large B-ADR
cerebral I-ADR
infarction I-ADR
during O
praziquantel B-DRUG
therapy O

the O
electrocardiogram O
( O
ecg O
) O
, O
which O
was O
read O
as O
normal O
prior O
to O
ritodrine B-DRUG
infusion O
, O
demonstrated O
a O
type B-ADR
i I-ADR
second-degree I-ADR
av I-ADR
block I-ADR
which O
disappeared O
upon O
discontinuation O
of O
ritodrine B-DRUG
therapy O

mefloquine-associated O
hypoglycaemia B-ADR
in O
a O
cachectic O
aids O
patient O

arterial B-ADR
hypertension I-ADR
associated O
with O
topical O
ocular O
use O
of O
phenylephrine B-DRUG
in O
dogs O

thrombocytosis B-ADR
under O
ciprofloxacin O
and O
tazobactam B-DRUG
/ O
piperacillin O

gabapentin-induced O
mood B-ADR
changes I-ADR
with O
hypomanic O
features O
in O
adults O

we O
report O
the O
case O
histories O
of O
identical O
twin O
brothers O
who O
developed O
concordant O
acute O
lymphoblastic O
leukemia O
at O
the O
age O
of O
4 O
years O
and O
who O
later O
developed O
leukoencephalopathy O
and O
hydrocephalus B-ADR
related O
to O
central O
nervous O
system O
prophylaxis O
by O
, O
in O
the O
first O
case O
intrathecally O
administered O
methotrexate B-DRUG
and O
, O
in O
the O
second O
by O
intrathecally O
administered O
methotrexate B-DRUG
and O
cranial O
irradiation O

we O
describe O
a O
case O
of O
poisoning B-ADR
with O
3,4-methylenedioxymet-amphetamine B-DRUG
ecstasy I-DRUG
that O
presented O
with O
all O
the O
features O
suggestive O
of O
a O
fatal O
outcome O
, O
including O
a O
creatinine O
phosphokinase O
level O
markedly O
higher O
than O
any O
previously O
reported O

we O
report O
a O
case O
of O
stevens-johnson O
syndrome O
/ O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
( O
sjs O
/ O
ten O
) O
secondary O
to O
trimethoprim-sulfamethoxazole B-DRUG
( O
tmp-sx O
) O
therapy O
for O
presumed O
community-associated O
methicillin-resistant O
staphylococcus O
aureus O
( O
ca-mrsa O
) O
infection O

in O
this O
healthy O
population O
, O
the O
relative O
risk O
of O
developing O
endometrial B-ADR
carcinoma I-ADR
in O
the O
tamoxifen B-DRUG
arm O
was O
2.54 O
, O
although O
when O
stratified O
by O
age O
, O
in O
women O
over O
50 O
, O
the O
risk O
grew O
to O
4.01 O

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness B-ADR
, O
difficulty O
with O
speech O
, O
weakness O
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

easily O
reversible O
hypoxemia B-ADR
and O
hypotension O
induced O
by O
nimodipine B-DRUG

she O
was O
administered O
metoclopramide B-DRUG
because O
of O
nausea O
and O
, O
within O
2 O
hours O
, O
developed O
agitation O
, O
dysarthria O
, O
diaphoresis O
, O
and O
a O
movement B-ADR
disorder I-ADR

the O
psychotic B-ADR
behavior I-ADR
resolved O
completely O
soon O
after O
the O
discontinuation O
of O
levetiracetam B-DRUG

soon O
after O
introduction O
of O
insulin B-DRUG
therapy O
, O
she O
developed O
severe O
anasarca O
, O
including O
marked O
peripheral O
oedema O
, O
ascites B-ADR
and O
pleural O
effusion O

a O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity O
drug O
reaction O
developed O
which O
consisted O
of O
fever O
, O
a O
pruritic O
desquamating O
erythrodermic O
rash O
, O
alopecia B-ADR
, O
icterus O
, O
protein-losing O
enteropathy O
, O
myositis O
, O
and O
nephritis O
, O
is O
described O

zolpidem B-DRUG
( O
ambien O
) O
, O
a O
relatively O
new O
nonbenzodiazepine O
sedative-hypnotic O
, O
was O
involved O
in O
the O
death B-ADR
of O
a O
39-year-old O
obese O
male O
who O
was O
being O
treated O
for O
depression O
and O
insomnia O

an O
encephalopathy B-ADR
and O
cardiomyopathy O
developed O
in O
a O
seventeen-year-old O
girl O
with O
chemotherapy-induced O
renal O
failure O
while O
receiving O
an O
intravesical O
aluminum B-DRUG
infusion O
for O
hemorrhagic O
cystitis O

hypoxia O
is O
a O
predisposing O
factor O
for O
premature B-ADR
ductal I-ADR
closure I-ADR
and O
often O
occurs O
after O
maternal O
indomethacin B-DRUG
therapy O

physicians O
should O
be O
aware O
of O
the O
potential O
for O
developing O
a O
gemcitabine-induced O
radiation B-ADR
recall I-ADR
reaction I-ADR
resulting O
in O
hemodynamically O
significant O
pericardial O
effusion O

objective O
: O
to O
report O
2 O
cases O
of O
serotonin O
syndrome O
with O
serious O
extrapyramidal B-ADR
movement I-ADR
disorders I-ADR
occurring O
when O
metoclopramide B-DRUG
was O
coadministered O
with O
sertraline O
or O
venlafaxine O

in O
both O
cases O
, O
high B-ADR
fever I-ADR
, O
skin O
rash O
, O
liver O
dysfunction O
and O
atypical O
lymphocytosis O
developed O
3 O
weeks O
after O
initiating O
treatment O
with O
sasp B-DRUG

we O
report O
4 O
patients O
, O
2 O
on O
methylphenidate B-DRUG
and O
2 O
on O
dextroamphetamine O
who O
presented O
with O
acral O
cyanosis O
, O
livedo O
reticularis O
, O
or O
raynaud B-ADR
phenomenon I-ADR

contrary O
to O
previous O
recommendations O
, O
our O
experience O
cautions O
against O
the O
further O
use O
of O
high-dose O
cytarabine B-DRUG
in O
patients O
who O
develop O
ppe B-ADR
, O
and O
is O
a O
timely O
reminder O
of O
the O
potential O
toxicity O
of O
this O
agent O
, O
which O
is O
now O
increasingly O
being O
used O
as O
first-line O
treatment O
in O
the O
management O
of O
haematologic O
malignancies O

the O
autopsy O
findings O
and O
a O
detailed O
medical O
history O
supported O
the O
conclusion O
that O
clozapine-induced O
hypersensitivity B-ADR
myocarditis I-ADR
was O
the O
most O
likely O
cause O
of O
death O

enalaprilat B-DRUG
induced O
acute B-ADR
parotitis I-ADR

bradycardia O
and O
congestive B-ADR
heart I-ADR
failure I-ADR
associated O
with O
ocular O
timolol B-DRUG
maleate I-DRUG

visual B-ADR
loss I-ADR
after O
a O
single O
small O
dose O
of O
vincristine B-DRUG
has O
never O
been O
reported O

three O
cases O
of O
acute B-ADR
renal I-ADR
toxicity I-ADR
in O
patients O
receiving O
long-term O
therapy O
with O
mitomycin O
c O
and O
5-fluorouracil B-DRUG
are O
reported O

the O
authors O
describe O
a O
case O
of O
interstitial B-ADR
granulomatous I-ADR
dermatitis I-ADR
associated O
with O
darifenacin B-DRUG

although O
fluoxetine-induced O
headache B-ADR
occurred O
in O
one O
patient O
, O
the O
other O
five O
reported O
no O
side O
effects O
at O
the O
doses O
used O

symptomatic B-ADR
hypoglycemia I-ADR
secondary O
to O
a O
glipizide-trimethoprim O
/ O
sulfamethoxazole O
drug O
interaction O

a O
rare O
case O
of O
advanced O
ovarian O
carcinoma O
who O
developed O
difficulty B-ADR
walking I-ADR
25 O
days O
after O
treatment O
with O
weekly O
paclitaxel B-DRUG

to O
date O
, O
only O
three O
cases O
of O
seizures B-ADR
associated O
with O
amphotericin B-DRUG
b I-DRUG
have O
been O
reported O
in O
the O
literature O
, O
but O
healthcare O
providers O
should O
be O
aware O
of O
the O
potential O
for O
this O
rare O
adverse O
effect O

results O
: O
ethambutol O
, O
and O
to O
a O
lesser O
extent O
isoniazid B-DRUG
, O
are O
both O
implicated O
in O
the O
development B-ADR
of I-ADR
visually I-ADR
related I-ADR
side I-ADR
effects I-ADR

putaminal O
infarct O
in O
methanol B-ADR
intoxication I-ADR
: O
case O
report O
and O
role O
of O
brain O
imaging O
studies O

two O
cases O
of O
lepromatous O
leprosy O
with O
erythema O
nodosum O
leprosum O
who O
were O
on O
high O
doses O
of O
clofazimine B-DRUG
, O
showed O
discoloration B-ADR
of I-ADR
nail I-ADR
plate I-ADR
, O
subungual O
hyperkeratosis O
and O
onycholysis O

objective O
: O
to O
describe O
a O
case O
of O
cefazolin-induced O
leukopenia B-ADR
in O
a O
critically O
ill O
patient O
who O
developed O
this O
adverse O
reaction O
upon O
rechallenge O
with O
cefoxitin O

we O
report O
a O
patient O
with O
inoperable O
pancreatic O
cancer O
who O
developed O
gastrointestinal O
bleeding O
secondary O
to O
radiation-recall B-ADR
related O
to O
gemcitabine B-DRUG
and O
review O
literature O

marked B-ADR
qt I-ADR
prolongation I-ADR
and O
torsades O
de O
pointes O
secondary O
to O
acute O
ischemia O
in O
an O
elderly O
man O
taking O
dofetilide B-DRUG
for O
atrial O
fibrillation O
: O
a O
cautionary O
tale O

a O
fatal B-ADR
pancytopenia I-ADR
occurred O
in O
a O
patient O
with O
an O
history O
of O
depression O
with O
hypomanic O
rebounds O
, O
admitted O
for O
a O
manic O
episode O
and O
treated O
with O
levomepromazine O
, O
diazepam B-DRUG
and O
lithium O
carbonate O

the O
temporal O
relationship O
suggests O
that O
the O
spinal B-ADR
cord I-ADR
infarction I-ADR
may O
be O
related O
to O
the O
use O
of O
zolmitriptan B-DRUG

based O
on O
these O
findings O
, O
the O
patient O
was O
diagnosed O
with O
diabetes B-ADR
insipidus I-ADR
secondary O
to O
lithium B-DRUG
therapy O
and O
was O
treated O
successfully O
with O
amiloride O

conclusions O
: O
this O
report O
indicates O
clindamycin B-DRUG
phosphate O
vaginal O
cream O
as O
the O
most O
probable O
cause O
of O
cdic O
due O
to O
the O
temporal O
relationship O
between O
the O
occurrence O
of O
diarrhea O
and O
clindamycin B-DRUG
administration O
, O
lack O
of O
concomitant O
medications O
, O
and O
documentation O
of O
c. B-ADR
difficile I-ADR
toxin I-ADR

we O
report O
the O
case O
of O
a O
17-year-old O
male O
who O
developed O
chest B-ADR
pain I-ADR
, O
elevated O
cardiac O
biomarkers O
, O
and O
acute O
left O
ventricular O
dysfunction O
following O
a O
single O
dose O
of O
methylphenidate B-DRUG

discussion O
: O
rhabdomyolysis O
is O
a O
clinical O
syndrome O
resulting O
from O
the O
destruction O
of O
skeletal O
muscle O
that O
may O
progress O
to O
renal O
failure O
several O
drugs O
have O
been O
associated O
with O
rhabdomyolysis B-ADR
, O
including O
lovastatin B-DRUG
, O
a O
hydroxymethylglutaryl-coenzyme O
a O
reductase O
inhibitor O

we O
report O
aza-induced O
drug B-ADR
eruption I-ADR
that O
developed O
in O
two O
cases O
of O
systemic O
scleroderma O
with O
polymyositis O

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal B-ADR
pain I-ADR
, O
general O
erythema O
, O
and O
fever O

mechanism O
of O
topiramate-induced O
acute-onset O
myopia O
and O
angle B-ADR
closure I-ADR
glaucoma I-ADR

the O
time O
course O
of O
events O
suggested O
that O
amphotericin B-DRUG
b I-DRUG
was O
the O
cause O
of O
the O
seizures B-ADR
in O
this O
aids O
patient O

conclusions O
: O
low O
dosages O
of O
quinacrine O
used O
for O
malaria O
prophylaxis O
can O
be O
associated O
with O
a O
delayed O
, O
severe O
maculopathy B-ADR
indistinguishable O
from O
chloroquine B-DRUG
maculopathy B-ADR
in O
certain O
patients O

results O
: O
a O
34-year-old O
man O
acquired O
visual B-ADR
field I-ADR
defects I-ADR
and O
severe O
vision O
loss O
in O
both O
eyes O
after O
intravitreal O
injection O
of O
triamcinolone B-DRUG
for O
diabetic O
macular O
edema O

therefore O
, O
we O
diagnosed O
her O
eruption O
as O
contact B-ADR
dermatitis I-ADR
due O
to O
sodium B-DRUG
bisulfite I-DRUG

one O
case O
of O
tacrolimus-induced O
hepatic B-ADR
vod I-ADR
developing O
after O
lung O
transplantation O
( O
lt O
) O
has O
been O
recently O
reported O

introduction-the O
aim O
of O
this O
case O
report O
is O
to O
present O
a O
15-year O
follow-up O
of O
a O
patient O
with O
phenytoin O
( O
pht B-DRUG
) O
intoxication O
with O
unilateral B-ADR
gingival I-ADR
hyperplasia I-ADR
( O
gh O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine O
and O
sulfadiazine B-DRUG
for O
reactivated O
chorioretinitis O
developed O
fever O
, O
severe B-ADR
cutaneous I-ADR
involvement I-ADR
, O
swelling O
, O
abdominal O
pain O
and O
transaminitis O
, O
persisting O
weeks O
after O
withholding O
medicines O

we O
report O
a O
case O
of O
a O
patient O
with O
pulmonary O
hypertension O
and O
undifferentiated O
connective O
tissue O
disease O
who O
, O
after O
2 O
months O
of O
treatment O
with O
epoprostenol B-DRUG
, O
presented O
with O
rapidly O
progressive O
erythema O
, O
scaling B-ADR
, O
nausea O
and O
vomiting O
, O
and O
fever O

conclusion O
: O
lipoid B-ADR
pneumonia I-ADR
as O
a O
result O
of O
mineral B-DRUG
oil I-DRUG
aspiration O
still O
occurs O
in O
the O
pediatric O
population O

one O
patient O
suffered O
coronary B-ADR
artery I-ADR
vasospasm I-ADR
, O
attributed O
to O
the O
use O
of O
topical O
1:1000 O
epinephrine B-DRUG
during O
surgery O

we O
report O
on O
three O
cases O
wherein O
treatment O
of O
dexmedetomidine-induced O
bradycardia B-ADR
with O
i.v. O
glycopyrrolate O
( O
5.0 O
microg O
/ O
kg O
) O
not O
only O
resulting O
in O
resolution O
of O
bradycardia B-ADR
but O
also O
resulting O
in O
an O
exaggerated O
increase O
of O
arterial O
blood O
pressure O

the O
development O
of O
systemic O
lupus O
erythematosus O
( O
sle B-ADR
) O
after O
38 O
months O
of O
therapy O
with O
recombinant B-DRUG
human I-DRUG
interferon I-DRUG
gamma I-DRUG
( O
rifn-gamma O
) O
was O
observed O
in O
a O
patient O
with O
rheumatoid O
arthritis O

refractory B-ADR
hypoglycemia I-ADR
from O
ciprofloxacin O
and O
glyburide B-DRUG
interaction O

flecainide-associated O
pneumonitis B-ADR
with O
acute O
respiratory O
failure O
in O
a O
patient O
with O
the O
leopard O
syndrome O

major O
points O
illustrated O
are O
, O
( O
1 O
) O
occurrence O
of O
hit B-ADR
with O
any O
dose O
or O
form O
of O
heparin B-DRUG
; O
( O
2 O
) O
misperceptions O
on O
the O
diagnostic O
criteria O
; O
( O
3 O
) O
correct O
( O
thrombin O
inhibitors O
) O
and O
incorrect O
( O
platelet O
transfusions O
and O
warfarin O
) O
management O
; O
( O
4 O
) O
influence O
of O
management O
strategy O
on O
clinical O
outcomes O
; O
( O
5 O
) O
severity O
of O
the O
syndrome O
; O
and O
( O
6 O
) O
potential O
for O
both O
anamnestic O
response O
to O
heparin B-DRUG
and O
disappearance O
of O
hit B-ADR
antibodies O
over O
time O

gold B-ADR
nephropathy I-ADR
due O
to O
auranofin O
obscured O
by O
tolmetin B-DRUG
pseudoproteinuria O

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness B-ADR
, O
difficulty O
with O
speech O
, O
weakness O
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

patients O
treated O
with O
captopril B-DRUG
who O
develop O
" O
atypical B-ADR
cholangitis I-ADR
" O
should O
be O
suspected O
of O
having O
captopril-associated O
liver O
damage O

well-known O
signs O
of O
methotrexate B-DRUG
toxicity O
include O
bone O
marrow O
suppression O
and O
oral B-ADR
and I-ADR
gastrointestinal I-ADR
ulceration I-ADR

after O
a O
second O
dose O
of O
metoclopramide B-DRUG
, O
these O
symptoms O
recurred O
and O
were O
associated O
with O
confusion O
, O
agitation O
, O
fever B-ADR
, O
diaphoresis O
, O
tachypnea O
, O
tachycardia O
, O
and O
hypertension O

we O
suggest O
that O
nicotinic B-DRUG
acid I-DRUG
was O
the O
cause O
of O
his O
liver B-ADR
disease I-ADR
, O
that O
this O
case O
is O
of O
particular O
note O
because O
of O
the O
rather O
short O
period O
of O
therapy O
before O
the O
onset O
of O
liver O
injury O
and O
the O
severity O
of O
the O
hepatic O
failure O
, O
and O
that O
the O
probable O
increased O
use O
of O
nicotinic B-DRUG
acid I-DRUG
for O
serum O
cholesterol O
control O
makes O
it O
especially O
important O
for O
physicians O
and O
their O
patients O
to O
be O
alert O
to O
the O
signs O
of O
hepatotoxicity O

the O
uncomplicated O
long-term O
use O
of O
adequately-dosed O
aza B-DRUG
and O
stable O
non-toxic O
metabolite O
levels O
could O
not O
acknowledge O
tpmt O
deficiency O
as O
a O
primary O
cause O
of O
the O
leukopenia B-ADR

she O
was O
administered O
metoclopramide B-DRUG
because O
of O
nausea O
and O
, O
within O
2 O
hours O
, O
developed O
agitation B-ADR
, O
dysarthria O
, O
diaphoresis O
, O
and O
a O
movement O
disorder O

a O
10-year-old O
boy O
with O
osteosarcoma O
and O
normal O
renal O
function O
manifested O
laboratory O
evidence O
of O
impending O
renal O
toxicity O
and O
extreme O
elevation O
of O
aspartate O
aminotrasferase O
and O
alanine O
aminotransferase O
within O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
infusion O
of O
high-dose O
methotrexate B-DRUG
( O
mtx O
) O
( O
12 O
g O
/ O
m2 O
) O
, O
and O
went O
on O
to O
develop O
acute B-ADR
renal I-ADR
failure I-ADR
with O
life-threatening O
hyperkalemia O
29 O
hours O
later O

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine B-DRUG
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema O
reaction O
, O
cross-reaction O
to O
promethazine O
, O
decreased B-ADR
med I-ADR
to I-ADR
both I-ADR
uva I-ADR
and I-ADR
uvb I-ADR
, O
and O
persistence O
of O
the O
photosensitivity O
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine B-DRUG

flutamide B-DRUG
withdrawal O
syndrome O
is O
characterized O
by O
a O
decrease B-ADR
in I-ADR
prostate-specific I-ADR
antigen I-ADR
( O
psa O
) O
after O
flutamide O
withdrawal O
in O
a O
subset O
of O
patients O
with O
progressing O
metastatic O
carcinoma O
of O
the O
prostate O

pulmonary O
hemorrhage O
is O
an O
uncommon O
feature O
in O
the O
hus B-ADR
, O
and O
seems O
to O
appear O
especially O
in O
the O
hus B-ADR
associated O
with O
mmc B-DRUG
therapy O

gynecomastia B-ADR
developed O
in O
two O
epileptic O
patients O
some O
months O
after O
the O
addition O
of O
oral O
fluoresone O
750 O
mg O
daily O
to O
the O
phenobarbital B-DRUG
and O
phenytoin O
already O
being O
administered O

quinine B-DRUG
induced O
coagulopathy B-ADR
-- O
a O
near O
fatal O
experience O

in O
patients O
with O
cirrhosis O
, O
the O
metabolism O
of O
meperidine B-DRUG
is O
decreased O
, O
leading O
to O
accumulation O
of O
the O
parent O
drug O
and O
possible O
cns B-ADR
depressive I-ADR
effects I-ADR
similar O
to O
hepatic O
encephalopathy O

after O
seven O
months' O
continuous O
treatment O
for O
suspected O
tuberculosis O
with O
rifampicin O
and O
ethambutol B-DRUG
a O
nine-year-old O
boy O
developed O
polyarthritis O
, O
rash O
and O
hepatitis O
in O
association O
with O
anti-native B-ADR
dna I-ADR
antibodies I-ADR
and O
positive O
antinuclear O
factor O

zidovudine B-DRUG
use O
in O
pregnancy O
: O
a O
report O
on O
104 O
cases O
and O
the O
occurrence O
of O
birth B-ADR
defects I-ADR

fixed B-ADR
drug I-ADR
eruption I-ADR
to O
rofecoxib B-DRUG

discussion O
: O
the O
naranjo O
probability O
scale O
indicated O
a O
probable O
relationship O
between O
sertraline B-DRUG
treatment O
and O
the O
onset O
of O
rhabdomyolysis B-ADR

neonatal O
mydriasis B-ADR
: O
intravenous O
lidocaine B-DRUG
adverse O
reaction O

a O
macrophage O
activation O
syndrome O
, O
possibly O
related O
to O
methotrexate B-ADR
toxicity I-ADR
, O
developed O
in O
a O
boy O
with O
systemic O
juvenile O
rheumatoid O
arthritis O

transient O
trazodone-induced O
hypomanic B-ADR
symptoms I-ADR
occurred O
in O
three O
depressed O
patients O

background O
: O
interferon O
( O
ifn B-DRUG
)- O
associated O
retinopathy O
is O
typically O
characterized O
by O
retinal B-ADR
hemorrhages I-ADR
and O
cotton O
wool O
spots O
at O
the O
posterior O
fundus O
, O
but O
visual O
function O
is O
usually O
maintained O

venlafaxine-induced O
urinary B-ADR
incontinence I-ADR
resolved O
after O
switching O
to O
sertraline O

he O
had O
an O
immediate O
hypersensitivity B-ADR
reaction I-ADR
during O
the O
initiation O
of O
the O
mtx B-DRUG
infusion O
with O
diffuse O
urticaria O
, O
facial O
swelling O
, O
cough O
, O
and O
chest O
tightness O

clinical O
course O
of O
macular O
edema O
in O
two O
cases O
of O
interferon-associated O
retinopathy B-ADR
observed O
by O
optical O
coherence O
tomography O

conclusion O
: O
during O
and O
after O
ifn B-DRUG
therapy O
, O
oct O
is O
a O
useful O
examination O
technique O
for O
revealing O
macular O
edema O
in O
patients O
who O
have O
decreased B-ADR
vision I-ADR

he O
was O
started O
on O
digoxin B-DRUG
, O
0.25 O
mg O
daily O
, O
because O
of O
echocardiographically O
demonstrated O
left O
ventricular O
dilatation O
and O
functional B-ADR
impairment I-ADR
; O
he O
died O
of O
ventricular O
fibrillation O
15 O
days O
later O

rifampin B-DRUG
( O
rfp O
) O
increases O
hepatic O
microsomal O
enzyme O
activity O
, O
and O
there O
are O
case O
reports O
of O
rfp-induced O
hypothyroidism O
, O
all O
associated O
with O
hashimoto B-ADR
's I-ADR
thyroiditis I-ADR

although O
they O
had O
only O
a O
few O
nodules B-ADR
at O
diagnosis O
, O
the O
nodules B-ADR
increased O
in O
number O
and O
size O
3 O
to O
4 O
months O
after O
the O
start O
of O
methotrexate B-DRUG
therapy O
in O
both O
patients O

the O
bleeding B-ADR
resolved O
on O
discontinuation O
of O
apv B-DRUG

multiple O
complications O
of O
propylthiouracil B-DRUG
treatment O
: O
granulocytopenia B-ADR
, O
eosinophilia O
, O
skin O
reaction O
and O
hepatitis O
with O
lymphocyte O
sensitization O

angioedema O
and O
maculopapular B-ADR
eruptions I-ADR
associated O
with O
carbamazepine B-DRUG
administration O

videopolysomnographic O
and O
pharmacokinetic O
studies O
with O
monitoring O
of O
plasma O
levodopa B-DRUG
levels O
demonstrated O
marked O
motor O
hyperactivity O
during O
augmentation O
, O
with O
anarchic O
discharges O
of O
motor O
unit O
potentials O
, O
tonic O
grouped O
discharges O
and O
flexor O
spasms O
, O
associated O
with O
painful B-ADR
dysesthesia I-ADR

a O
36-y-o O
patient O
with O
schizophrenia O
, O
who O
had O
consumed O
gradually O
increasing O
quantities O
of O
oolong B-DRUG
tea I-DRUG
that O
eventually O
reached O
15 O
l O
each O
day O
, O
became O
delirious B-ADR
and O
was O
admitted O
to O
a O
psychiatric O
hospital O

pulmonary B-ADR
fibrosis I-ADR
is O
a O
severe O
complication O
associated O
with O
bis-chloronitrosourea B-DRUG
( O
bcnu O
) O
therapy O

after O
1 O
week O
of O
nefazodone B-DRUG
therapy O
the O
patient O
experienced O
headache O
, O
confusion O
, O
and O
" O
gray B-ADR
areas I-ADR
" O
in O
her O
vision O
, O
without O
abnormal O
ophthalmologic O
findings O

the O
favourable O
outcome O
in O
these O
two O
patients O
contrasts O
with O
the O
fatal O
outcome O
of O
the O
two O
other O
reported O
cases O
of O
nitrofurantoin B-ADR
induced I-ADR
boop I-ADR

disseminated B-ADR
cellulitic I-ADR
cryptococcosis I-ADR
in O
the O
setting O
of O
prednisone B-DRUG
monotherapy O
for O
pemphigus O
vulgaris O

interferon-alpha-induced O
focal B-ADR
segmental I-ADR
glomerulosclerosis I-ADR
in O
chronic O
myelogenous O
leukemia O
: O
a O
case O
report O
and O
review O
of O
the O
literature O

based O
upon O
the O
observed O
fall O
of O
the O
filtration O
fraction O
, O
the O
rise O
in O
the O
relative O
clearance O
of O
99tc-dimercaptosuccinic O
acid O
and O
the O
increase B-ADR
in I-ADR
proteinuria I-ADR
, O
we O
suggest O
that O
in O
this O
case O
the O
tubules O
and O
/ O
or O
interstitium O
are O
the O
main O
targets O
for O
cyclosporine B-DRUG
a I-DRUG
nephrotoxicity O

diagnosis O
: O
severe O
temozolomide-induced O
immunosuppression B-ADR
, O
exacerbated O
by O
corticosteroids O
, O
with O
profound O
t-cell O
lymphocytopenia O
and O
simultaneous O
opportunistic O
infections O
with O
pneumocystis O
jiroveci O
pneumonia O
, O
brain O
abscess O
with O
listeria O
monocytogenes O
, O
and O
cutaneous O
kaposi O
's O
sarcoma O

a O
patient O
who O
had O
been O
treated O
with O
large O
doses O
of O
thyroid B-DRUG
hormone I-DRUG
for O
several O
years O
developed O
features O
of O
secondary O
hypothyroidism B-ADR
after O
thyroid B-DRUG
hormone I-DRUG
withdrawal O

objectives O
: O
a O
delayed O
stroke-like B-ADR
leukoencephalopathy I-ADR
has O
been O
observed O
in O
patients O
receiving O
methotrexate B-DRUG
( O
mtx O
) O
for O
childhood O
leukemia O

the O
diagnosis O
was O
based O
on O
the O
rapid O
onset O
of O
renal O
failure O
, O
presence O
of O
eosinophilia B-ADR
, O
skin O
rash O
, O
and O
characteristic O
renal O
biopsy O
finding O
, O
following O
the O
administration O
of O
ampicillin B-DRUG

a O
69-year-old O
man O
developed O
pure B-ADR
red I-ADR
cell I-ADR
aplasia I-ADR
after O
taking O
fenoprofen B-DRUG
for O
ten O
months O

morphine B-DRUG
, O
an O
opium O
alkaloid O
, O
frequently O
causes O
side O
effects O
such O
as O
hyperhidrosis B-ADR
and O
facial O
flushing O
, O
but O
serious O
cutaneous O
adverse O
drug O
reactions O
are O
seldom O
observed O

teicoplanin-induced O
agranulocytosis B-ADR
that O
followed O
vancomycin-induced O
agranulocytosis B-ADR
suggests O
a O
possible O
cross-reactivity O
between O
the O
2 O
drugs O

atrial B-ADR
fibrillation I-ADR
occurring O
in O
a O
patient O
taking O
etanercept O
plus O
methotrexate B-DRUG
for O
rheumatoid O
arthritis O

nephrogenic O
diabetes O
insipidus O
( O
ndi B-ADR
) O
is O
a O
well-documented O
complication O
of O
lithium B-DRUG
use O

ncse B-ADR
, O
an O
epileptic O
disorder O
in O
which O
typical O
convulsive O
activity O
is O
absent O
, O
has O
previously O
been O
reported O
in O
only O
4 O
patients O
receiving O
ifosfamide B-DRUG

patients O
receiving O
neutral O
protamine O
hagedorn O
( O
nph O
) O
insulin O
are O
at O
increased O
risk O
for O
the O
development O
of O
protamine B-ADR
hypersensitivity I-ADR

a O
52-year-old O
black O
woman O
on O
phenytoin B-DRUG
therapy O
for O
post-traumatic O
epilepsy O
developed O
transient B-ADR
hemiparesis I-ADR
contralateral O
to O
the O
injury O

methylphenidate B-DRUG
and O
dextroamphetamine-induced O
peripheral B-ADR
vasculopathy I-ADR

severe B-ADR
acute I-ADR
encephalopathy I-ADR
following O
inadvertent O
intrathecal O
doxorubicin B-DRUG
administration O

after O
a O
six-week O
course O
of O
low-dose O
cyclosporine B-DRUG
a I-DRUG
, O
she O
developed O
a O
severe O
but O
reversible O
loss O
of O
glomerular O
filtration O
rate O
and O
effective B-ADR
renal I-ADR
plasma I-ADR
flow I-ADR
despite O
of O
low O
cyclosporine B-DRUG
a I-DRUG
plasma O
levels O

case O
1 O
, O
a O
62-year-old O
woman O
, O
developed O
bilateral O
optic O
neuritis O
with O
decreased B-ADR
sensation I-ADR
of I-ADR
vibration I-ADR
and O
increased O
deep O
tendon O
reflex O
in O
the O
lower O
extremities O
after O
a O
seven-month O
use O
of O
recombinant B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
for O
chronic O
active O
hepatitis O
c O

we O
report O
a O
case O
of O
a O
patient O
with O
ciprofloxacin-induced O
sjs B-ADR
and O
acute O
onset O
of O
vbds O
, O
and O
reviewed O
the O
related O
literature O

ibuprofen B-DRUG
overdose O
is O
usually O
characterized O
by O
gi O
upset O
, O
dizziness O
, O
and O
mild B-ADR
sedation I-ADR

although O
both O
the O
spontaneous O
occurrence O
of O
sle B-ADR
and O
the O
psychosis O
as O
a O
sign O
of O
cns O
involvement O
of O
sle B-ADR
cannot O
be O
excluded O
, O
sle B-ADR
could O
be O
considered O
as O
an O
adverse O
effect O
of O
carbamazepine B-DRUG

we O
report O
a O
43-year-old O
woman O
who O
developed O
sore O
throat O
, O
swelling B-ADR
of I-ADR
the I-ADR
lips I-ADR
and I-ADR
oral I-ADR
cavity I-ADR
and O
dysphagia O
, O
2 O
weeks O
after O
the O
use O
of O
budesonide B-DRUG
spray O
( O
budefat O
) O
for O
treatment O
of O
bronchial O
asthma O

we O
describe O
the O
development O
of O
cutaneous B-ADR
scleroderma I-ADR
in O
3 O
patients O
coincident O
with O
the O
use O
of O
bleomycin B-DRUG
in O
low O
cumulative O
doses O
of O
less O
than O
100 O
u O

drug B-ADR
eruption I-ADR
caused O
by O
azathioprine B-DRUG
: O
value O
of O
using O
the O
drug-induced O
lymphocytes O
stimulation O
test O
for O
diagnosis O

despite O
a O
response O
of O
the O
meningeal O
tumor O
the O
patient O
developed O
in O
the O
third O
week O
of O
mtx B-DRUG
treatment O
a O
progressive B-ADR
visual I-ADR
loss I-ADR
and O
loss O
of O
consciousness O
which O
worsened O
during O
subsequent O
ara-c O
treatment O
and O
led O
to O
death O
within O
3 O
weeks O

type B-ADR
i I-ADR
second-degree I-ADR
av I-ADR
block I-ADR
( O
mobitz O
type O
i O
, O
wenckebach O
av O
block O
) O
during O
ritodrine B-DRUG
therapy O
for O
preterm O
labor O

we O
report O
the O
case O
of O
an O
87-year-old O
white O
woman O
with O
myasthenia O
gravis O
who O
presented O
with O
nausea B-ADR
, O
shortness O
of O
breath O
, O
azotemia O
, O
and O
hyperkalemia O
shortly O
after O
completing O
a O
course O
of O
intravenous O
immunoglobulin B-DRUG
( O
ivig O

we O
report O
a O
patient O
of O
organic O
bipolar O
affective O
disorder O
who O
developed O
hiccups B-ADR
with O
the O
atypical O
antipsychotic O
aripiprazole B-DRUG

leflunomide-induced O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
in O
a O
patient O
with O
rheumatoid O
arthritis O

this O
patient O
developed O
sequential O
symptoms O
including O
alternative O
hemiparesis O
, O
dysarthria O
and O
altered B-ADR
consciousness I-ADR
5 O
days O
after O
the O
second O
course O
of O
hd-mtx B-DRUG
( O
8 O
gm O
/ O
m2 O
by O
6 O
h O
continuous O
infusion O
) O
with O
leucovorin O
rescue O

it O
should O
be O
recognized O
that O
ibuprofen B-DRUG
may O
be O
associated O
with O
salt B-ADR
and I-ADR
water I-ADR
retention I-ADR
in O
the O
same O
fashion O
as O
previously O
described O
with O
phenylbutazone O
and O
indomethacin O

here O
, O
we O
report O
a O
case O
of O
angio-oedema B-ADR
associated O
with O
vrc B-DRUG
therapy O

it O
should O
be O
emphasized O
that O
the O
recurrence O
of O
nephrotic B-ADR
syndrome I-ADR
was O
observed O
after O
the O
following O
chemotherapy O
, O
including O
m-csf B-DRUG
, O
whereas O
the O
bone O
marrow O
still O
remained O
completely O
remitted O

a O
fatal B-ADR
massive I-ADR
pulmonary I-ADR
embolus I-ADR
developed O
in O
a O
patient O
treated O
with O
streptokinase B-DRUG
for O
acute O
deep O
vein O
thrombosis O

acetazolamide B-DRUG
may O
have O
accelerated O
the O
development O
of O
osteomalacia B-ADR
by O
several O
mechanisms O
, O
including O
increased O
renal O
calcium O
excretion O

hyperammonemia B-ADR
has O
been O
described O
as O
a O
complication O
of O
valproic B-DRUG
acid I-DRUG
therapy O
but O
may O
often O
be O
overlooked O
as O
a O
cause O
of O
lethargy O
in O
the O
postictal O
patient O
who O
presents O
to O
the O
emergency O
department O

quinine-induced O
hearing B-ADR
loss I-ADR

in O
this O
case O
, O
unlike O
those O
previously O
reported O
, O
hyponatremia B-ADR
recurred O
5 O
months O
after O
switching O
from O
citalopram B-DRUG
to O
mirtazapine O
, O
which O
is O
believed O
to O
be O
a O
safe O
antidepressant O

a O
36-year-old O
man O
being O
treated O
with O
cisplatinum B-DRUG
, O
vinblastine O
, O
and O
bleomycin O
for O
testicular O
carcinoma O
developed O
a O
dense O
left O
homonymous O
hemianopsia O
, O
encephalopathy B-ADR
, O
and O
a O
partial O
nondominant O
parietal O
lobe O
syndrome O

conclusion O
: O
squamous B-ADR
metaplasia I-ADR
in O
these O
cases O
appears O
to O
be O
a O
consequence O
of O
progestin B-DRUG
therapy O

by O
means O
of O
the O
in O
vitro O
heparin-induced O
platelet B-ADR
activation I-ADR
( O
hipa O
) O
assay O
it O
was O
shown O
that O
standard O
heparin B-DRUG
and O
the O
lmw O
heparins O
fragmin O
and O
fraxiparin O
( O
sanofi O
labaz O
, O
munich O
, O
frg O
) O
, O
as O
well O
as O
the O
enoxaparine O
clexane O
( O
nattermann O
, O
cologne O
, O
frg O
) O
, O
all O
induced O
platelet B-ADR
activation I-ADR
with O
the O
patient O
's O
serum O

we O
report O
a O
patient O
with O
pulmonary O
adenocarcinoma O
complicated O
by O
the O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
secretion I-ADR
of I-ADR
antidiuretic I-ADR
hormone I-ADR
( O
siadh O
) O
following O
systemic O
chemotherapy O
with O
cisplatin B-DRUG
( O
cddp O
) O
and O
vindesine O
( O
vds O

three O
patients O
who O
had O
experienced O
neuroleptic-induced O
akathisia B-ADR
in O
the O
past O
reported O
that O
the O
symptoms O
of O
fluoxetine-induced O
akathisia B-ADR
were O
identical O
, O
although O
somewhat O
milder O

a O
10-year-old O
asthmatic O
boy O
began O
to O
suffer O
from O
urticarial B-ADR
rash I-ADR
and O
moderately O
severe O
bronchospasm O
after O
8 O
weeks' O
treatment O
with O
disodium B-DRUG
cromoglycate I-DRUG

however O
, O
each O
infant O
demonstrated O
hemodynamic B-ADR
decompensation I-ADR
shortly O
after O
verapamil B-DRUG
administration O
and O
required O
cardiopulmonary O
resuscitation O

dental B-ADR
and I-ADR
gingival I-ADR
pain I-ADR
as O
side O
effects O
of O
niacin B-DRUG
therapy O

fulminant O
metoclopramide B-DRUG
induced O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
rapidly O
responsive O
to O
intravenous O
dantrolene O

we O
report O
a O
case O
of O
acute B-ADR
generalized I-ADR
exanthematous I-ADR
pustulosis I-ADR
( O
agep O
) O
in O
a O
50-year-old O
woman O
that O
was O
attributed O
to O
the O
ingestion O
of O
nimesulide B-DRUG

we O
present O
two O
cases O
of O
anaphylaxis B-ADR
under O
anaesthesia O
where O
return O
of O
spontaneous O
circulation O
was O
refractory O
to O
epinephrine O
, O
but O
occurred O
following O
the O
administration O
of O
the O
alpha-agonist O
metaraminol B-DRUG

the O
noted O
increase B-ADR
in I-ADR
the I-ADR
theophylline I-ADR
level I-ADR
after O
zafirlukast O
administration O
is O
in O
contrast O
to O
the O
original O
reports O
by O
the O
manufacturer O

sertraline-induced O
rhabdomyolysis B-ADR
in O
an O
elderly O
patient O
with O
dementia O
and O
comorbidities O

rapid O
onset O
of O
quetiapine-induced O
diabetic B-ADR
ketoacidosis I-ADR
in O
an O
elderly O
patient O
: O
a O
case O
report O

anaphylaxis B-ADR
to O
intravenous O
cyclosporine B-DRUG
and O
tolerance O
to O
oral O
cyclosporine B-DRUG
: O
case O
report O
and O
review O

severe B-ADR
diffuse I-ADR
interstitial I-ADR
pneumonitis I-ADR
induced O
by O
carmustine O
( O
bcnu B-DRUG

several O
such O
hbv B-ADR
reactivations I-ADR
were O
reported O
after O
combined O
rituximab B-DRUG
and O
multiagent O
chemotherapy O
for O
b-cell O
lymphomas O

patient O
and O
method O
: O
a O
34-year-old O
woman O
with O
chronic O
hepatitis O
c O
, O
genotype O
3 O
, O
receiving O
pegylated O
interferon O
alpha-2a O
and O
ribavirin B-DRUG
for O
6 O
months O
, O
developed O
progressive B-ADR
malaise I-ADR
and O
anemia O
6 O
months O
after O
the O
end O
of O
treatment O

thus O
, O
tacrolimus-induced O
hus O
is O
a O
rare O
cause O
of O
arf B-ADR
in O
nephrotic O
syndrome O

we O
describe O
a O
patient O
with O
acute O
myeloblastic O
leukemia O
( O
aml O
) O
who O
developed O
nephrotic B-ADR
syndrome I-ADR
after O
receiving O
several O
courses O
of O
chemotherapy O
, O
including O
macrophage-colony-stimulating B-DRUG
factor I-DRUG
( O
m-csf O

codeine B-ADR
intoxication I-ADR
in O
the O
neonate O

a O
healthy O
, O
30-year-old O
man O
, O
exposed O
to O
sulindac B-DRUG
on O
two O
separate O
occasions O
, O
had O
an O
incapacitating O
isolated B-ADR
idential I-ADR
sensory I-ADR
neuropathy I-ADR

new O
onset O
of O
cd B-ADR
may O
be O
considered O
as O
an O
immune-mediated O
injury O
induced O
by O
etanercept B-DRUG

we O
report O
the O
development O
of O
scrotal B-ADR
ulcer I-ADR
in O
a O
patient O
with O
acute O
promyleocytic O
leukemia O
( O
apl O
) O
within O
10 O
days O
of O
treatment O
with O
atra B-DRUG
at O
a O
dose O
of O
40 O
mg O
orally O
twice O
daily O

we O
report O
a O
case O
of O
an O
infant O
with O
complex O
congenital O
heart O
disease O
who O
was O
placed O
on O
captopril B-DRUG
for O
afterload O
reduction O
following O
cardiac O
surgery O
and O
subsequently O
developed O
pulmonary B-ADR
infiltrates I-ADR
with I-ADR
eosinophilia I-ADR

autopsy O
findings O
were O
consistent O
with O
bleomycin B-DRUG
and O
oxygen-induced O
pulmonary B-ADR
damage I-ADR

